CUA 2012 : Final Programme
description
Transcript of CUA 2012 : Final Programme
GENERAL INFORMATION
Message from the Co-chairs of the Local Organizing Committee . . . . . . . 1Message from the CUA President . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2CUA Executive & Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6Continuing Professional Development . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Future CUA Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Floor Plan of the Fairmont The Banff Springs Hotel . . . . . . . . . . . . . . . . 10Social Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11CUASF Fun Run/Walk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14Companions' Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Kids' Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
RENSEIGNEMENTS GÉNÉRAUX
Mot de bienvenue des co-présidents du Comité organisateur local . . . . 17Mot de bienvenue du Président de l'AUC . . . . . . . . . . . . . . . . . . . . . . . . 18Membres de l'Éxécutive et Comités de l'AUC . . . . . . . . . . . . . . . . . . . . . 19Renseignements généraux . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22Développement professionnel continu . . . . . . . . . . . . . . . . . . . . . . . . . . 24Congrès futurs de l'AUC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Plan du Fairmont Banff Springs Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . 26Programme Social . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27Course et marche amicale au profit de la FBAUC . . . . . . . . . . . . . . . . . . 30Programme des accompagnateurs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31Programme Jeunesse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
SPONSORS AND EXHIBITORS / COMMANDITAIRES ET EXPOSANTS
CUA Sponsors 2012 / Commanditaires de l’AUC 2012 . . . . . . . . . . . . . . 33CUASF 2012 Sponsors / Commanditaires de la FBAUC 2012 . . . . . . . . . 34Sponsored Sessions / Séances commanditées . . . . . . . . . . . . . . . . . . . 35Exhibit Information / Renseignements sur l'Exposition . . . . . . . . . . . . . . 36Exhibit Floor Plan / Plan de l'exposition . . . . . . . . . . . . . . . . . . . . . . . . . 37Exhibitor Listing / Liste des exposants . . . . . . . . . . . . . . . . . . . . . . . . . . 38Exhibit Directory / Répertoire des exposants . . . . . . . . . . . . . . . . . . . . . 39
TABLE OF CONTENTS / TABLE DES MATIÈRES
CUA 2012 BANFF 1
2 CUA 2012 BANFF
SCIENTIFIC PROGRAM / PROGRAMME SCIENTIFIQUE
Invited Faculty / Conférenciers invités . . . . . . . . . . . . . . . . . . . . . . . . . . 63CUA Prize Essays / Travaux primés de l'AUC . . . . . . . . . . . . . . . . . . . . . 64CUA and Affiliated Meetings / Réunions des sociétés affiliées et des comités de l'AUC . . . . . . . . . . . . 65Canadian Academy Of Urological Surgeons (CAUS) Banff 2012 . . . . . . . 68
DETAILED PROGRAM / PROGRAMME DÉTAILLÉS
Friday / Vendredi - June 22 juin . . . . . . . . . . . . . . . . . . . . . . 69Saturday / Samedi - June 23 juin . . . . . . . . . . . . . . . . . . . . . 70Sunday / Dimanche - June 24 juin . . . . . . . . . . . . . . . . . . . . 73Monday / Lundi - June 25 juin . . . . . . . . . . . . . . . . . . . . . . . 83Tuesday / Mardi - June 26 juin . . . . . . . . . . . . . . . . . . . . . . . 93Unmoderated Posters / Posters non-modérés . . . . . . . . . . . 127
Disclosures / Divulgations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxx
INDEX
Invited Speakers Index / Index des conférenciers invités . . . . . . . . . . . . xxPresenters Index / Index des présentateurs . . . . . . . . . . . . . . . . . . . . . . xx
TABLE OF CONTENTS / TABLE DES MATIÈRES
CUA 2012 BANFF 1
Well it is finally upon us…CUA 2012. Welcome to Banff!
As we have been promising all year we have quite a meeting in store for you. The academic sessions are filled with many educational opportunities and the nightsare filled with things that will provide an opportunity for relaxation and enjoyment. I expect you may hear the mountains and meadows calling to you from the meeting,so be sure to answer, because it is a world of wonder out there. Come and learn lots,get involved, and catch up with old friends and new. But most of all HAVE FUN!
Marty & HowardCo-chairs, CUA 2012 Local Organizing Committee
MESSAGE FROM THE CO-CHAIRS OF THE LOCAL ORGANIZING COMMITTEE
2 CUA 2012 BANFF
Welcome to the 67th Annual Meeting CUA Meeting in beautiful Banff Alberta, the crown jewel of the Canadian Rocky’s.
Our host hotel is the historic Fairmont Banff Springs Hotel. It’s castle like designnestled along the banks of the Bow River is stunning and will provide the perfectvenue for our gathering
Drs. Jay Lee and Trevor Schuler and their Scientific Committee have planned the scientific portion of the meeting with a superb list of speakers and engaging educational fora.
Drs. Howard Evans and Marty Duffy, Chairs of the Local Organizing Committee (LOC),have worked hard to create an entertaining social program for us to enjoy after a“hard day at the office”.
As President of the CUA, it is my pleasure to welcome you to Banff and to wish you a wonderful and productive CUA Annual Meeting.
Michael ChetnerPresident, CUA
MESSAGE FROM THE CUA PRESIDENT
CUA 2012 BANFF 3
EXECUTIVE COMMITTEE
President Michael ChetnerPresident-Elect Joseph ChinPast-President Sender HerschornVice-President Peter AndersonTreasurer Anne Marie
HouleSecretary Denis LavoieSecretary-Elect Karen PsooyVP Education Gerald BrockMembers-at-LargeGreg Bailly
British ColumbiaJohn DushinskiPrairiesVladimir KurganskyOntarioChristopher MorashQuébecAndrew McNeillyAtlantic
ANNUAL MEETINGPLANNING COMMITTEE
Gerald Brock, ChairArmen AprikianFrançois BénardIan BrownSerge CarrierMichael ChetnerJoseph ChinMarty DuffyHoward EvansDianne HeritzJonathan IzawaAnil KapoorDenis LavoieJay LeeTiffany PizioliNadia PaceTrevor Schuler
AWARDS COMMITTEE
Peter Anderson, ChairJohn-Paul CapolicchioMichael ChetnerDenis LavoieJohn Mahoney
BY-LAWS COMMITTEE
Joseph Chin, ChairMichael ChetnerSender HerschornDenis Lavoie
CONTINUING PROFESSIONALDEVELOPMENT COMMITTEE
François Bénard, ChairKevin CarlsonMarc Anthony FischerScott MurrayThomas Whelan
ENDORSEMENT COMMITTEE
Sender Herschorn, ChairPeter AndersonGerald BrockMichael ChetnerJoseph ChinAnne-Marie HouleDenis Lavoie
CUA EXECUTIVE AND COMMITTEES
4 CUA 2012 BANFF
FINANCE COMMITTEE
Anne-Marie Houle, ChairGerald BrockIan BrownMichael ChetnerJoseph ChinMarty DuffyHoward EvansDenis LavoieRob Siemens
GUIDELINES COMMITTEE
Antonio Finelli, ChairGreg BaillyJohn DushinskiVladimir KurganskyChristopher MorashAndrew MacNeily
HISTORIAN
Vacant
INFORMATION TECHNOLOGY COMMITTEE
Christopher Nguan, ChairMike Leveridge
LOCAL ORGANIZING COMMITTEE
Marty Duffy and Howard Evans, Co-Chairs
NOMINATING COMMITTEE
Sender Herschorn, ChairPeter BlackJohn-Paul CapolicchioJoe ChinJay LeeDawn MacLellanYves Fradet
PATIENT INFORMATIONCOMMITTEE
Ben Chew, ChairNafisa DharamsiSamer HannaJay Lee Rob Siemens Troy Sitland Thomas Whelan
PRIZE ESSAY COMMITTEE
Jay Lee and Trevor Schuler, Co-ChairsArmen AprikianFrançois BénardJonathan IzawaAnil KapoorDawn MacLellanRyan Paterson
CUA EXECUTIVE AND COMMITTEES
CUA 2012 BANFF 5
POST-GRADUATE TRAINING COMMITTEE
Joseph Chin, ChairTurki Al-EssawiGreg BaillyDiego BarrierasGerald BrockBill GourlayAnil KapoorWassim KassoufYves PonsotKeith RourkeRob SiemensRob StewartFrederic SoucyJim Watterson
SCIENTIFIC COMMITTEE
Jay Lee and Trevor Schuler, Co-ChairsArmen AprikianFrançois BénardJonathan IzawaAnil KapoorDawn MacLellanRyan Paterson
SOCIO-ECONOMIC COMMITTEE
Darrel Drachenberg, ChairLorne AaronScott BagnellJack BarkinGreg KozakAlan So
CUASF EXECUTIVE COMMITTEE
Michael Chetner, ChairAnne-Marie HouleDenis LavoieRicardo RendonRobert Siemens
CUASF ADMINISTRATIVECOMMITTEE
Robert Siemens, ChairAnne-Marie HouleJun KawakamiChris MorashPaul Whelan
CUASF SCIENTIFIC COUNCIL
Ricardo Rendon, ChairLuis GuerraWassim KassoufPatrick LukeRon MooreAlan So
CUA/ASTELLAS GRANT PROGRAM, SCIENTIFIC COUNCIL
Peter BlackLeslie CarrSerge CarrierJonathan IzawaJay LeeAndrew MacNeillyBobby Shayegan
CUA EXECUTIVE AND COMMITTEES
6 CUA 2012 BANFF
VENUE
The Fairmont Banff Springs Hotel is the CUA Annual Meeting headquarter hotel and meeting venue. All scientific programactivities listed take place at the hotel, unless otherwise indicated.
The Fairmont Banff Springs Hotel 405 Spray AvenueBanff, AB, T1L 1J4(403) 762-6866
ADMISSION POLICIES
Name badges are required to gain access to all meeting functions. Tickets must be presented at social events and optional events.
Registration categories are indicated by thecolour band of the badge holder included inthe registration package. Tickets for socialand optional activities are included in thepackage.
Upon claiming your registration material,please ensure that all of the activities youpurchased have been included, and that yourbadge holder correctly corresponds to the legend below:Full Program (Scientific & Social) . . . . BlueScientific Program Only . . . . . . . . . . . RedIndustry . . . . . . . . . . . . . . . . . . . . . . GreenCompanion . . . . . . . . . . . . . . . . . . . YellowMedia . . . . . . . . . . . . . . . . . . . . . . . . Black
Full Program delegates and companionshave access to the Opening Brunch, FunNight, President’s Reception and Banquet.
Registered companions are entitled to dailybreakfast in the Companions’ Lounge.
Registered teens and children have accessto the Opening Brunch as well as the following activities and meals:
1 Activities, snacks and dinner on Sundayat the Kids'lounge (from 14:00)
2 Breakfast on Monday and Tuesday at the Kid's lounge
3 Activities, snacks and lunch, on Mondayand Tuesday at the Banff SpringsHotel Kids' Club (8:45 to 16:30)
4 Monday night dinner and activities at the Kids' lounge
Delegates registered for the Scientific Program Only may purchase tickets to the social optional events in the main registration area.
BOOK OF ABSTRACTS
The book of abstracts is included in the delegate bag. It is published by the CanadianUrological Association Journal (CUAJ).
CERTIFICATE OF ATTENDANCE
A personalized certificate of attendance willbe available via email after the event. Thiscertificate can be used to claim CPD credits.
EXHIBIT HALL
The Canadian Urological Association and theLocal Organizing Committee wish to expresstheir gratitude to the companies who havegiven their support to this meeting by takingpart in the Exhibit. We invite you to visit ourIndustry partners and gain valuable, up-to-date knowledge of their products and services. Please refer to theSponsors/Exhibitors section of this Program for a complete list and floor plan.
The Exhibit Hall is located in Van Horne BCand will be open during the following hours:Sunday, June 24. . . . . . . . . . . . 0800-1700Monday, June 25 . . . . . . . . . . . 0800-1530
GENERAL INFORMATION
CUA 2012 BANFF 7
INTERNET
Wireless Internet is available on the convention level of the hotel. Please verifythe housekeeping notes for the password.
LIABILITY
The CUA Banff 2012 Annual Meeting and theSecretariat IS Event Solutions cannot acceptresponsibility for any accidents, injuries orillness that may occur during the AnnualMeeting.
LOST AND FOUND
Found items should be handed in promptlyto staff at the Registration Desk.
PHOTOGRAPHS
Souvenir photographs taken at the AnnualMeeting will be posted online after theevent.
REGISTRATION DESK
The Registration Desk is located in the Hotel’s Convention Center, across the streetfrom the Hotel’s main building. Hours of operation are as follows:Saturday, June 23 . . . . . . . . . . 1100-1800Sunday, June 24. . . . . . . . . . . . 0630-1700Monday, June 25 . . . . . . . . . . . 0630-1800Tuesday, June 26 . . . . . . . . . . . 0630-1630
SPEAKER READY ROOM Room: NR Crump
All podium, moderated video, moderatedposter, educational fora and invited lecturepresenters with PowerPoint slides andvideos are asked to check in at the SpeakerReady Room, located in the NR Crump room,24 hours before their scheduled talk.Saturday, June 23 . . . . . . . . . . 1300-1800Sunday, June 24. . . . . . . . . . . . 0630-1730Monday, June 25 . . . . . . . . . . . 0630-1700Tuesday, June 26 . . . . . . . . . . . 0630-1600
A technician will be at the speaker’s disposal to assist with any audio-visualqueries. Speakers are asked to bring theirfiles on portable media devices (USB stick,flashcard, CD, etc.). The use of individual laptop computers is prohibited.
UNMODERATEDPOSTER DISPLAYS
Unmoderated e-poster stations will be available in the President’s Hall Foyer from 0930 on Sunday, June 24, until Tuesday,June 26, at 1400.
5-STAR POSTERS
The moderators of each Moderated Postersession will select 5-star posters. The 5-starposter presenters will be announced in the Closing Session at 1600 on Tuesday,June 26.
GENERAL INFORMATION
8 CUA 2012 BANFF
GOAL
The goal of this program is to provide a forum to identify and discuss "state-of- the-art" information concerning urologicaldiseases, including the prevention diagnosisand treatments, and to support basic science and clinical research by urologistsand other healthcare professionals.
LEARNING OBJECTIVES AND CANMEDS ROLE COMPETENCIES OBJECTIVES1 To Identify modifications in SWL treatment
protocols designed to maximize efficacy anddecrease morbidity
2 To Identify techniques to optimize preoperativeplanning and intraoperative implementation ofpercutaneous renal access
3 To discuss relevant epidemiologic studies onpatient safety
4 To review complications of medical manage-ment of kidney stone disease including medication interactions and side effects
5 To understand the methodology of analysis regarding the literature supported recommen-dations presented on urethral reconstruction
6 Gain an appreciation for the treatment ofpelvic fracture urethral distraction defects(PFUDD)
7 Discuss the diagnosis and treatment of common genital injuries
8 To better understand the Regional Differences in Practice Patterns and Outcomes after Radical Cystectomy
9 To identify long term side effects of testis cancer chemotherapy
10 To conduct a critical evaluation of the treatment strategies for superficial Bladder cancer
11 To better understand the Understand the morbidity of cystectomy and the alternativesto this this surgery in bladder cancer
12 To discuss rules and regulations regarding diet and supplement for men's health
13 To discuss clinical studies that support or doe not support recommending specific dietary changes and supplements to your patients
14 To understand how potential risks (side effects /complications) of medical andsurgical intervention for benign prostatic enlargement drives patient decision making
15 To gain an awareness of how to prevent the development of LUTS through lifestylemanagement
16 To learn that long term financial implicationsof medical and surgical management for benign prostatic enlargement does not play arole in current decision making
17 To understand the future health problems formen with infertility (higher risk of cancer etc.)
18 To Appreciate the technical aspects of current sling procedures that can be incorporated into surgical armamentarium
19 Formulate a rational and effective plan for the evaluation and treatment of elderly patients with OAB symptoms
20 To correlate clinical findings of VUR with itsgenetic basis
21 To review the evidence for and against the use of 5-ARI in prostate cancer prevention
22 To better understand Need for Intervention andSurvival in a Cohort of Patients on Active Sur-veillance (AS) for Low-risk Prostate Cancer
23 To Assess state-of-the-art management of CRCP, both in terms of guidelines as well as novel agents that will be available inthe near future
24 To assess the existing scientific support foruse of PDE5i's in BPH/LUTS
25 To discuss ethics in surgery and professional applications of these concepts
MoCert CREDITS
This program has been accredited by theCUA as a Section 1 Group Learning Activityas defined by the Maintenance of Certifica-tion Program of the Royal College of Physi-cians and Surgeons of Canada. For the spe-cialist, this activity qualifies for 1 credit perhour of participation as articulated in Section1 of the Maintenance of Certification Pro-gram of the Royal College of Physicians andSurgeons of Canada for a maximum of 22credits. Participants should only claim thecredit corresponding to their attendance.
CONTINUING PROFESSIONAL DEVELOPMENT
CUA 2012 BANFF 9
2013 JUNE 23-25
68th CUANiagara Falls, ONSheraton on the Falls Hotel
2014 JUNE 29-JULY 1
69th CUASt. John’s, NLDelta St. John’s Hotel & Conference Center
2015 JUNE 28-30
70th CUAOttawa, ONThe Westin Ottawa Hotel
2016 JUNE 26-28
71st CUAVancouver, BCThe Westin Bayshore Hotel
2017 JUNE 25-27
72nd CUAToronto, ONWestin Harbour Castle
Hote
FUTURE CUA MEETINGS
2015 OTTAWA
2013 NIAGARA FALLS
2014 ST. JOHN’S
2017 TORONTO
2016 VANCOUVER
10 CUA 2012 BANFF
FLOOR PLAN OF THE FAIRMONT BANFF SPRINGS HOTEL
CUA 2012 BANFF 11
SOCIAL PROGRAM GRID
TIME SOCIAL PROGRAMCOMPANION'S
PROGRAMKID'S PROGRAM
SUNDAY, JUNE 24
0800-1100Breakfast & Privateconcierge Services
Companion's Lounge: Oak room
1130-1230 Opening Brunch VanHorne BC
1400-2200Fun Activities, Dinner
& EntertainementKid's lounge: Norquay room
1900-2230FUN NIGHT Rockies & RailThe Fairmont Banff Springs Hotel
Riverview Lounge, Alberta & New-Brunswick rooms
MONDAY, JUNE 25
0700-0845 BreakfastKid's Lounge: Norquay room
0800-1100Breakfast & Privateconcierge Services
Companion's Lounge: Oak room
0845-1630 Fun ActivitiesBanff Springs Kid's Club
1630-2300Fun Activities, Dinner
& EntertainementKid's lounge: Norquay room
1900-2300
President's Reception & BanquetFire & Ice Ball / Cocktail at 18:30The Fairmont Banff Springs Hotel
Alberta room
TUESDAY, JUNE 26
0630-0730CUASF Fun Run/Walk
Lobby The Fairmont Banff SpringsHotel
0700-0845 BreakfastKid's Lounge: Norquay room
0800-1100Breakfast & Privateconcierge Services:
Companion's Lounge: Oak room
0845-1630 Fun ActivitiesBanff Springs Kid's Club
12 CUA 2012 BANFF
All Social Events are by ticket admission/ registration badge only. Additional Social Event tickets are available forpurchase at the Registration Desk.
SUNDAY, JUNE 24
1130-1230 Opening BrunchExhibit Hall – Van Horne BC
Included for all registered participants
After a session-filled morning, CUA2012 officially kicks off with a meet-and-greet brunch in the Exhibit Hall.Catch up with friends you haven't seensince the last CUA meeting in Montrealand prepare yourself for 3 full days ofexciting scientific updates.
An assigned CUA concierge will be ableto make restaurant reservations for youduring the day on Sunday, June 24.
1900-2230 CUA Fun Night –Rockies & RailThe Fairmont Banff Springs HotelRiverview Lounge, Alberta & New Brunswick Room
Included for Full Program delegates and registered companions.Cost of additional ticket: $125, plus tax
All aboard! For the first-time in CUA history, the Fun Night will take place on Sundayevening, once the exhibit hall closes andthe sessions are over. You can expect afull house filled with CUA members andpartners in industry.
Eat, dance and relive the Golden Age ofthe Canadian Rockies at the grandioseBanff Springs Hotel, while the Livin’ inSwing band takes you back in time! This six-piece band will have attendeeson their feet and dancing the nightaway. Playing Swing music as well as a variety of other tunes, this ensemble’slively flair also has an extensiverepertoire of sing along melodies.
Let yourself be taken back in time in afashionable décor and savor the manyflavors of the Great-Canadian-West withBuffalo mini-burgers, beef tenderloinpies, cedar planked salmon… just toname a few. The night is sure to makeCUA Fun Night history as we have amultitude of surprises planned whichwill keep you on the edge of your seat!
SOCIAL PROGRAM
CUA 2012 BANFF 13
M O N D AY , J U N E 2 5
1900-2300 President's Reception and Banquet – The CUA Fire & Ice Ball(Cocktails at 1830)Alberta & New Brunswick room The Fairmont Banff Springs Hotel
Included for Full Program delegates and registered companions.Cost of additional ticket: $150, plus tax
The LOC Chairs have planned an eventthat will incorporate some of nature’selements; let your senses take over and expect the unexpected!
Join us to salute and to pay tribute to the Local Organizing Chairs, the Scientific Committee and CUA Presi-dent, Dr. Michael Chetner, and to wel-come the new CUA 2013 cast who are enthusiastically preparing to greet you in Niagara Falls!
This year’s President’s Reception andBanquet featuring a tantalizing 4-coursedinner will bring you to a world whereFire & Ice create an explosion of dazzling beauty and refinement.
Gentlemen, pull out your tuxedos and ladies, wear THAT stunning dressthat will surprise and astonish! With themeeting drawing to an end, take sometime to reflect on the previous 3 days ofsessions and start looking forward tonext year's meeting.
SOCIAL PROGRAM
14 CUA 2012 BANFF
T U E S D AY , J U N E 2 6
0630-0730 CUASF Charity Run/Walk
*A fee of $50 applies (non-taxable)
CUA will hold a Charity Run & Walk to support the Canadian Urological Association Scholarship Fund (CUASF)for a third time. The objective of theCUASF is to provide financial support forurologic research to be conducted inCanada.
Participants can choose a 2km walk or a 5km fun-run through the streets of Banff. Strike up some friendly competition as we band together tosupport this important CUA initiative!
All proceeds will be donated to theCUASF.
CUASF FUN RUN/WALK
CUA 2012 BANFF 15
Registration for companions includes:1 Welcome gift2 Access to Exhibit Hall3 Daily breakfast in
Companions’ Lounge4 Exhibit Opening and Opening
Brunch (Sunday)5 Fun Night (Sunday) 6 President’s Reception & Banquet
(Monday)
COMPANIONS’ LOUNGE
Companions are invited to use theLounge at the Fairmont Banff SpringsHotel to meet friends and enjoy the daily continental breakfast. The Loungewill be open Sunday, Monday & Tuesday,from 08:00-11:00. A private CUAconcierge is posted in the Loungeduring opening hours on Sunday,Monday and Tuesday to assist you inmaking your stay a memorable one.
Information & Tour booking will be available on-site.
If you are interested in visiting the Fairmont Banff Springs Hotelinternationally acclaimed Willow Stream Spa, please contact the hotel Concierge desk, located in the hotel lobby.
TUESDAY, JUNE 26
0630-0730 CUASF Charity Run/Walk
*A fee of $50 applies (non-taxable) See page 18 for details.
COMPANIONS’ PROGRAM
16 CUA 2012 BANFF
KIDS’ LOUNGE
The 2012 CUA Kids’ Program will be extra-special as the Fairmont BanffSprings features a fantastic kids’ clubwhich will be open for CUA’s kids onMonday and Tuesday.
The Banff Springs Kid’s Club, the hotel’sactivity hub for kids, will be the star attraction for our young guests betweenthe ages of 6 and 16 years old. TheKid’s Club offers supervised activitieswith enthusiastic camp leaders. Everyday is a new adventure and each childreceives a complimentary Banff SpringsKids Club ball cap, nametag, and lan-yard on their first visit.
Outdoor activities will focus on learningnew wilderness skills like navigation,emergency survival and cooking over anopen fire. Inside, the centre has plentyof great games, crafts and activities tokeep kids entertained.
Registration for Kids’ Program includes:1 Welcome kit
2 Activities from 14:00 on Sunday atthe Kids’ Lounge
3 Breakfast in Kids’ Lounge on Monday& Tuesday
4 Bowling & pizza on Sunday evening
5 Dinner and movie night on Monday
6 Two full-days of activities on Mondayand Tuesday indoor and outdoor atthe hotel’s Kids’ Club
7 Lunch and snacks on Monday andTuesday at the hotel’s Kids’ Club.
KIDS’ PROGRAM HOURS
Sunday, June 24Fun Activities in Kids’ Lounge......................14:00-23:00
Monday, June 25 Breakfast in Kids’ Lounge ..07:00-08:45 Activities at the Banff Springs Kids’ Club..............08:45-16:30 Dinner & Entertainment......16:30-23:00
Tuesday, June 26 Breakfast in Kids’ Lounge ..07:00-08:45 Activities at the Banff Springs Kids’ Club..............08:45-16:30
BABYSITTING
A babysitting service is available starting from 16$/hour for up to 2 children, and a minimum of 4 hours. The caregiver can look after the childrenin the room or take them to different hotel activities (swimming, bowling,movie theatre, etc...)
Advance reservations are required andmay be made through the concierge at [email protected] 24-hour cancellation policy applies to all reservations.
KIDS’ PROGRAM
CUA 2012 BANFF 17
Finalement, nous y voilà...AUC 2012. Bienvenue à Banff!
Comme nous vous l'avions promis toute l'année, nous avons tout un congrès enréserve pour vous, en passant par un programme scientifique des plus complet,vous permettant de saisir de nombreuses opportunités éducatives de qualités,jusqu'à nos célèbres soirées remplies comme toujours de moments mémorables!
Comme nous sommes certains que vous entendrez l'appel des montagnesrocheuses et de leurs prés verdoyants, nous vous suggérons fortement d'être prêt à y répondre sans faute, car vous êtes entourés d'un monde de merveilles à découvrir...ou à redécouvrir. Apprenez, découvrez, épaulez et revoyez d'anciennesconnaissances ainsi qu'à vous en faire de nouvelles. Mais surtout, surtout, amusez-vous!'
Marty & HowardCo présidents, CUA 2012 Comité scientifique
MOT DE BIENVENUE DES CO-PRÉSIDENTS DU COMITÉ ORGANISATEUR LOCAL
18 CUA 2012 BANFF
Bienvenue au 67e Congrès annuel de l’AUC, dans la magnifique ville de Banff en Alberta, le joyau des Rocheuses canadiennes.
Notre hôte est l’hôtel historique Fairmont Banff Springs. Son architecture semblableà celle d’un château blotti sur la rive de la rivière Bow est tout à fait impressionnanteet offre un lieu de réunion idéal.
Les docteurs Jay Lee et Trevor Schuler, ainsi que les membres de leur comité scientifique ont préparé dans le cadre de ce congrès un programme scientifique quiprévoit une liste impressionnante de conférenciers ainsi qu’un forum éducatif desplus intéressants.
Les docteurs Howard Evans et Marty Duffy, présidents du comité local d’organisationont déployé tous les efforts pour mettre sur pied un programme social à notre intention, après ‘une dure journée de travail’.
En qualité de président de l’AUC, je suis très heureux de vous souhaiter la bienvenue à Banff et je vous souhaite un magnifique congrès annuel de l’AUC, intéressant et fructueux.
Michael ChetnerPrésident, CUA
MOT DE BIENVENUE DU PRÉSIDENT DE L'AUC
CUA 2012 BANFF 19
COMITÉ EXÉCUTIF
Président Michael ChetnerPrésident désigné Joseph ChinPrésident Sortant Sender HerschornVice-président Peter AndersonTrésorier Anne Marie HouleSecrétaire Denis LavoieSecrétaire désigné Karen PsooyVice-président Education
Gerald BrockExécutifs extraordinaires
Greg BaillyColombie-BritanniqueJohn DushinskiLes PrairiesVladimir KurganskyOntarioChristopher MorashQuébecAndrew McNellyAtlantic
COMITÉ DE PLANIFICATIONDU CONGRÈS ANNUEL
Gerald Brock, ChairArmen AprikianFrançois BénardIan BrownSerge CarrierMichael ChetnerJoseph ChinMarty DuffyHoward EvansDianne HeritzJonathan IzawaAnil KapoorDenis LavoieJay LeeTiffany PizioliNadia PaceTrevor Schuler
COMITÉ DES PRIX
Peter Anderson, ChairJohn-Paul CapolicchioMichael ChetnerDenis LavoieJohn Mahoney
COMITÉ DES RÉGLEMENTS
Joseph Chin, ChairMichael ChetnerSender HerschornDenis Lavoie
COMITÉ DU DÉVELOPPEMENTPROFESSIONNEL CONTINU
François Bénard, ChairKevin CarlsonMarc Anthony FischerScott MurrayThomas Whelan
COMITÉ DES APPROBATIONS
Sender Herschorn, ChairPeter AndersonGerald BrockMichael ChetnerJoseph ChinAnne-Marie HouleDenis Lavoie
MEMBRES DE L'EXÉCUTIF ET COMITÉS DE L'AUC
20 CUA 2012 BANFF
COMITÉ DES DES FINANCES
Anne-Marie Houle, ChairGerald BrockIan BrownMichael ChetnerJoseph ChinMarty DuffyHoward EvansDenis LavoieRob Siemens
COMITÉ DES GUIDES DE PRATIQUE
Antonio Finelli, ChairGreg BaillyJohn DushinskiVladimir KurganskyChristopher MorashAndrew MacNeily
HISTORIEN
Vacant
COMITÉ DES TECHNOLOGIES DE L'INFORMATION
Christopher Nguan, ChairMike Leveridge
COMITÉ ORGANISATEUR LOCAL
Marty Duffy and Howard Evans, Co-Chairs
COMITÉ DES NOMINATIONS
Sender Herschorn, ChairPeter BlackJohn-Paul CapolicchioJoe ChinJay LeeDawn MacLellanYves Fradet
COMITÉ INFO-PATIENTS
Ben Chew, ChairNafisa DharamsiSamer HannaJay Lee Rob Siemens Troy Sitland Thomas Whelan
COMITÉ DES TRAVAUX PRIMÉS
Jay Lee and Trevor Schuler, Co-ChairsArmen AprikianFrançois BénardJonathan IzawaAnil KapoorDawn MacLellanRyan Paterson
MEMBRES DE L'EXÉCUTIF ET COMITÉS DE L'AUC
CUA 2012 BANFF 21
COMITÉ DES AFFAIRES DES RÉSIDENTS
Joseph Chin, ChairTurki Al-EssawiGreg BaillyDiego BarrierasGerald BrockBill GourlayAnil KapoorWassim KassoufYves PonsotKeith RourkeRob SiemensRob StewartFrederic SoucyJim Watterson
COMITÉ SCIENTIFIQUE
Jay Lee and Trevor Schuler, Co-ChairsArmen AprikianFrançois BénardJonathan IzawaAnil KapoorDawn MacLellanRyan Paterson
COMITÉ SOCIOÉCONOMIQUE
Darrel Drachenberg, ChairLorne AaronScott BagnellJack BarkinGreg KozakAlan So
COMITÉ EXÉCUTIF DE LA FBAUC
Michael Chetner, ChairAnne-Marie HouleDenis LavoieRicardo RendonRobert Siemens
CONSEIL D'ADMINISTRATION DE LA FBAUC
Robert Siemens, ChairAnne-Marie HouleJun KawakamiChris MorashPaul Whelan
CONSEIL SCIENTIFIQUE DE LA FBAUC
Ricardo Rendon, ChairLuis GuerraWassim KassoufPatrick LukeRon MooreAlan So
CUA/ASTELLAS GRANT PROGRAM, SCIENTIFIC COUNCIL
Peter BlackLeslie CarrSerge CarrierJonathan IzawaJay LeeAndrew MacNeillyBobby Shayegan
MEMBRES DE L'EXÉCUTIF ET COMITÉS DE L'AUC
22 CUA 2012 BANFF
SIÈGE DU CONGRÈS
Toutes les activités du programme scien-tifique ci-dessous s'y déroulent, à moinsd'indication contraire.
Le Fairmont Banff Springs Hotel 405, Spray AvenueBanff, AB, TIL 2J4(403) 762-6866
ADMISSION
Vous devez porter votre badge pour entrerau congrès. Vous devez présenter votre billetlors des événements sociaux facultatifs.La catégorie d'inscriptions se reconnaît à lacouleur de la cocarde comprise dans votretrousse d'inscription. Les billets pour lesévénement sociaux et facultatifs se retrou-vent également dans la trousse.
Lorsque vous récupérerez vore matérield'inscription, veuillez vous assurer quetoutes les activités que vous avez payéessont bien indiquées et que la couleur devotre badge correspond à la légende ci-dessous:Programme complet (scientifique et social) : . . . . . . . . . .BleuProgramme scientifiqueseulement : . . . . . . . . . . . . . . . . . . .RougeIndustrie : . . . . . . . . . . . . . . . . . . . .VertAccompagnateur : . . . . . . . . . . . . .JauneMédia : . . . . . . . . . . . . . . . . . . . . . .Noir
Les délégués inscrits à tout le programmeainsi que les accompagnateurs ont accès auBrunch de bienvenue, à la Grande soirée del'AUC et au Banquet présidentiel.
Les accompagnateurs inscrits peuventégalement prendre leur petit-déjeuner dans le Salon des accompagnateurs.
Les enfants et adolescents inscrits ont accès au Brunch de bienvenue ainsi qu'aux activités et repas suivants:1 Activités, collation et souper le dimanche
au salon des enfants (à partir de 14h00)2 Petits déjeuners les lundi et mardi au
salon des enfants3 Activités, collations et lunch, les lundis
et mardis au Club des enfants du BanffSprings Hotel (8h45 à 16h30)
4 Souper et activités du lundi soir au salondes enfants
Les délégués inscrits au Programme scientifique seulement peuvent acheter des billets pour les activités sociales et facultatives au bureau d'inscription.
RECUEIL DES RÉSUMÉS
Un recueil des résumés présentés, publiépar le Journal de l'Association des urologuesdu Canada, est inclus dans la trousse desdélégués.
ATTESTATION DE PARTICIPATION
Une attestation de participation vous seraenvoyée par courriel, sur demande, aprèsl'événement. Cette attestation peut être utilisée pour réclamer vos crédits de DPC.
HALL D'EXPOSITION
L'Association des urologues du Canada etleur Comité organisateur désirent exprimerleur reconnaissance envers les compagniesqui ont prêté leur soutien à ce congrès enparticipant à cette exposition. Nous vous in-vitons à rendre visite à nos partenaires del'industrie et à vous mettre à jour sur leursproduits et services. Veuillez vous reporter à la section Commanditaires/ Exposants dece livret pour consulter le répertoire des exposants et la plan de la salle.
RENSEIGNEMENTS GÉNÉRAUX
CUA 2012 BANFF 23
L'exposition se tiendra dans le salon Van Horne BC selon l'horaire suivant:Dimanche 24 juin: . . . . . . . . . . 0800-1700Lundi 25 juin: . . . . . . . . . . . . . 0800-1530
INTERNET
Un accès internet sans fil gratuit estdisponible au niveau de Centre des Congrèsde l'hôtel. Le mot de passe sera affiché surles écrans LCD.
RESPONSABILITÉ
Le congrès annuel de l'AUC 2012 et le Secrétariat du congrès IS Event Solutions ne peuvent être tenus responsables de tout accident, blessure ou maladie survenant lors du congrès.
OBJETS TROUVÉS
Les objets trouvés devraient être remis rapidement au personnel du bureau d'inscription.
PHOTOGRAPHIES
Des photographies seront prises lors duCongrès annuel et seront affichées en ligne après l'événement.
BUREAU D'INSCRIPTION
Le bureau d'inscription est situé dans lefoyer President's Hall, au centre des congrèsde l'hôtel. Ce dernier est situé en face dubâtiment principal de l'hôtel. Les heuresd'ouverture sont les suivantes:Samedi 23 juin: . . . . . . . . . . . . 1100-1800Dimanche 24 juin: . . . . . . . . . . 0630-1700Lundi 25 juin: . . . . . . . . . . . . . 0630-1800Mardi 26 juin: . . . . . . . . . . . . . 0630-1630
SALON DES CONFÉRENCIERS Salle : NR Crump
Tous les présentateurs ayant diapositives ou vidéos doivent se présenter au Salon des conférenciers, 24 heures avant leurprésentation.Samedi 23 juin . . . . . . . . . . . . . 1300-1800Dimanche 24 juin. . . . . . . . . . . 0630-1730Lundi 25 juin . . . . . . . . . . . . . . 0630-1700Mardi 26 juin . . . . . . . . . . . . . . 0630-1600
Les conférenciers sont priés d'apporter leurs fichiers sur des dispositifs courant de stockage de données (clés USB, cartemémoire flash, DC, etc.) au moins 24 heuresavant leur présentation. Un technicien serasur place en tout temps. L'utilisation duportable personnel est interdit.
POSTERS NON-MODÉRÉS
Cette année, les posters non-modérésseront présentés en format ''en-ligne''.Plusieurs stations seront disponibles dans le foyer du Président's Hall à partir du 0930,dimanche le 24 juin , jusqu'au mardi 26 juin 1400.
POSTERS 5-ÉTOILES
Les modérateurs des séances de postersmodérés sélectionneront des affiches 5-étoiles de chaque session de postersmodérés. Les présentateurs d'affiches 5-étoiles seront annoncés dans la séance de clôture à 1600, mardi le 26 juin.
RENSEIGNEMENTS GÉNÉRAUX
24 CUA 2012 BANFF
OBJECTIFL’objectif du programme est d’offrir un forumd’échange qui permette d’identifier les toutesdernières données sur les maladies urologiques,notamment sur le diagnostic et les traitementspréventifs, et de s’assurer que les urologues etd’autres professionnels de la santé soutiennent la science fondamentale et la recherche clinique.
OBJECTIFS D’APPRENTISSAGEET RÔLE, COMPÉTENCES ET OBJECTIFS DE CanMEDS1 Identifier les modifications aux protocoles de
traitement par ondes de choc SWL afin d’enmaximiser l’efficacité et de réduire la morbidité.
2 Déterminer les techniques destinées à optimiser la planification préopératoire et l’accès rénal percutané peropératoire.
3 Discuter des études épidémiologiques pertinentes sur la sécurité des patients.
4 Examiner les complications liées à la gestiondes services médicaux dans le cas d’unenéphrite, notamment les interactions médicamenteuses et les effets secondaires.
5 Comprendre la méthodologie utilisée pouranalyser la documentation étayant les recommandations de reconstruction urétrale.
6 Mieux comprendre le traitement des problèmes de distraction urétrale d’une fracture du bassin (PFUDD).
7 Discuter du diagnostic et du traitement des lésions génitales communes.
8 Mieux comprendre les différences régionalesdans les modèles de pratiques et les résultatsd’une cystectomie radicale.
9 Déterminer les effets secondaires à long termede la chimiothérapie pour le cancer des testicules.
10 Effectuer une évaluation critique des stratégiesde traitement du cancer superficiel de la vessie.
11Mieux comprendre la morbidité relative à lacystectomie et les solutions autres que lachirurgie pour traiter le cancer de la vessie.
12 Discuter des règles et modes d’application concernant l’alimentation et les supplémentspour les hommes.
13 Discuter des études cliniques qui appuient ounon les recommandations prônant un changement de régime alimentaire et l’apportde suppléments pour les patients.
14 Comprendre comment les risques éventuels(effets secondaires ou complications) d’une in-tervention médicale et chirurgicale dans le cas
d’une hypertrophie bénigne de la prostate permettent au patient de prendre une décision.
15Mieux connaître la façon de prévenir les infections des voies urinaires inférieures (LUTS)par une meilleure hygiène de vie.
16 Savoir que les incidences financières à longterme de la gestion médicale et chirurgicaled’une hypertrophie bénigne de la prostate n’influent pas sur les décisions actuelles.
17 Comprendre les problèmes de santé dont souffriront plus tard les hommes présentantune infertilité (risque plus élevé de cancer, etc.)
18 Connaître les aspects techniques des interven-tions de fronde qui peuvent être intégrées àl’arsenal chirurgical.
19 Élaborer un plan rationnel et efficace d’évaluation et de traitement des patients plusâgés souffrant de symptômes associés à unehyperactivité vésicale (OAB).
20 Corréler les résultats cliniques du reflux urinaire vésico-urétéral (VUR) à sa base génétique.
21 Examiner les preuves en faveur ou contre l’utilisation du 5-ARI pour prévenir le cancer de la prostate.
22Mieux comprendre la nécessité d’intervenir et la survie d’une cohorte de patients sous surveillance active en raison d’un cancer de la prostate à faible risque
23 Évaluer la gestion de pointe du CRCP, à la foisses lignes directrices et les nouveaux agentsqui seront disponibles dans un avenir rapproché.
24 Évaluer le soutien scientifique actuel concernant l’utilisation des PDE5i dans le casde BPH/LUTS.
25Discuter de questions d’éthique dans l’application de ces concepts au niveau chirurgical et professionnel.
CRÉDITS DE FORMATION MDCCe programme est agréé par la AUC en tantqu'activité de la section 1 (formation collective)comme défini par le Programme de maintien du certificat du Collège royal des médecins etchirurgiens du Canada. Pour un médecin spécial-iste, cette activité lui permet d'obtenir un (1) créditpar heure de participation, comme défini dans lasection 1 du Programme de maintien du certificatdu Collège royal des médecins et chirurgiens duCanada, jusqu'à un maximum de 22 crédits. Lesparticipants ne doivent réclamer que les créditscorrespondant à leur participation.
DÉVELOPPEMENT PROFESSIONNEL CONTINU
CUA 2012 BANFF 25
2013 23-25 JUIN
68e AUCNiagara Falls, ONHôtel Sheraton on the Falls
2014 29 JUIN-1 JUILLET
69e AUCSt. John’s, NLDelta St. John’s Hotel & Conference Center
2015 28-30 JUIN
70e AUCOttawa, ONThe Westin Ottawa Hotel
2016 26-28 JUIN
71e AUCVancouver, BCThe Westin Bayshore Hotel
2017 25-27 JUIN
72e AUCToronto, ONWestin Harbour Castle Hotel
CONGRÈS FUTURS DE L'AUC
2015 OTTAWA
2013 NIAGARA FALLS
2014 ST. JOHN’S
2017 TORONTO
2016 VANCOUVER
26 CUA 2012 BANFF
PLAN DU FAIRMONT BANFF SPRINGS HOTEL
CUA 2012 BANFF 27
GRILLE DU PROGRAMME SOCIAL
HEURESPROGRAMME
SOCIALPROGRAMME DES
ACCOMPAGNATEURSPROGRAMME
JEUNESSE
SUNDAY, JUNE 24
0800-1100
Petit-déjeuner & Service de concierge privé
Salon des Accompagnateur : Oak room
1130-1230 Brunch de bienvenue VanHorne BC
1400-2200
Activités, souper et divertissementSalon des enfants :
Norquay room
1900-2230GRANDE SOIRÉE DE L'AUC Rails & Rocheuses
Le Fairmont Banff Springs HotelRiverview Lounge, Alberta & New-Brunswick rooms
MONDAY, JUNE 25
0700-0845Petit-DéjeunerSalon des enfants :
Norquay room
0800-1100Breakfast & Privateconcierge Services
Companion's Lounge: Oak room
0845-1630Activités
Club des Jeunes du Banff Springs Hotel
1630-2300
Activités amusantes,souper et divertissement
Salon des enfants : Norquay room
1900-2300Réception et banquet du Président
Le bal de feu et de glace / RÉCEPTION À 18:30Le Fairmont Banff Springs Hotel / Alberta room
TUESDAY, JUNE 26
0630-0730Course et marche amicale
au profit de la FBAUCLobby The Fairmont Banff Springs Hotel
0700-0845Petit-DéjeunerSalon des enfants :
Norquay room
0800-1100
Petit-déjeuner & Service de concierge privé
Salon des Accompagnateur : Oak room
0845-1630Activités
Club des Jeunes du Banff Springs Hotel
28 CUA 2012 BANFF
Tous les événements sociaux sont parbillet d'admission / badge d'inscriptionseulement. Les billets additionnels pourdes événements sociaux sontdisponibles à l'achat au bureau d'enregistrement.
DIMANCHE 24 JUIN
1130-1230 Brunch de bienvenueSalle d'exposition - VanHorne BC
Compris dans toutes les catégoriesd'inscription
Partez du bon pied en démarrant l'AUC2012 par un brunch de bienvenue dansle hall d'exposition. Retrouvez les amisque vous n'avez pas vu depuis ledernier congrès annuel de l'AUC àMontréal, et préparez-vous à passertrois jours stimulants remplis desdernières nouveautés scientifiques.
1900-2230 Grande Soirée de l'AUC –Rails & RocheusesLe Fairmont Banff Springs HotelRiverview Lounge, salles Alberta & New Brunswick
Inclus dans le programme complet etpour les accompagnateurs inscrits.Prix d'un billet supplémentaire : $125, plus tax
Tout le monde à bord! Pour la première fois dans l’histoire descongrès de l’AUC, la Grande Soirée auralieu le dimanche soir, après la fermeturedu hall des exposants et la fin des
séances scientifiques. Nous prévoyonsque de nombreux membres de l'AUC etpartenaires de l'industrie répondront ànotre invitation.
Festoyez, dansez et revivez l’âge d’or des Rocheuses canadiennes augrandiose hôtel Banff Springs, pendantque l’orchestre Livin’ in Swing vous fera revivre le bon vieux temps! Cetensemble de six musiciens vous feradanser toute la nuit sur des airs deswing et une variété d’autres styles. Ce groupe plein d’entrain comporteaussi à son répertoire un grand nombrede mélodies que vous vous plairez àfredonner.
Laissez-nous vous faire voyager dans le temps dans un décor branché etdélectez-vous des nombreuses saveursde l’Ouest canadien : miniburgers debison, pâtés de filet de bœuf, saumongrillé sur planche de cèdre… pour n’ennommer que quelques-unes. La soiréepassera sans aucun doute à l'histoiredes congrès de l'AUC, car nous avonsen réserve de nombreuses surprises qui vous tiendront en haleine!
PROGRAMME SOCIAL
CUA 2012 BANFF 29
L U N D I L E 2 5 J U I N
1900-2300 Réception et Banquet du Président - Le bal de feu et de glace de l'AUC(Réception à 1830)Salles Alberta & New BrunswickLe Fairmont Banff Springs Hotel
Inclus dans le programme complet et les accompagnateurs inscrits.Prix du billet supplémentaire :$150, plus tax
Les présidents du Comité d'organisationlocale ont mis sur pied un événementqui intégrera certains éléments de lanature. Laissez-vous emporter par vossens et attendez-vous à… l’inattendu!
Joignez-vous à nous pour saluer etféliciter les présidents du Comité d'or-ganisation locale, les membres duComité scientifique et le président del'AUC, le Dr Michael Chetner, et pour ac-cueillir la nouvelle équipe du congrès de2013 qui se prépare avec enthousiasmeà vous recevoir à Niagara Falls!
Cette année, le cocktail et le banquetprésidentiel, qui comprendront un suc-culent repas à quatre services, vousmèneront dans un univers où l’union dufeu et de la glace engendrera une ex-plosion dont la beauté et le raffinementvous éblouiront.
Messieurs, sortez votre smoking! Mesdames, l'heure est arrivée d'acheterLA fabuleuse robe qui vous rendraépoustouflante!
PROGRAMME SOCIAL
30 CUA 2012 BANFF
M A R D I 2 6 J U I N
0630-0730 Course et marche amicale au profit de la FBAUC
*Un tarif de 50$ s'applique(non-taxable)
Levez-vous tôt pour une matinéesportive! Pour la troisième fois l'AUCtiendra une Marche/Course bénéficeafin de soutenir la Fondation desbourses de l'Association des urologuesdu Canada (FBAUC). Son objectif est de fournir un soutien financier pour effectuer de la recherche en urologie auCanada. Les participants peuvent choisird'effectuer une marche de 2 km ou unecourse amusante de 5 km dans les rues de Banff. Lancez la concurrenceamicale dans ce rassemblement poursoutenir cette importante initiative de l'AUC.
Tous les dons seront remis à la FBAUC.
COURSE ET MARCHE AMICALE AU PROFIT DE LA FBAUC
CUA 2012 BANFF 31
Les frais d'inscription pour les accompagnateurs incluent :1 un cadeau de bienvenue2 accès à la salle d'exposition3 petit déjeuner continental le matin
dans le salon des accompagnateurs4 brunch d'ouverture (dimanche)5 la Grande Soirée de l'AUC
(dimanche)6 ainsi que le banquet présidentiel
(lundi)
SALON DES ACCOMPAGNATEURSSalle: Oak
Les accompagnateurs sont invités àutiliser le Salon des accompagnateurssitué au Fairmont Banff Springs pourrencontrer des amis ainsi que pourprofiter du petit déjeuner continentalquotidien.
Le Salon des accompagnateurs seraouvert les dimanche, lundi et mardi de8h à 11h.
Un concierge privé de l'AUC seraprésent pendant ces heures pour vousaider à rendre votre séjour mémorable.
Information et réservation de visitesguidées seront disponibles sur place.
Si vous êtes intéressés à visiter leréputé Willow Stream Spa de l'hôtelFairmont Banff Springs, nous vousinvitons à communiquer avec leconcierge de l'hôtel situé au Lobbyprincipal.
MARDI 26 JUIN
0630-0730 Course et marche amicale au profit de la FBAUC
*Un tarif de 50$ s'applique(non-taxable)Voir page XXX pour détails
PROGRAMME DES ACCOMPAGNATEURS
32 CUA 2012 BANFF
KIDS’ LOUNGE
Le programme pour les jeunes du congrès2012 sera très spécial! En effet, le FairmontBanff Springs comprend un superbe clubdes jeunes qui sera à la disposition des en-fants des membres de l’AUC lundi et mardi.
Le Club des jeunes du Banff Springs, laplaque tournante des activités pour les jeunes à l’hôtel, sera la principale attractionpour nos jeunes de 6 à 16 ans. Le club offredes activités supervisées par des moniteursenthousiastes. Chaque jour sera une nou-velle aventure et les jeunes recevront tousgratuitement une casquette du Club des jeunes du Banff Springs et un porte-nomavec cordon lors de leur première visite.
Les activités extérieures permettront aux enfants d’acquérir de nouvelles habiletéscomme la navigation, la survie en cas d’urgence et la préparation de nourriture sur feu ouvert. Les activités intérieures comprennent une grande variété de jeux,d’activités de bricolage et d'autres activitéspour amuser les jeunes.
L’inscription au programme pour les jeunes comprend : 1 Trousse de bienvenue
2 Activités à partir de 14 h dimanche auSalon des jeunes (Kids’ Lounge)
3 Petit-déjeuner au Salon des jeunes lundi et mardi
4 Partie de quilles et pizza dimanche soir
5 Souper et cinéma lundi soir
6 Deux journées complètes d'activitéslundi et mardi à l’intérieur et à l’extérieurau Club des jeunes de l’hôtel
7 Dîner et collation lundi et mardi au Club des jeunes de l’hôtel
KIDS’ PROGRAM HOURS
Dimanche 24 juinActivités et jeux au Salon des jeunes ...............................14:00-23:00
Le Salon des jeunes comprend des jeux surconsole Wii, des activités de bricolage et desjeux de société. Les activités sont superviséespendant les heures d'ouverture du salon.
Lundi 25 JuinDéjeuner au Salon des jeunes ..07:00-08:45
Activités au Club des jeunes du Banff Springs Hotel ..............08:45-16:30
Souper & divertissement...........16:30-23:00
Mardi 26 JuinDéjeuner au Salon des jeunes...07:00-08:45
Activités au Club des jeunes du Banff Spring.........................08:45-16:30
SERVICE DE GARDE
Les services de gardiennage sont offerts à16 $ l'heure pour un maximum de deux en-fants et pour un minimum de quatre heuresde service. Les gardiens peuvent s'occuperdes enfants dans la chambre ou ils peuventparticiper à différentes activités à l'intérieurde l'hôtel (baignade, quilles, cinéma, etc.) Le service de concierge peut se charger d'effectuer les réservations. La politiqued'annulation pour ce service est de 24heures.
À noter que les prix sont sujets à changement sans préavis. Veuillez réserver ce service en communi-quant avec le concierge de l'hôtel [email protected] ou en vousprésentant au bureau du concierge situé au Lobby principal de l'hôtel.
PROGRAMME JEUNESSE
CUA 2012 BANFF 33
The members of the CUA would like to acknowledge the following organizations for their generous support for the 67th Annual Meeting.
Their outstanding commitment to urological research and education willbenefit urologists and their patients throughout Canada.
Les membres de l’AUC tiennent à souligner le soutien généreux des laboratoires suivants pour la tenue du 67e Congrès annuel. Leur
implication dans le recherche et la formation en urologie fait bénéficier les urologues et leurs patients dans tout le Canada.
PATRON SPONSORS OF THE CUA /GRANDS COMMANDITAIRES DE L’AUC
CUA 2012 ANNUAL MEETING SPONSORS / COMMANDITAIRES DU CONGRÈS ANNUEL 2012
Platinum Pfizer
GoldAllerganGSK
Janssen OrthoSanofi
Silver Bayer Healthcare
CUA SPONSORS 2012 / COMMANDITAIRES DE L’AUC 2012
34 CUA 2012 BANFF
The Canadian Urological Association Scholarship Foundation (CUASF) was estab-lished in 1973 as a means of supporting promising Canadian urological researchers.
More recently, scholarship funding has also been provided to support internationalurologists to visit Canadian centres of excellence. These scholarships would not be
possible without the generous financial support of our Industry sponsors.
The Canadian Urological Association Scholarship Foundation (CUASF) recognizes thefollowing companies for their generous contributions in 2012 and their ongoing
commitment to fostering high-caliber urological research in Canada.
FRENCH TO COME
PATRON SPONSORS OF THE CUA /GRANDS COMMANDITAIRES DE L’AUC
CUASF 2012 SPONSORS / COMMANDITAIRES DE LA FBAUC 2012
CUA 2012 BANFF 35
PLENARY SESSIONS AND EDUCATIONAL FORA ARE SUPPORTED BY OUR CUA PATRON SPONSORS
PODIUM SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING PLATINUM SPONSOR
MODERATED POSTER SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING GOLD SPONSORS
AllerganGSK
Janssen Orthosanofi
UNMODERATED POSTER SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING SILVER SPONSOR
Bayer Healthcare
SPONSORED SESSIONS / SÉANCES COMMANDITÉES
36 CUA 2012 BANFF
EXHIBIT HALL LOCATION
The Exhibit Hall is located in the VanHorne Ballroom BC.
EXHIBIT HOURS
Registered exhibitors with badges, will be allowed into the Exhibit Hall 30 minutes before opening and 30minutes after closing.
Sunday, June 24 . . . . . . . . . 0800-1700Monday, June 25 . . . . . . . . 0800-1530
ACTIVITIES IN THE EXHIBIT HALL
Sunday, June 240940-1010Networking Break
1130-1230Opening Brunch
1430-1500Networking BreakLaparoscopic Skills Competition
Monday, June 250950-1020Networking Break
1150-1300Luncheon
1450-1520Networking Break
EXHIBIT INFORMATION / RENSEIGNEMENTS SUR L’EXPOSITION
CUA 2012 BANFF 37
EXHIBIT FLOOR PLAN / PLAN DE L’EXPOSITION
38 CUA 2012 BANFF
Abbott Laboratories. . . . . . . . . . . . . . 24/25
Allergan Canada . . . . . . . . . . . . . . . . 27/32
American Urological Association (AUA) . 63
American Urological Association (AUA) - Western Section . . . Table in Foyer
Amgen Canada Inc. . . . . . . . . . . . . . . 16/17
AMS Canada Inc. . . . . . . . . . . . . . . . . 10/11
AMT Electrosurgery . . . . . . . . . . . . . . . . 15
Anexxa Medical Technologies Inc. . . . . . . 3
Astellas Pharma Canada Inc. . . . . . . 22/23
Baxter . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
BK Medical . . . . . . . . . . . . . . . . . . . . . . . 42
Bladder Cancer Canada. . . . Table in Foyer
Boston Scientific . . . . . . . . . . . . . . . . 53/54
Bracco Imaging Canada . . . . . . . . . . . . . 34
Calmoseptine, Inc. . . . . . . . . Table in Foyer
CAN-AM HIFU . . . . . . . . . . . . . . . . . . . . . 38
Canadian Urological Association (CUA) - Corporate Office . . . . . . . . . . . . . 62
Canadian Urological Association Journal (CUAJ) . . . . . . . . . . . . . . . . . . . . 62
Clarion Medical Technologies . . . . . . 44/45
Coloplast Canada . . . . . . . . . . . . . . . 30/31
Cook Medical . . . . . . . . . . . . . . . . . . . . 1/2
Covidien . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Ethicon . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Ethicon Endo-Surgery . . . . . . . . . . . . . . 20
European Association of Urology (EAU) . 65
Ferring Pharmaceuticals . . . . . . . . . . . . 41
Fibertech Canada E.R. Inc. . . . . . . . . . . . 26
GlaxoSmithKline . . . . . . . . . . . . . 40/51/52
Jac-Cell Medic Inc. . . . . . . . . . . . . . . . . . 35
Janssen Inc. . . . . . . . . . . . . . . . . . . . . . . 18
Karl Storz Endoscopy Canada . . . . . . 46/47
Kidney Cancer Canada . . . . Table in Foyer
Laborie Medical . . . . . . . . . . . . . . . . . . . 33
Eli Lilly Canada . . . . . . . . . . . . . . . . . 59/60
mdBriefCase Inc. . . . . . . . . . Table in Foyer
Mediwatch USA Inc. . . . . . . . . . . . . . . . . 36
Medtronic of Canada Ltd. . . . . . . . . . . . . 12
Minogue Medical Inc. . . . . . . . . . . . . . . . 39
Novartis Oncology . . . . . . . . . . . . . . . . . 29
Olympus Canada Inc. . . . . . . . . . . . . . . 8/9
Paladin Labs Inc. . . . . . . . . . . . . . . . . . . 4/5
Pendopharm. . . . . . . . . . . . . . . . . . . . . . . 7
Pfizer Canada Inc. . . . . . . . . . . . . . . . 48/50
Prostate Cancer Canada . . . Table in Foyer
Red Leaf Medical Inc. . . . . . . . . . . . . . . . 21
Royal College of Physicians and Surgeons of Canada . . . Table in Foyer
sanofi aventis Canada Inc. . . . . . . . . . . . 43
Science and Medicine . . . . . Table in Foyer
SeeMore Imaging Canada . . . . . . . . . . . 66
Siemens . . . . . . . . . . . . . . . . . . . . . . . . . 13
Société internationale d'urologie (SIU). . 64
Thunder Bay Regional Health Sciences Centre . . . . . . . . . . . . . . . . . . . 67
Triton Pharma Inc . . . . . . . . . . . . . . . . . . 37
Ultramed Inc. . . . . . . . . . . . . . . . . . . . . . 61
Urology Nurses of Canada . . Table in Foyer
Vantage Endoscopy . . . . . . . . . . . . . . . . 14
Warnex Medical Laboratories. . . . . . . . . 56
Watson Pharma Company. . . . . . . . . 57/58
EXHIBITOR LISTING / LISTE DES EXPOSANTS
CUA 2012 BANFF 39
ABBOTT LABORATORIESBooths / Kiosques : 24/25
Contact: Mike Tweedle8401 TransCanada HighwaySt. Laurent, QC, H4S 1Z1T: 705-733-4466F: 514-832-7837E: [email protected]
AndroGel once daily provides provenefficacy for hypogonadism in a clearodourless gel.
Lupron has been helping prostate cancerpatients for 25 years.
AndroGel est un gel transparent et sansodeur qui a l'efficacité éprouvée dansl'hypogonadisme.
Lupron aide les patients atteint de cancerde la prostate depuis 25 ans.
ALLERGAN CANADABooths / Kiosques : 27/32
Contact: Geoff Morrow500-85 Enterprise Blvd.Markham, ON, L6G 0B5T: 905-940-7020F: 416-606-7198E: [email protected]
Allergan Canada is proud to bring Botox(onabotulinumtoxin A) to CanadianUrologists for treatment of UrinaryIncontinence due to Neurogenic DetrusorOveractivity resulting from Neurogenicbladder associated with Multiple Sclerosisor subcervical spinal cord injury in adultswho had an inadequate response to or areintolerant of anticholinergic medications.
AMERICAN UROLOGICAL ASSOCIATION (AUA)
Booth / Kiosque : 63Contact: Caroline Williams1000 Corporate Boulevard Linthicum, MD 21090, United States T: 410-689-3933F: 410-689-3939E: [email protected]
The American Urological Association(AUA), founded in 1902, works towardsthe advancement of urologic patient care,and ensures that its more than 18,000members are current on the latestresearch and practices in urology. TheAUA also pursues its mission of fosteringthe highest standards of urologic care byproviding a wide range of services—including publications, research, theAnnual Meeting, continuing medicaleducation (CME) and the formulation of health policy.
L'Association Urologique Américaine(AUA), fondée en 1902, travaille versl'avancement de soin patient urologique et s’assure que ses plus de 18,000membres sont actuels sur la dernièrerecherche et les pratiques dans l'urologie.L'AUA poursuit aussi sa missiond'encourager les plus hautes normes desoin urologique en fournissant une largegamme de services en incluant despublications, la recherche, la RéunionAnnuelle, l'éducation médicale continuée(CME) et la formulation de politique de santé.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
40 CUA 2012 BANFF
AMERICAN UROLOGICAL ASSOCIATION (AUA) - WESTERN SECTION
Table in FoyerContact: Teri Sechler1950 Old Tustin AvenueSanta Ana, CA, 92705, United StatesT: 714-550-9155F: 714-550-9234E: [email protected]
The Western Section AUA invites CUAmembers to join us October 7-12, 2012on the Big Island of Hawaii at themagnificent Hilton Waikoloa Hotel for our88th Annual Meeting. Please visit ourwebsite at 2012meeting.wsaua.org for all the meeting details. We look forward to seeing you in Hawaii!
AMGEN CANADA INC.Booths / Kiosques : 16/17
Contact: James Austin6775 Financial Dr., Suite 100Mississauga, ON, L5N 0A4 T: 905-285-3215F: 905-286-4991 E: [email protected]
Amgen, a biotechnology pioneer,discovers, develops and deliversinnovative human therapeutics. Ourmedicines have helped millions of patientsin the fight against cancer, kidney disease,rheumatoid arthritis and other seriousillnesses. With a deep and broad pipelineof potential new medicines, we continueto advance science to serve patients.
Amgen, pionnière en biotechnologie,découvre, élabore et distribue destraitements novateurs. Nos médicamentsont aidé des millions des patients àcombattre le cancer, les maladies rénales,la polyarthrite rhumatoïde et d’autresmaladies graves. Nantis d’une solidepépinière de produits, nous faisonsavancer la science pour toujours mieuxservir les patients.
AMS CANADA INC.Booths / Kiosques : 10/11
Contact: Lisa Cribb381 Elmira Rd. N., Unit #1 Guelph, ON, N1K 1H3T: 800-265-2611F: 519-821-1356E: [email protected]
AMS is the world's leading independentcompany focused on developing,manufacturing and marketing medicaldevices that restore pelvic health. We arecommitted to serving the increasingnumber of people coping with male andfemale incontinence, erectile dysfunction,prostate disorders, urethral strictures andother pelvic floor conditions includingprolapse.
AMS est le leader mondial pour lafabrication et la mise en marché dedispositifs médicaux pour la SantéPelvienne. Nous sommes engagés à servir le nombre croissant d'hommes etde femmes aux prises avec l'incontinence, la dysfonction érectile, les troubles de laprostate, le rétrécissement urétral et lesautres conditions pelviennes incluant lesprolapsus.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 41
AMT ELECTROSURGERYBooth / Kiosque : 15
20 Steckle Place, Unit 16Kitchener, ON, N2E 2C3T: 888-803-6799 F: 519-895-2299E: [email protected]
AMT Electrosurgery is focused onproviding our customers with surgicalsolutions that optimize patient safety,clinical performance, ease of use and cost effectiveness in Electrosurgery,Laparoscopic Surgery and Cyrotherapy.
AMT Electrosurgery vise à fournir à nosclients des solutions chirurgicales quioptimisent la sécurité des patients, laperformance clinique, la facilitéd'utilisation et la rentabilité dans lesdomaines d’électrochirurgie, la chirurgielaparoscopique et cyrothérapierapy.
ANEXXA MEDICAL TECHNOLOGIES INC.
Booth / Kiosque : 3Contact: Jean Catafard13-5115 Harvester Rd. Burlington, ON, L7L 0A3T: 905-333-1557F: 888-234-2063E: [email protected]
Anexxa will showcase new andunprecedented technology at CUA. Zephyr,an Artificial Urinary Sphincter, the firstnew artificial sphincter in over a decade.Axogen creates the first nerve Allograft to the medical area. Medafor, a uniquehemostatic agent and Cuda, a powerfulcordless headlight. Come by and seewhat’s new!
Anexxa présentera des nouvellestechnologies sans précédent à l'AUC.Zephyr, un sphincter urinaire artificiel, le premier depuis plus d’une décennie.AxoGen, une matrice pour la régénerationdes nerfs. Arista, un agent hémostatiqueunique à base de plante et finalementCuda, une lampe frontale sans corde. On vous attends!
ASTELLAS PHARMA CANADA INC.
Booths / Kiosques : 22/23Contact: Neil Sarin675 Cochrane Drive, Suite 500, West TowerMarkham, ON, L3R 0B8T: 905-470-7990F: 905-470-2538E: [email protected]
Astellas Pharma Canada Inc. is committedto improving patient’s lives. In addition tooffering Vesicare (solifenacin succinate)for overactive bladder Astellas continuesits commitment to add value throughresearch, innovation and partnerships in Urology and Uro-Oncology.
Astellas Pharma Canada, Inc. estdéterminée à améliorer la vie despatients. En plus de proposer Vesicare(succinate de solifénacine) pour letraitement de l'hyperactivité vésicale,Astellas poursuit son engagement àapporter une valeur ajoutée par le biais de la recherche, de l'innovation et departenariats tant en urologie qu'en uro-oncologie.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
42 CUA 2012 BANFF
BAXTERBooth / Kiosque : 28
Contact: Gordon Blair7125 Mississauga RoadMississauga, ON, L5N 0C2T: 905-369-6791F: 905-659-5398E: [email protected]
In Canada, Baxter BioSurgery provides acomplete portfolio of surgical sealants thatcan be used to achieve haemostasis, sealor glue tissues, and support woundhealing. The core products of theBioSurgery portfolio are TISSEEL VH/SD,Floseal and CoSeal. They have a longtrack record in terms of safety andefficacy and are supported by anextensive number of clinical studies.
La division Biochirurgie de Baxter offre une gamme complète d’agenthémostatique, de scellant, de colle avecdes facteurs de croissance qui favorisentla guérison des plaies. Les principauxproduits de biochirurgie sont Floseal,Tisseel et Coseal. Nous possédons toutesles données cliniques prouvant leurefficacité et la sécurité des produits.
BAYER, INC.Booth / Kiosque : 55
Contact: Jodi Benowski77 Belfield RoadToronto, ON, M9W 1G6T: 416-240-5338F: 416-248-8072E: [email protected]
As an inventor company, Bayer createsinnovative products, breakthroughtreatments and healthier alternatives toimprove the quality of life for people,
animals and communities. We put scienceto work in the vital areas of health,nutrition and high-tech materials, bothacross Canada and around the world.
Entreprise innovatrice, Bayer crée des produits novateurs, traitementsrévolutionnaires et solutions saines quiaméliorent la vie des gens, des animauxet des communautés. Nous mettons lascience à profit dans les domaines de lasanté, de la nutrition et des matériaux dehaute technologie, au Canada et ailleursdans le monde.
BK MEDICALBooth / Kiosque : 42
Contact: Natacha Treskin8 Centennial DrivePeabody, MA 01960, United StatesT: 978-326-1300F: 978-326-1399E: [email protected]
BK Medical’s Flex Focus 800 Ultrasoundsystem featuring Quantum Technology istailored for the Surgical Suite. It islightweight and mobile and supports awide range of sterilizable transducers, and can be battery powered.
Le système à ultrasons, Flex Focus 800 deBK médical est doté de la technologiequantique et est adapté pour les Suites deChirurgie. Il est léger, mobile et prend encharge un large éventail de sondesstérilisables. Le système est autonome,alimenté par piles.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 43
BLADDER CANCER CANADATable in Foyer
Contact: David Guttman21 Jason CrescentGeorgetown, ON, L7G 4Z3T: 416-571-0016E: [email protected]
Bladder Cancer Canada is a nationalorganization helping bladder cancerpatients and their support team. We raise awareness of bladder cancer andadvocate for allocation of government and private funds directed to medicalresearch. Canadian Bladder CancerNetwork is our research group comprisedof leading Canadian researchers.
Cancer de la Vessie Canada est unorganisme national qui aide les patientsatteints de cancer de la vessie et leuréquipe de soutien. Nous voulonssensibiliser les gens pour le cancer de la vessie et plaidons pour l’allocation des fonds publics et privés destinés à la recherche médicale dans ce domaine.Réseau canadien du cancer de la vessieest notre groupe de recherche composéd’éminents chercheurs canadiens.
BOSTON SCIENTIFICBooths / Kiosques : 53/54
Contact: Kristin Muzylo500-5060 Spectrum Way Mississauga, ON, L4W 5N5 T: 905-696-1947F: 905-696-1893E: [email protected]
Boston Scientific’s mission: improvequality of patient care and productivity ofhealth care delivery through developmentand advocacy of less-invasive medical
devices and procedures. This isaccomplished through continuingrefinement of existing products andprocedures and investigation anddevelopment of technologies that reduce risk, trauma, cost, procedure time & aftercare.
Notre mission : l’amélioration de la qualitédes soins cliniques et de la productivité del’administration des soins par promotionet la défense de méthodes et dispositifsmédicaux moins invasifs. Tout cela estatteint grâce à un perfectionnementcontinuel des produits et méthodesexistants par recherche ainsi q’te parla de nouvelles technologies réduisant lesrisques, traumatismes, coûts, durée desinterventions et nécessité de suivi.
BRACCO IMAGING CANADABooth / Kiosque : 34
Contact: Hélène Potier 11065 boul. Louis-H. LafontaineAnjou, QC, H1J 2Z4 T: 800-465-5820, x 5308F: 514-807-9499E: [email protected]
BRACCO IMAGING Canada, located inMontréal, is a member of the BraccoGroup, a global leader in the manufactureof contrast agents, medical devices, andinjection systems dedicated to medicalimaging.
At the CUA, BRACCO IMAGING Canada will be presenting Invivo’s DynaCAD forProstate, a digital imaging system with a comprehensive set of advancevisualization tools for performing real-time
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
44 CUA 2012 BANFF
image analysis of prostate MRI studiesand precise biopsy.
BRACCO IMAGING Canada, situé àMontréal, est un membre du GroupeBracco, un leader mondial dans lafabrication d’agents de contraste,instruments médicaux, et systèmesd’injection dédiés à l’imagerie médicale.Au congrès de l’AUC, BRACCO IMAGINGCanada présentera DynaCAD pourProstate, un système d’imagerie digitalecomportant des outils avancés devisualisation, permettant une analyse entemps réel des images par RésonanceMagnétique de la prostate et des biopsiesprécises.
CALMOSEPTINE, INC.Table in Foyer
Contact: Kim Saeng16602 Burke LaneHuntington Beach, CA 92647, United StatesT: 714-840-3405F: 714-840-9810E: [email protected]
Calmoseptine Inc. promotes CalmoseptineOintment for the prevention and treatmentof skin irritations from moisture such asurinary and fecal incontinence. It is alsoeffective for irritations from perspiration,wound drainage, fecal & vaginal fistulasand feeding tube site leakage.Calmoseptine Ointment temporarilyrelieves discomfort and itching. Free samples at our booth!
Un onguent multifonctionnel agissantcomme barrière contre l'humidité et quiprotège, apaise et aide à favoriser la
guérison de l’irritation de la peau contre:l'urine, la diarrhée, la transpiration, lesécoulements venant d'une fistule ou d'une plaie, l'érythème fessier, les petitesbrulûres, les coupures, les écorchures, les gerçures et les démangeaisons.
CAN-AM HIFUBooth / Kiosque : 38
Contact: Mary Duggan123 Edward St., Suite 1401Toronto, ON, M5G 1E2T: 647-654-1499F: 905-873-1811E: [email protected]
High Intensity Focused Ultrasound (HIFU)is a minimally invasive, outpatientprocedure for men diagnosed withlocalized prostate cancer. The Sonablate®
500 is the medical device that deliversHIFU to the tissues affected by prostatedisease.
CANADIAN UROLOGICAL ASSOCIATION (CUA) - CORPORATE OFFICE
Booth / Kiosque : 62Contact: Raffaella Leroux185 Dorval, Suite 401Dorval, QC, H9S 5J9T: 514-395-0376F: 514-395-1664E: [email protected]
The Canadian Urological Associationrepresents and provides a voice for allCanadian urologists and fostersdedications of all members of theprofession toward ensuring the highestpossible standard of urologic care ofCanadians.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 45
La vocation de l’AUC est de représentertous les urologues canadiens et incitertous les membres de la profession à seconsacrer à l’optimisation de la qualitédes soins urologiques offerts au Canada.
CANADIAN UROLOGICAL ASSOCIATION JOURNAL (CUAJ)
Booth / Kiosque : 62Contact: Joesphine Sciortino185 Dorval, Suite 401Dorval, QC, H9S 5J9T: 514-395-0376F: 514-395-1664E: [email protected]
The Canadian Urological AssociationJournal (CUAJ) is a peer reviewed,indexed journal, specializing in originalscientific publications and selected reviewarticles from Canadian and internationalauthors.
Le Journal de L’Association des urologuesdu Canada (JAUC) est une revuescientifique indexé dans le domaine del’urologie et chaque manuscrit est soumisà un examen critique par les pairs. LeJAUC publie aussi des rapports de cas,des articles de résidents et des articlesd’opinion.
CLARION MEDICAL TECHNOLOGIES
Booths / Kiosques : 44/45125 Fleming Drive Cambridge, ON, N1T 2B8 T: 800-668-5236F: 866-320-7287
Clarion Medical Technologies is one of the leading specialty medical technologyproviders in Canada, offering the mostsophisticated and high performancetechnologies including 100W holmium and980 diode laser systems, and specialtyinstruments for urologic and endourologicapplications. The Clarion product portfoliogives office-based physicians andhospitals the ability to treat a wide rangeof conditions.
Clarion Medical Technologies Inc. est le chef de file des fournisseurs detechnologie médicale spécialisée auCanada, offrant les technologies les plusperfectionnées au rendement supérieur,notamment les appareils Laser Holmiumde 100 watts et Diode 980. Le portefeuillede produits spécialisés de Clarion offreaux praticiens en cabinet ainsi qu'auxhôpitaux la capacité de traiter une vastegamme de conditions médicales enUrologie.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
46 CUA 2012 BANFF
COLOPLAST CANADABooths / Kiosques : 30/31
Contact: Joe Holloway3300 Ridgeway Drive, Unit #12Mississauga, ON, L5L 5Z9 T: 416-578-0427F: 905-820-8218E: [email protected]
Coloplast develops products that make lifeeasier for people with very personal andprivate medical conditions. Within the fieldof urology, Coloplast offers a wide rangeof devices that help people who sufferfrom urinary incontinence and erectiledysfunction.
Coloplast développe des produits etservices qui simplifient la vie despersonnes aux prises avec des problèmesmédicaux intimes et très personnels. Dansle domaine de l’urologie, Coloplast offreune vaste gamme de dispositifs pour aiderles personnes qui souffrent d’incontinenceurinaire et de dysfonction érectile.
COOK MEDICALBooths / Kiosques : 1/2
Contact: Alex Szabo165 Mostar Street Stouffville, ON, L4A 0Y2 T: 905-640-7110F: 905-640-7408E: [email protected]
Cook Group companies develophealthcare devices. We are at the forefront of medical research and product development in minimallyinvasive medical device technology fordiagnostic and therapeutic procedures.
Les sociétés du Groupe Cook effectuent ledéveloppement des dispositifs médicaux.Nous sommes au premier rang de larecherche médicale et du développementdes produits et de la technologie desdispositifs médicaux à effraction minimaleaux fins des interventions diagnostiqueset thérapeutiques.
COVIDIENBooth / Kiosque : 6
Contact: Caroline Robert7300 TransCanada HighwayPointe-Claire, QC, H9R 1C7T: 514-695-1220F: 514-695-2379E: [email protected]
The V-Loc™ Wound Closure Device familyis a revolutionary technology that supportsoptimal patient outcomes by closingwounds securely without the need to tieknots. It has evenly-spaced unidirectionalbarbs throughout the strand which allowsfor a secure closure of the incision. It alsofeatures premium cutting needles withNuCoat technology. The benefits include:distribution of tension throughout thewound, closing wounds up to 50% fasterthan conventional sutures withcomparable holding strength and apotential to reduce knot-relatedcomplications.
Le dispositif de fermeture de plaiesV-LocMC présente une technologierévolutionnaire qui permet d’obtenir desrésultats optimaux grâce à la fermeturede plaies sans nœud. Le dispositifpossède des crans unidirectionnelsuniformément répartis tout le long du filqui permettent de fermer l’incision de
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 47
façon sûre. Il est offert avec des aiguillestranchantes de qualité supérieure dotéede la technologie NuCoat. Ses principauxavantages comprennent la répartition dela tension sur toute la longueur de la plaie,la fermeture de plaies 50 % plus rapideque les sutures traditionnelles pour uneforce de maintien comparable et lepotentiel de réduction des complicationsliées aux nœuds.
ETHICONBooth / Kiosque : 19
Contact: Kendal SinghT: 1-800-642-6748E: [email protected] Info: Ethicon, a division ofJohnson & Johnson Medical Companies
For nearly a century products fromJohnson and Johnson’s MedicalCompanies have been in the hands ofhealthcare practitioners, transforming theirwork and restoring the lives of patientsthey serve. As part of the Surgical CareGroup of Johnson & Johnson, ourcommitment to improving and enhancingthe lives of patients is fully realized whenour products are in the hands of ourcustomers. With a legacy of innovation and industry-leading experience, we’vecreated new ways to care for patients. By understanding the complex ways inwhich materials interact with tissue we’ve created a portfolio of products thatadvance healthcare across the spectrumof medicine. Such products can becategorized into the following productlines, Biosurgery, Sutures & Dermabond.
Ethicon Products est le chef de filemondial des produits et des technologiesde suture. Ses marques sont parmi lesplus reconnues et respectées dans ledomaine hospitalier. Cette division estforte d’une longue tradition d’innovation,notamment en matière de solutions desuture, d’adhésifs topiques et de méchagechirurgical, sans compter qu’elle proposeune gamme complète de produitsd’hémostase chirurgicale.
ETHICON ENDO-SURGERYBooth / Kiosque : 20
Contact: Maria AltomareE: [email protected]
At Ethicon Endo-Surgery, we want totransform patient care through innovation.We believe that advances in surgery andsurgical education, in particular, minimallyinvasive techniques, offer value andimportant advantages for all stakeholders.Our partnerships have proveninstrumental in the design anddevelopment of new surgical productsthat benefit patients, surgeons, andhospitals.
To find out more about how we aretransforming patient care, visitwww.ethiconendosurgery.com
Chez Ethicon Endo-Surgery, nous voulonstransformer les soins aux patients aumoyen de l'innovation. Nous croyons queles percées en matière de chirurgie et deformation chirurgicale, particulièrementen ce qui a trait aux techniques peueffractives, offrent de la valeur et desavantages importants à tous lesintervenants. Nos partenariats ont joué un
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
48 CUA 2012 BANFF
rôle clé dans la conception et l'élaborationde nouveaux produits chirurgicaux quisont avantageux pour les patients, leschirurgiens et les hôpitaux.
Pour en savoir plus sur la façon dont nous transformons les soins aux patients, visitez le sitewww.ethiconendosurgery.com
EUROPEAN ASSOCIATION OF UROLOGY (EAU)
Booth / Kiosque : 65Contact: Angela TerbergMr. E.N. van Kleffensstraat 56842 CV Arnhem, The NetherlandsT: +31 26 3890 680F: +31 26 3890 674E: [email protected]
The European Association of Urology (EAU) represents more than 16,000urology professionals across Europe andworldwide. Its mission is to raise the levelof urological care in Europe. The EAUAnnual Congress is one of the largesturological congresses in the world. Check our website for more information:www.uroweb.org.
FERRING PHARMACEUTICALSBooth / Kiosque : 41
Contact: Stephen Zisis200 Yorkland Blvd., Suite 800North York, ON, M2J 5C1T: 416-490-0121F: 416-493-1692E: [email protected]
Ferring’s FirmagonTM is a first class GnRHantagonist for prostate cancer patients.Learn why Firmagon’s direct mechanismof action with no initial surge providesfaster, more profound and sustained
testosterone control for better cancermanagement.
FirmagonMD de Ferring est le premierantagoniste de la GnRH de sa classe pourles patients atteints de cancer de laprostate. Apprenez pourquoi lemécanisme d’action direct de Firmagonsans élévation initiale du niveau detestostérone permet d’offrir un contrôleplus complet et soutenu pour un meilleurtraitement du cancer.
FIBERTECH CANADA E.R. INC.Booth / Kiosque : 26
Contact: Paul Laborie6513A Mississauga Road N.Mississauga, ON, L5N1A6E: [email protected]
Fibertech Canada E.R. Inc. is now theexclusive Canadian distributor for EDAPExtracorporeal Lithotriptors with ExclusiveIntuitive Localization System technology.In addition, Fibertech provides a widerange of endoscopic services and offersthe Endoboy Surgical Assist Arm.
Fibertech Canada Inc. ER est maintenantle distributeur canadien exclusif pourEDAP Lithotripteurs extracorporelles avecla technologie exclusive de localisationsystème intuitif. En outre, Fibertech offreune vaste gamme de servicesendoscopiques et offre le bras ENDOBOYPneumatique, la troisième main duchirurgien.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 49
GLAXOSMITHKLINEBooths / Kiosques : 40/51/52
Contact: Patricia Gauthier7333 Mississauga RoadMississauga, ON, L5N 6L4T: 905-819-3015E: [email protected]
GlaxoSmithKline (GSK) is a leadingresearch-based pharmaceutical companywith a challenging and inspiring mission:to improve the quality of human life byenabling people to do more, feel better,and live longer. This mission gives GSK thepurpose to develop innovative medicines,vaccines and healthcare solutions thathelp millions of people. GSK is consistently recognized as one ofthe 50 best employers in Canada and is atop 20 investor in Canadian research anddevelopment, contributing more than$100 million in 2011 alone. With a proudtradition of charitable and communitysupport, GSK is designated a CaringCompany by Imagine Canada. Discovermore at www.gsk.ca.
GSK has a strong presence in biologicals,pharmaceuticals and vaccines, with aproduct portfolio that extends across avariety of therapeutic areas and diseasesincluding urology.
GlaxoSmithKline (GSK) est un géantpharmaceutique voué à la recherche dontla mission ambitieuse et édifiante estd’améliorer la qualité de la vie en aidantles gens à être plus actifs, à se sentirmieux et à vivre plus longtemps. De cettemission découle l’objectif de GSK qui estde concevoir des médicaments, desvaccins et des solutions de soins de santé
novateurs qui aident des millions depersonnes. GSK est constammentreconnue comme l’un des 50 employeursde choix au Canada et figure parmi les 20entreprises qui investissent le plus enrecherche et développement au Canada,ayant consacré plus de 100 millions dedollars à ce secteur en 2011 seulement.De plus, grâce à sa fière tradition dephilanthropie et de soutiencommunautaire, GSK a été désignéeSociété généreuse par le programmeImagine Canada.
GSK joue un rôle prépondérant dans lessecteurs des agents biologiques, desspécialités pharmaceutiques et desvaccins; sa gamme de produits vise unlarge éventail de champs thérapeutiqueset de maladies, y compris urologie.www.gsk.ca
JAC-CELL MEDIC INC.Booth / Kiosque : 35
Contact: Mark Meltzer 5764 Pare Street Mont-Royal, QC, H4P 2M2T: 514-731-4567, x 222F: 514-731-0002E: [email protected]
Jac-cell Medic is a leading distributor ofinstruments and accessories for cosmeticsurgery. We provide value and savings onthe highest quality of disposable andreusable products. Breast retractors,microsurgery instruments, precisiondissection needles, cautery pens, salinetransfer kits, aspiration and infiltrationtubing and the lowest prices on silicondrains and reservoirs, including the new“ouchless” 2 in 1 round drains.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
50 CUA 2012 BANFF
Specialists in Fat Grafting equipment with our Autoclavable fat transfersystems, 60cc & 10cc Manual Centrifuge,Fat harvesting Canula and reinjection needles, transfer adaptors…
JANSSEN INC.Booth / Kiosque : 18
Contact: Luis Fernandes19 Green Belt DriveToronto, ON, T3C 1L9T: 416-382-5000F: 416-449-2658E: [email protected]
As a member of the JanssenPharmaceutical Companies of Johnson & Johnson, Janssen Inc. is dedicated toaddressing the most important unmetmedical needs in pain management,psychiatry, oncology, immunology,psoriasis, virology, anemia, attentiondeficit hyperactivity disorder, dementia,gastroenterology and women’s health.Driven by our commitment to thepassionate pursuit of science for thebenefit of patients, we work together to bring innovative ideas, products andservices to patients around the world.
À titre de membre du groupe desentreprises pharmaceutiques Johnson & Johnson, Janssen Inc. s’emploie àrépondre aux besoins non satisfaits lesplus importants dans le domaine de ladouleur, la psychiatrie, l’oncologie,l’immunologie, le psoriasis, la virologie,l’anémie, le trouble déficitaire del’attention avec hyperactivité, la démence,la gastroentérologie et la santé de lafemme. Poussés par notre passion demettre la science au service des patients,
nous collaborons à de nouvelles solutions,produits et services pour le bien despatients dans le monde entier.
KARL STORZ ENDOSCOPYCANADA LTD.
Booths / Kiosques : 46/47Contact: Florian Stegen7171 Millcreek DriveMississauga, ON, L5N 3R3T: 905-816-4500F: 905-816-4599E: [email protected]
Karl Storz Endoscopy Canada is a leaderin Endoscopic equipment and instrumentsthat emphasize visionary design,craftsmanship and clinical effectivenessand facilitate demanding Urologyprocedures.
Karl Storz Endoscopy Canada est unmeneur dans la production d’équipementet d’instruments endoscopiques. Leconcept visionnaire de nos artisans metl'accent sur l'efficacité clinique de tousnos produits avec emphase de facilitervos procédures d’urologie.
KIDNEY CANCER CANADATable in Foyer
Contact: Joan Basiuk27 Bayberry CrescentToronto, ON, M2K 1T9T: 416-223-8001E: [email protected]
Kidney Cancer Canada (KCC) is acharitable patient-led support organizationestablished to improve the quality of lifefor patients living with kidney cancer. KCCadvocates for access to new treatments,provides support and information to
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 51
patients, funds much-needed kidneycancer research, and works to increaseawareness of kidney cancer.
L’Association canadienne du cancer du rein (ACCR) est un organisme debienfaisance créé et dirigé par despatients avec mission d’améliorer laqualité de vie de ceux-ci et de leursproches. L’ACCR milite pour l’accès auxnouveaux traitements, informe et soutientles patients, finance la recherche ettravaille à faire connaître cette forme rare de cancer.
LABORIE MEDICALBooth / Kiosque : 33
Contact: Christine Frewen6415 Northwest Drive, Unit 10 Mississauga, ON, L4V 1X1T: 1-888-522-6743, x 4232F: 450-671-7182E: [email protected]
LABORIE, the worldwide industry leader inUrodynamics, is pleased to provide youwith the most advanced solutions in PelvicFloor Dysfunction Management. LABORIEis committed to bringing you the mostinnovative products: from private officesto world class research institutions, oursolutions are designed to expand withyour practice.
LABORIE, leader mondial de l’urodynamie,vous offre les solutions les plusperformantes dans la gestion desdysfunctions du plancher pelvien.LABORIE s’engage a vous apporter lesproduits les plus innovants: pour votreconsultation privée ou votre centre de
recherche, nos solutions sont conçuespour évoluer avec votre pratique.
ELI LILLY CANADABooths / Kiosques : 59/60
Contact: Monita Chan3650 Danforth Ave.Toronto, ON, M1N 2E8T: 416-693-3790F: 416-699-7234E: [email protected]
Lilly is a leading, innovation-drivenPharmaceutical Corporation committed todeveloping a growing portfolio of best-in-class/first-in-class pharmaceuticalproducts that help people live longer,healthier and more active lives. We arecommitted to providing answers thatmatter through medicines andinformation, for some of the world's most urgent medical needs.
Lilly est une société pharmaceutique depointe axée sur l’innovation qui s’appliqueà développer un portefeuille toujourscroissant de produits pharmaceutiques,parmi les meilleurs et les premiers de leurclasse, afin de permettre aux patients devivre plus longtemps, en meilleure santéet de mener une vie plus active. Lilly estfermement résolue à apporter desréponses qui comptent, sous forme demédicaments et d'informations, à certainsdes impératifs médicaux les plus urgentsdans le monde.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
52 CUA 2012 BANFF
MDBRIEFCASE INC.Table in Foyer
Contact: Janet Kimura20 Eglinton Avenue West, Suite 1300Toronto, ON, M4R 1K8 T: 416-488-5500, x 221F: 416-288-0566E: [email protected]
mdBriefCase Inc. has been the leadingprovider of online continuing education for Canadian health care professionalssince 2002. mdBriefCase creates morethan 100 online learning programsannually in collaboration with leadingexperts, professional societies andacademic institutions for its 85,000+health care professional membership.Programs are offered throughwww.mdBriefCase.com,www.AdvancingIn.com,andwww.rxBriefCase.com.
mdBriefCase Inc. est le principalprestataire de formation médicalecontinue en ligne pour les professionnelsde la santé au Canada depuis 2002.mdBriefCase crée chaque année plus de100 programmes d’apprentissage en ligneen collaboration avec des spécialistes depremier plan, des associationsprofessionnelles et des établissementsd’enseignement à l’intention de sesmembres : plus de 85 000 professionnelsde la santé. Les programmes sont offertspar www.mdBriefCase.com,www.AdvancingIn.com, etwww.rxBriefCase.com.
MEDIWATCH USA INC.Booth / Kiosque : 36
Contact: Nick Darker1501 Northpoint Parkway, Suite 103West Palm Beach, FL 33407, United StatesT: 561-471-2611F: 866-871-8262E: [email protected]
The Mediwatch range of urology & pelvicfloor diagnosis products includes:
Intuitive Sensic urodynamics systems,Encompass anorectal manometry &pudendal stimulation, Portascan+ PVRscanners, Uroval bulbocavernosus reflextesting, Venus pelvic floor rehabilitationand Urodyn+ & Portaflow uroflowmeters.
Ask for more information on any productand a demonstration at our stand.
Mediwatch possède une gamme deproduits servant au diagnostique desproblèmes urinaires et du plancherpelvien : Le système Sensic pourl’urodynamie, Encompass pour lamanométrie rectal et la stimulation du nerf pudendal, Portascan+ PVR, Uroval pour vérifier le réflexebulbocaverneux,Vénus pour laréhabilitation du plancher pelvien etUrodyn+ & Portaflow pour lesdébimétries.
Pour toute autre information oudémonstration, s’il vous plait visiter notre kiosque.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 53
MEDTRONIC OF CANADA LTD.Booth / Kiosque : 12
Contact: Kitty Zanata99 Hereford Street Brampton, ON, L6Y 0R3T: 905-460-3642F: 905-460-3999E: [email protected]
Medtronic is the world’s leading medicaltechnology company offering InterStimtherapy for the management of chronicintractable fecal and urinary incontinence.We offer a simple functional evaluationtest to select patients and a minimallyinvasive implant procedure for the system.Clinical evidence for long term success iswell established. Come to our booth to seehow easy it is to do the peripheral nerveevaluation.
Medtronic est l’entreprise chef mondialeen technologie médicale, offrant lathérapie InterStim pour le traitement del'incontinence fécale et urinaire réfractairechronique. Nous vous offrons un testsimple pour l'évaluation fonctionnellesimple pour aider à sélectionner lespatients et une procédure d'implantminimalement invasive. Les évidencesclinicaux de réussite à long terme sontbien établie pour l'incontinence fécale.Venir nous visiter notre table pour voircomment il est facile de faire l'évaluationdes nerfs périphériques.
MINOGUE MEDICAL INC.Booth / Kiosque : 39
Contact: Danny Minogue 180 Peel Street, Suite #300 Montreal, QC, H3C 2G7 T: 1-800-665-6466F: 514-287-0853E: [email protected]
Minogue Medical Inc. is the exclusiveCanadian distributor of the IntuitiveSurgical da Vinci® Si HD™ SurgicalSystem. The da Vinci® Prostatectomy(dVP) is the fastest growing treatment forprostate cancer today. Other proceduresinclude the da Vinci® Nephrectomy/PartialNephrectomy, Radical Cystectomy, andPyeloplasty. We are also the exclusiveCanadian distributor for Neotract whohave developed the innovative Urolift®
System for treating lower urinary tractsymptoms due to benign prostatichyperplasia (BPH).
Minogue Medical Inc. est le distributeurcanadien exclusif du système chirurgicalda Vinci® Si HD™. La prostatectomie daVinci® (dVP) est le traitement en évolutionle plus rapide pour le cancer de laprostate aujourd’hui. Les autresprocédures incluent la néphrectomie/néphrectomie partielle, cystectomieradicale, et pyeloplastie. Egalement ledistributeur canadien exclusif pourNeotract qui a mis au point le SystèmeUrolift®, une technologie pour letraitement des symptômes du tractusurinaire causé par une hyperplasiebénigne de la prostate.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
54 CUA 2012 BANFF
NOVARTIS ONCOLOGYBooth / Kiosque : 29
Contact: Paule Racine385 Bouchard Blvd.Dorval, QC, H9S 1A9T: 514-631-6775, x 3207F: 514-631-1867E: [email protected]
Novartis Oncology is dedicated toanswering unmet medical needs. Ourpriority is to discover, develop and makebroadly available novel therapies that mayimprove and extend the lives of patients.
Novartis Oncologie se consacre àsatisfaire les besoins médicaux noncomblés. Notre priorité est de découvrir,de mettre au point, et d’offrir à tous destraitements novateurs pouvant amélioreret prolonger la vie des patients.
OLYMPUS CANADA INC.Booths / Kiosques : 8/9
Contact: Roxanne DeAbreu-Breen25 Leek Crescent Richmond Hill, ON, L4B 4B3T: 289-269-0204F: 905-886-7469E: [email protected]
Olympus Canada offers urologists thevision to see and the power to treat withleading edge visualization and best inclass surgical tissue management. Ourleading edge technologies enableurologists to perform a wide range ofprocedures with pinpoint precision andmaximum safety. For more information on our products, please contact OlympusCanada: 1-800-387-0437www.olympuscanada.com
Olympus Canada offre aux urologues lavision et le pouvoir de traiter avec unevisualisation de pointe et une gestion destissus chirurgicaux reconnue commemeilleure dans sa catégorie. Nostechnologies permettent aux urologuesd'effectuer une variété de procédures avechaute précision et sécurité maximale. Pourde plus amples informations sur nos produits,veuillez contacter Olympus Canada : 1-800-387-0437www.olympuscanada.com
PALADIN LABS INC.Booths / Kiosques : 4/5
Contact: Philippe Leblond100 Alexis Nihon Blvd., Suite 600St-Laurent, QC, H4M 2P2T: 514-340-1112 x 5445F: 514-344-4675E: [email protected]
Paladin Labs is a Canadian specialtypharmaceutical company focused onbringing innovative therapies to Canada.Key products include Trelstar (LHRHa),Testim (testosterone gel), and Urocit-K(potassium citrate) in urology. Visit ourbooth to find out more about our products!www.paladinlabs.com
Paladin est une compagniepharmaceutique canadienne avec missiond’apporter des produits pharmaceutiquesspécialisés au Canada. Les produitsprincipaux comprennent Trelstar (LHRHa),Testim (gel de testostérone) et Urocit-K(citrate de potassium) en urologie. Visitez notre kiosque pour en savoir plus sur nosproduits! www.paladinlabs.com
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 55
PENDOPHARMBooth / Kiosque : 7
Contact:6111 Royalmount Ave., Suite 100Montreal, QC, H4P 2T4 T: 514-340-9800F: 514-733-9684
A Strong Focus on Specialty Medicines
PENDOPHARM is a rapidly growing andindependent business that focuses oncommercializing a portfolio of specialtyprescription products and an establishedline of OTC/BTC products.
Strategically committed to growth,PENDOPHARM is actively engaged inlicensing, developing and marketing late-stage prescription products as well as consumer brands.
Axée sur les produits pharmaceutiquesspécialisés
PENDOPHARM est une entreprisepharmaceutique indépendante ayant uneforte croissance et dont les activités decommercialisation se concentrent sur un portefeuille de produits d’ordonnancespécialisés ainsi qu’une gammeimportante et établie de produits offertsen vente libre et derrière le comptoir de la pharmacie.
Engagée par sa stratégie commerciale à prendre de l’expansion, PENDOPHARMtravaille activement pour acquérir deslicences, établir des partenariats ainsi
que réaliser les derniers stages dedéveloppement de médicamentsd’ordonnance spécialisés et de produitsdestinés aux consommateurs, afin de lescommercialiser.
PFIZER CANADA INC.Booths / Kiosques : 48/50
Contact: Karen Southin17300 TransCanada HighwayKirkland, QC, H9J 2M5T: 514-426-7549E: [email protected]
Pfizer Canada Inc. is the Canadianoperation of Pfizer Inc, the world's leadingbiopharmaceutical company. Pfizerdiscovers, develops, manufactures andmarkets prescription medicines forhumans and animals. At Pfizer, we'reworking together for a healthier world. For more information, visit www.pfizer.ca
Pfizer Canada inc. est la filiale canadiennede Pfizer Inc., première entreprisepharmaceutique à l'échelle mondiale.Pfizer découvre, met au point, fabrique et commercialise des médicamentsd’ordonnance pour les humains et lesanimaux. Chez Pfizer, nous bâtissonsensemble un monde en meilleure santé.Pour en savoir plus, visitez le sitewww.pfizer.ca
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
56 CUA 2012 BANFF
PROSTATE CANCER CANADATable in Foyer
Contact: Katherine patterson 2 Lombard Street, 3rd FloorToronto, ON, M5C 1M1T: 416-441-2131E: [email protected]
Prostate Cancer Canada is the onlynational foundation dedicated to theelimination of the disease throughresearch, education support andawareness.
Our goals are twofold – to fund researchthat will uncover better diagnostic andtreatment options and to providecomprehensive support services for thoseliving with prostate cancer.
Cancer de la Prostate Canada est la seulefoundation nationale vouée à l’éliminationde la maladie par la recherche, soutien àl’éducation et la sensibilisation.
Nos objectfs sont de deux ordres – pourfinancer la recherche qui va découvrir desmeilleures façons de diagnostiquer et lesoptions de traitement et de fournir desservices de soutien complets pour lespersonnes vivant avec le cancer de laprostate.
RED LEAF MEDICAL INC.Booth / Kiosque : 21
Contact: Charles Ko4055 Sladeview Crescent, Unit 12 Mississauga, ON, L5L 5Y1 T: 905-569-7771F: 905-569-7778E: [email protected]
Red Leaf Medical Inc. is a provider
of premier medical products to help patients get the most out of life every day. The Company is rapidly growing and specializes in the acquisition,development and commercialization ofinnovative medical devices in the field of urology.
Red Leaf Medical Inc. est un fournisseurde produits médicaux de premier planpour aider les patients à mieux profiter de la vie chaque jour. La société, dont la croissance est rapide, se spécialisedans l'acquisition, le développement et la commercialisation d'instrumentsmédicaux novateurs dans le domaine de l'urologie.
ROYAL COLLEGE OF PHYSICIANSAND SURGEONS OF CANADA
Table in FoyerContact: Sandra Canniff774 Echo DriveOttawa, ON, K1S 5N8 T: 613-730-6243F: 613-730-2410E: [email protected]
The Royal College sets the higheststandards for specialty medical educationin Canada. At the same time, we supportlifelong learning for specialist physiciansand promote sound health policy.
Le Collège royal établit les normes lesplus élevées qui soient en formationmédicale spécialisée au Canada.Parallèlement, nous soutenonsl'apprentissage continu des médecinsspécialistes et faisons la promotion depolitiques de santé réfléchies.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 57
SANOFI AVENTIS CANADA INC.Booth / Kiosque : 43
Contact:2150 St. Elzear Blvd. WestLaval, QC, H7L 4A8T: 514-331-92201-800-363-6364 (general enquiries);1-800-265-7927 (customer service)
As a leading healthcare partner weprovide, and are developing, innovativemedicines for treatments in severaltherapeutic areas: cardiovascular disease,thrombosis, oncology, metabolicdisorders, the central nervous system, andinternal medicine. We also play a role byinvesting in activities that improve healthand quality of life in our communities.
Partenaire de premier plan du secteur dela santé, nous fournissons et mettons aupoint des médicaments innovants dansdes domaines thérapeutiques variés : lacardiologie, la thrombose, le systèmenerveux central, l’oncologie, les maladiesmétaboliques et la médecine interne.Nous investissons aussi dans des activitésqui améliorent la santé et la qualité de viedans les collectivités où nous sommesimplantés.
SCIENCE AND MEDICINE CANADATable in Foyer
Contact: Gary Browne120 East Beaver Creek Road, Suite 315Richmond Hill, ON, L4B 4V1T: 905-762-0772, x 304F: 905-762-0776E: [email protected]
Science & Medicine Canada (SMC) is aToronto-based continuing healtheducation (CHE) agency with over 20
years of experience in urology/uro-oncology and demonstrated excellence inmedical education. The CanadianUrological Association has recentlypartnered with SMC to develop andprovide urology-related CHE to healthcareproviders across Canada.
Science & Medicine Canada (SMC) est uneagence basée à Toronto offrant de laformation médicale continue (FMC).Possédant plus de 20 annéesd’expérience, elle a fait preuved’excellence en formation médicale dansles domaines de l’urologie et del’uro‑oncologie. L’Association desurologues du Canada (AUC) s'estrécemment associée à SMC pour mettresur pied et fournir des activités de FMC enlien avec l'urologie aux fournisseurs desoins de santé partout au Canada.
SEEMORE IMAGING CANADABooth / Kiosque : 66
Contact: Jane Timmis4099 Burkehill RoadWest Vancouver, BC, V7V 3L9T: 604-922-0874F: 604-922-0875E: [email protected]
SeeMore USB ultrasound probes areaffordable & application-specific -abdominal, endocavity, vascular access,MSK, and regional nerve block. Thesystem is compatible with most laptop,netbook & tablet computers runningWindows; all software is included and canbe downloaded to any number ofcomputers – the ultimate in portability.www.seemore.ca
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
58 CUA 2012 BANFF
SIEMENSBooth / Kiosque : 13
Contact: Richard Newman6865 Century Ave., Suite 3001Mississauga, ON, L5N 2E2T: 416-786-1949F: 905-593-4602E: [email protected]
For 100 years the innovative ideas fromSiemens have helped make Canada abetter place. From the Atlantic to Pacificoceans, more than 4,400 employees inCanada work together to provide answersthat last in the fields of industry, energyand healthcare, as well as deliverinfrastructure solutions for cities. Since it was federally chartered in Augustof 1912, Siemens has stood for technicalachievements, innovation, quality andreliability. Sales for Siemens in Canada infiscal 2011 (ended September 30), were$3.0 billion CAD. The company has 61offices and 13 manufacturing/assemblyfacilities across Canada. Furtherinformation is available atwww.siemens.ca.
Depuis 100 ans, les idées novatrices deSiemens contribuent à la qualité de vie auCanada. De l’Atlantique au Pacifique, plusde 4 400 employés travaillent ensembleau Canada pour apporter des réponsesdans les domaines de l’industrie, del’énergie et de la santé, tout en proposantdes solutions pour les infrastructuresurbaines. Depuis qu’elle a obtenu sacharte fédérale en août 1912, Siemens estsynonyme de réalisations techniques,d’innovation, de qualité et de fiabilité. Lesventes de Siemens Canada pour l’exercicefinancier 2011 (qui a pris fin le 30
septembre) s’élevaient à 3 milliards dedollars canadiens. La compagnie exploite61 bureaux et 13 usines au Canada. Pouren savoir davantage, consultez le sitewww.siemens.ca.
SOCIÉTÉ INTERNATIONALED'UROLOGIE (SIU)
Booth / Kiosque : 64Contact: 1155 University, Suite 1155Montreal, QC, H3B 3A7T: 514-875-5665F: 514-875-0205E: [email protected]
The SIU is an international professionalorganization serving urologists and actingas a platform for sustainable urologicaleducation and collaborative humanitarianactivities to improve urological careworldwide.
Visit our booth for details on SIU 2012 inFukuoka, Japan, September 30-October 4,and our 2013 Congress in Vancouver,October 20-24!
La SIU est une organisation internationaleprofessionnelle au service des urologues,une tribune servant à l’education continueet au développement de projetshumanitaires pour l’amélioration et leperfectionnement des soins urologiques à travers le monde.
Visitez notre stand pour obtenir plus dedétails sur les prochains congrès de laSIU, à Fukuoka au Japon, du 30Septembre au 4 octobre 2012 et àVancouver, du 20 au 24 octobre 2013!
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 59
THUNDER BAY REGIONALHEALTH SCIENCES CENTRE
Booth / Kiosque : 67Contact: Linda Molenda980 Oliver RoadThunder Bay, ON, P7B 6V4 T: 807-684-6028F: 807-684-5893E: [email protected]
Thunder Bay Regional Health SciencesCentre (TBRHSC) is recruiting a full timeUrologist. TBRHSC is a state-of-the-artAcademic Health Sciences Centre, with375 acute care beds, providing regionalservices to a population base of 250,000people. We are the Regional Trauma and Cancer Referral Centre(s) forNorthwestern Ontario, and are affiliatedwith the Northern Ontario School ofMedicine (NOSM) and the Thunder BayRegional Research Institute (TBRRI).
TRITON PHARMA INC.Booth / Kiosque : 37
Contact: Robert Ohayon1001, de Maisonneuve Blvd. West, Room #940Montreal, QC, H3A 3C8 T: 514-288-0333, x 22F: 514-288-5397E: [email protected]
Privately held - President: Sybil Dahan
Operational as of January 2005
Markets several products with particularfocus on women’s health
- Vaniqa: unwanted facial hair- Enablex: overactive bladder- Oesclim Patch: estrogen TD therapy- Bellergal Spacetabs: non-hormonal
treatment of menopause- Estragyn Vaginal Cream: atrophic
vaginitis
Dermatology:
- Topiderm HC 2% cream: dermatoses- Dermaflex-20 cream: urea cream- Dermaflex HC 1% cream & lotion:
urea & hydrocortisone 1%
Q-Urol: Natural Health Product: chronicpelvic pain syndrome (CPPS)
Cysta-Q: Natural Health: painful bladdersyndrome/interstitial cystitis
Website: www.tritonpharma.ca
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
60 CUA 2012 BANFF
ULTRAMED INC.Booth / Kiosque : 61
Contact: 50 Steeles Avenue East, Suite 15Milton, ON, L9T 4W9T: 905-878-4400F: 905-878-5044E: [email protected]
Ultramed Inc. is pleased to exhibit thefinest quality equipment for members.
R. Wolf Endoscopy, Downs Surgical handheld instruments, PNN (Wallsten) BalloonAblation, Uroplasty Urinary Incontinenceand Wallach Diagnostic and TherapeuticGynaecology equipment are just some ofthe superior products we have availablefor no charge trial and evaluation.
Ultramed Inc. est heureuse de présenterson matériel de la plus grande qualité àvos membres.
Les instruments de gynécologiediagnostique et thérapeutique R. WolfEndoscopy, Downs Surgical hand heldinstruments, PNN (Wallsten) BalloonAblation, Uroplasty Urinary Incontinence etWallach ne sont que quelques-uns desproduits supérieurs que nous offrons dansle cadre d’un programme gratuit d’essaiet d’évaluation.
UROLOGY NURSES OF CANADATable in Foyer
Contact: Francis StewartEast Wing - 3rd Floor, Women's CollegeHospitalToronto, ON, M5S 1B6T: 416-323-6400, x 4437F: 416-323-6237E: [email protected]
The Urology Nurses of Canada is aNational Not-for-Profit Organization whosemandate is to enhance the specialty ofUrologic nursing in Canada by promotingeducation research and clinical practice.The activities of the UNC are designed toenrich members' professional growth anddevelopment. We thank the CUA for theirongoing support.
VANTAGE ENDOSCOPYBooth / Kiosque : 14
Contact: Kevin Noseworthy151 Amber St., Unit 14Markham, ON, L3R 3B3T: 866-677-4121F: 866-677-4122E: [email protected]
Vantage Endoscopy based in Markhamwith national Canadian representation ispleased to service the urology and Uro-gynecological markets as the exclusivesupplier of Life-Tech urodynamics andNeomedic slings. With outstandingproducts, Canadian service and supportand very competitive pricing, please stopby our booth and come see what we haveto offer.
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 61
WARNEX MEDICAL LABORATORIES
Booth / Kiosque : 56Contact: Catherine Sartoros3885 Industriel Blvd.Laval, QC, H7L 4S3T: 450-663-6724, x 277F: 450-663-4428E: [email protected]
Warnex Medical Laboratories offers aPCA3 testing service, a new gene-basedtool to help detect prostate cancer from aurine sample. PCA3 can be used to helpidentify new prostate cancers, patientswho should have a repeat biopsy, orcandidates for active surveillancefollowing a prostate cancer diagnosis.
Warnex laboratoires médicaux offre unservice d’analyse PCA3, un nouvel outilbasé sur la génétique aidant à détecter le cancer de la prostate à partir d’unéchantillon d’urine. L’analyse PCA3 peutêtre utilisé pour aider à détecter unnouveau cancer de la prostate, identifierles patients chez qui une autre biopsieserait nécessaire et identifier lescandidats nécessitant une surveillanceactive suite à un diagnostic de cancer de la prostate.
WATSON PHARMA COMPANYBooths / Kiosques : 57/58
Contact: Peter Dale2295 Bristol Circle, Unit 104Oakville, ON, L6H 6P8T: 905-855-4428F: 905-855-4433E: [email protected]
Watson Pharma Company is the newlyformed Canadian subsidiary of WatsonPharmaceuticals, Inc. (NYSE: WPI), aleading integrated global pharmaceuticalcompany. Watson Pharma Company is engaged in the marketing, sale anddistribution of branded pharmaceuticalproducts and biologics within theCanadian market. We are focused ondelivering innovative products thataddress key therapeutic categories in Urology and Women's Health.
Watson Pharma Company est la nouvelle filiale canadienne de WatsonPharmaceuticals, Inc. (NYSE : WPI), uneimportante société pharmaceutiqueinternationale intégrée. Watson PharmaCompany s’occupe du marketing, de lavente et de la distribution de produits etbiologiques’ pharmaceutiques de marquesur le marché canadien. Nous nousconcentrons à offrir des produitsinnovateurs dans les domainesthérapeutiques de l’urologie et de la santé des femmes. Abbott
EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS
CUA 2012 BANFF 63
Richard S. Foster, MDIndiana University School of MedicineDepartment of UrologyIndianapolis, IN
Keith Jarvi, MDProfessor of Surgery, Division of Urology, Department of Surgery at theUniversity of Toronto, Chief of Urology;Director of the Murray Koffler UrologicWellness Centre at the Mount Sinai HospitalToronto, ON
Gerald Jordan, MDUrology Professor, Eastern Virginia Medical SchoolChairman Devine Center for Genitourinary Reconstructive Surgery, Sentara Norfolk General HospitalNorfolk, VA
Kevin T. McVary, MD, FACSAttending UrologistProfessor of Urology, Feinberg SchoolNorthwestern Memorial HospitalChicago, IL
Manoj Monga, MD, FACS Director, Stevan B. Streem Center for Endourology & Stone DiseaseGlickman Urological & Kidney InstituteThe Cleveland Clinic FoundationShaker Heights, OH
Mark A. Moyad, MD, MPHJenkins/Pokempner Director of Preventive & Complementary Medicine at the University of MichiganMedical Center (Department of Urology)Ann Arbour, MI
Victor Nitti, MD Professor and Vice Chairman Department of Urology New York University Langone MedicalCenterNew York, NY
Hiep Nguyen, MD UrologyChildren's Hospital Boston, HarvardMedical SchoolBoston, MA
Richard M. Satava, MD, FACSProfessor of SurgeryDepartment of SurgeryUniversity of Washington Medical CenterSeattle, WA
Mark Schoenberg, MD Director of Urologic OncologyThe James Buchanan Brady Urological InstituteThe Johns Hopkins Medical InstitutionsBaltimore, MD
Pramod C. Sogani, MDAttending SurgeonProfessor of UrologyMemorial Sloan-Kettering Cancer CenterNew York, NY
INVITED FACULTY / CONFÉRENCIERS INVITÉS
64 CUA 2012 BANFF
WINNER IN A CLINICAL TOPIC
The prize for the winning essay in a Clinical topic is awarded to Dr. Philippe DenisViolette of Division of Urology, McGill University Health Centre, Montreal, QC, for his essay Solitary Solid Renal Mass: Can We Predict Malignancy?(abstract POD-03.05).
No essays were submitted in the Basic Science category.
GAGNANT DE LA CATÉGORIE SUJET CLINIQUE
Le prix du meilleur travail portant sur un sujet en recherche clinique a été décerné au Dr. Philippe Denis Violette de la Division of Urology, McGill University Health Centre, Montréal, QC, pour son travail intitulé Solitary Solid Renal Mass: Can We Predict Malignancy? (résumé POD-03.05).
Aucun travail n’a été soumis dans la catégorie recherche fondamentale.
CUA PRIZE ESSAY / TRAVAIL PRIMÉ DE L’AUC
CUA 2012 BANFF 65
FRIDAY / VENDREDIJUNE 22 JUIN
0900-1200 CUA Finance CommitteeComité des finances de l’AUCRoom / Salle : Angus
1000-1700 7th Annual Canadian Association of Genito-urinary Medical Oncology(CAGMO) Meeting | Part 17ième Assemblée annuelle de l’Association canadienned’oncologie médicale génito-urinaire I Part 1Room / Salle : New Brunswick
1200-1700 CUA Executive CommitteeComité exécutif de l’AUCRoom / Salle : Alberta
1700-1800 Medical Advisory Boardof Kidney Cancer CanadaLe Conseil médical consultatifde l'Association canadienne du cancer du reinRoom / Salle : Angus
SATURDAY / SAMEDIJUNE 23 JUIN
0730-1330 7th Annual Canadian Association of Genito-urinary Medical Oncology(CAGMO) Meeting | Part 27ième Assemblée annuelle de l’Association canadienned’oncologie médicale génito-urinaire I Part 2Room / Salle : New Brunswick
0800-1200 Canadian Academy of Urological Surgeons (CAUS)Académie canadienne deschirurgiens oncologues (CAUS)Room / Salle : Baron Shaughnessy
0800-1230 CUA Patient InformationCommittee (PIC)Comité info-patients de l’AUC (PIC)Room / Salle : Empress
0830-1300 CUA SocioeconomicCommitteeComité socioéconomique de l’AUCRoom / Salle : Victoria
1200-1430 CUOG Executive Committee MeetingComité exécutif du CUOGRoom / Salle : Angus
1200-1700 CUA Executive CommitteeComité exécutif de l’AUCRoom: Alberta
CUA AND AFFILIATED MEETINGS / CUA ET ÉVÈNEMENTS AFFILIÉS
66 CUA 2012 BANFF
1200-1700 Specialty Committee,Royal College of Physicians and Surgeons of CanadaComité des Spécialités, Collège royal des médecinset chirurgiens du CanadaRoom / Salle : Coleman
1230-1400 CKCIS MeetingRéunion CKCISRoom / Salle : Ivor Petrak
1300-1700 Residency Affairs Committee (RAC)Comité des affaires des résidents (RAC)Room / Salle : McKenzie
1400-1600 Canadian EndourologyGroupGroupe canadien d’endo-urologieRoom / Salle : Beatty
1430-1700 CUOG Annual GeneralMeetingAssemblée générale annuelle du CUOGRoom / Salle : Baron Shaughnessy
SUNDAY / DIMANCHEJUNE 24 JUIN
0700-0830 Canadian Urological Research Consortium(CURC)Réunion du CURCRoom / Salle : Beatty
0800-1100 CUAJ - Peer-ReviewedWorkshopAtelier JAUC: Évaluation par les pairsRoom / Salle : Coleman
0830-1000 CUA NominatingCommitteeComité des candidatures de l’AUCRoom / Salle : Angus
0840-0940 Clinical EpidemiologyGroup Réunion du Grouped’épidémiologie cliniqueRoom / Salle : Ivor Petrak
1000-1100 CUASF Scientific CouncilConseil scientifique de la FBAUCRoom / Salle : Empress
1015-1115 Continuing ProfessionalDevelopment MeetingConseil scientifique de l'AUC - Programmede bourse AstellasRoom / Salle : Strathcona
CUA AND AFFILIATED MEETINGS / CUA ET ÉVÈNEMENTS AFFILIÉS
CUA 2012 BANFF 67
1100-1200 CUA Astellas Grant Program Scientific CouncilComité de développementprofessionnel continu (CDP)Room / Salle : Empress
1300-1500 CUASF AdministrativeCouncilComité administratif de la FBAUCRoom / Salle : Empress
1330-1730 Pediatric Urologists ofCanada (PUC) MeetingRéunion de la PUCRoom / Salle : Ivor Petrak
MONDAY / LUNDIJUNE 25 JUIN
0700-0900 CUA Annual GeneralMeetingAssemblée générale annuelle de l’AUCRoom / Salle : Baron Shaughnessy/Beatty
0900-1130 Canadian Male SexualHealth Council (CMSHC)Conseil canadien sur lasanté sexuelle de l’homme(CMSHC)Room / Salle : Strathcona
1200-1300 SIU Canadian SectionSection Canadienne de la SIURoom / Salle : Beatty
1600-1730 Bladder Cancer CanadaMedical Advisory Boardand Medical ResearchBoard MeetingCancer de la vessie CanadaRoom / Salle : Frontenac
1600-1800 Urology Nurses of CanadaInfirmières en urologie duCanadaRoom / Salle : Baron Shaughnessy
1700-1800 International VolunteerUrology - CancircBénévoles en urologie internationaleRoom / Salle : Beatty
TUESDAY / MARDIJUNE 26 JUIN
0630-0800 Council of CanadianUniversity Urology Chairs (CCUUC)CCUUCRoom / Salle : Palliser
0800-1000 CUAJ Editorial BoardMeetingComité de redaction du Journal de l’AUCRoom / Salle : AngusThis event isan Accredited Group Learning Ac-tivity (Section 1) as defined by theMaintenance of Certification Pro-gram of the Royal College ofPhysicians and Surgeons ofCanada and is co-developed andapproved by the Canadian Urologi-cal Association
CUA AND AFFILIATED MEETINGS / CUA ET ÉVÈNEMENTS AFFILIÉS
68 CUA 2012 BANFF
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and is co-developed and approved by the Canadian Urological Association
AGENDAHOW TO DEVELOP A STRONG ACADEMIC PROGRAM IN CANADARoom: Baron Shaughnessy Date: Saturday June 23rd, 2012
8:00 to 8:30 Breakfast
8:30 to 8:40 Welcome and Opening Remarks
8:40 to 9:10 Dr. Larry Goldenberg - Department of Urology vs. Division. Does It Matter?
9:10 to 9:20 Discussion
9:20 to 9:50 Dr. Sender Herschorn- Developing a Culture of Research and Academics
9:50 to 10:00 Discussions
10:00 to 10:20 Health Break
10:20 to 10:50 Dr. John Denstedt- Academic Urology: A Chairman of Surgery's Perspective
10:50 to 11:00 Discussion
11:00 to 11:30 Panel Discussion (Financial and Funding Strategies)Dr. Armen Aprikian (Moderator).
11:30 to 12:00 Business Meeting
CANADIAN ACADEMY OF UROLOGICAL SURGEONS (CAUS) BANFF 2012
0900-1200 CUA Finance Committee / Comité des finances de l’AUC
Room – Salle: Angus
1000-1700 7th Annual Canadian Association of Genitourinary Medical Oncology (CAGMO) Meeting | Part 17e Réunion annuelle de l’Association canadienne d’oncologie médicale génito-urinaire
Room – Salle: New Brunswick
1200-1700 CUA Executive Committee / Comité exécutif de l’AUC
Room – Salle: Alberta
1700-1800 The Medical Advisory Board of Kidney Cancer CanadaLe Conseil médical consultatif de l’Association canadienne du cancer du rein
Room – Salle: Angus
FRIDAY / VENDREDI JUNE 22 JUIN
CUA 2012 BANFF 69
0730-1330 7th Annual Canadian Association of Genitourinary Medical Oncology(CAGMO) Meeting | Part 27ième Assemblée Annuelle de l’Association canadienne d’oncologiemédicale génito-urinaire
Room – Salle: New Brunswick
0800-1200 Canadian Academy of Urological Surgeons (CAUS)Académie canadienne des chirurgiens oncologues (CAUS)
Room – Salle: Baron Shaughnessy
0800-1230 CUA Patient Information Committee (PIC)Comité info-patients de l’AUC (PIC)
Room – Salle: Empress
0800-1300 CUA Socioeconomic Committee / Comité socioéconomique de l’AUC
Room – Salle: Victoria
1200-1430 CUOG Executive Committee Meeting / Comité exécutif du CUOG
Room – Salle: Angus
1200-1700 CUA Executive Committee / Comité exécutif de l’AUC
Room – Salle: Alberta
SATURDAY / SAMEDI JUNE 23 JUIN
70 CUA 2012 BANFF
1200-1700 RCPSC – Specialty Committee Meeting in UrologyComité des Spécialités, Collège Royal des médecins et chirurgiens du Canada
Room – Salle: Coleman
1230-1400 CKCIS Meeting / Réunion CKCIS
Room – Salle: Ivor Petrak
1300-1700 Residency Affairs Committee (RAC)Comité des affaires des residents (RAC)
Room – Salle: McKenzie
1400-1600 Canadian Endourology Group / Groupe canadien d’endo-urologie
Room – Salle: Beatty
1430-1700 CUOG Annual General MeetingAssemblée générale annuelle du CUOG
Room – Salle: Baron Shaughnessy
SATURDAY / SAMEDI JUNE 23 JUIN
CUA 2012 BANFF 71
0700-0830 Canadian Urological Research Consortium (CURC) MeetingRéunion du CURC
Room – Salle: Beatty
0800-1100 CUAJ Peer-Reviewed WorkshopAtelier JAUC: Évaluation par les pairs
Room – Salle: Coleman
0800-0810 Welcome / Mot de Bienvenue
Room – Salle: Van Horne AMichael Chetner, CUA President | Président de l’AUCJay Lee & Trevor SchulerScientific Committee Co-chairs | Co-président du comité scientifique
0810-0840 SOA1State-of-the-Art Lecture 1 / Conférence d'honneur 1
Room – Salle: Van Horne A
Update in Endourology: SWL and PCNLMise à jour en endo-urologie : LECOC et NLPC
Objectives / Objectifs1 Review current literature to refine patient selection for SWL
2 Identify modifications in SWL treatment protocols designedto maximize efficacy and decrease morbidity
3 Discuss role for ureteral stenting and medical expulsive therapy
4 Identify techniques to optimize preoperative planning andintraoperative implementation of percutaneous renal access
5 Describe new innovations in technique and technology for PCNLdesigned to optimize results
1 Passer en revue les articles récents afin d'améliorer la sélection des patients pour une LECOC
2 Préciser les modifications à apporter aux protocoles thérapeutiques par LECOCen vue de maximiser l’efficacité et de réduire la morbidité
3 Discuter du rôle des endoprothèses urétérales et du traitement par desmédicaments favorisant l'expulsion
Introduction:Trevor Schuler, Edmonton, AB
Speaker/Conférencier:Manoj Monga, Shaker Heights, OH
SUNDAY / DIMANCHE JUNE 24 JUIN
CUA 2012 BANFF 73
74 CUA 2012 BANFF
4 Identifier les techniques permettant d’optimiser la planification préopératoire et l’instauration peropératoire d’un accès rénal percutané
5 Décrire les récentes innovations techniques et technologiques concernant la NLPC en vue de l’optimisation des résultats
0830-1000 CUA Nominating Committee / Comité des candidatures de l’AUC
Room – Salle: Angus
0840-0940 Clinical Epidemiology Group Réunion du Groupe d’épidémiologie clinique
Room – Salle: Ivor Petrak
0840-0940 POD-01Podium Session 1: Stones and ImagingSéance Podium 1: Lithiases et imagerie
Room – Salle: Van Horne AModerators/Modérateurs: Ben Chew, Vancouver, BC Manoj Monga, Shaker Heights, OH
0840-0850 POD-01.01 Surgical Management of Kidney Stone Disease: a Population-based Time Series Analysis
Ordon, Michael1; Saskin, Refik2; Mamdani, Muhammad3; Urbach, David2; Honey, R. John D'A.1; Pace, Kenneth11St. Michael's Hospital, Toronto, ON, Canada; 2Institute for Clinical and Evaluative Sciences,Toronto, ON, Canada; 3Applied Health Research Centre, St. Michael's Hospital, Toronto, ON, Canada
0850-0900 POD-01.02 Ultra-low Dose CT Comparable to Standard CT in Patients with Suspected Renal Colic
Archambault, Jason1; Sivalingam, Sri2; Hrymak, Carmen1; Kirkpatrick, Iain11University of Manitoba, Winnipeg, MB, Canada; 2University of Wisconsin, Madison, WI, United States
SUNDAY / DIMANCHE JUNE 24 JUIN
0900-0910 POD-01.03 Therapeutic Benefits of Solifenacin (Vesicare) in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms(LUTS) Post Ureteroscopy for Stone Management
Zadra, Joseph1; Hoare, Dylan2; Hartsburg, Cory1; Ray, Andrew1; Iocca, Angelo11Barrie Urology Associates, Barrie, ON, Canada; 2Queen's University, Kingston, ON, Canada
0910-0920 POD-01.04 Impact of Radiological Technologists on the Outcome of Shock Wave Lithotripsy
Elkoushy, Mohamed; Morehouse, Douglas; Anidjar, Maurice; Elhilali, Mostafa; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada
0920-0930 POD-01.05 Cost-effectiveness of Shock Wave Frequencies of 60 versus 120 Shocks per Minute for Upper Ureteral Stones: Economic Analysis of a Randomized, Double-blind Trial
Klinghoffer, Zachary1; Tu, Hin Yu Vincent1; Pace, Kenneth21McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada
0930-0940 POD-01.06 The Influence of Body Mass Index on Outcomes FollowingPercutaneous Nephrolithotomy: a Global Perspective
Fuller, Andrew1; Razvi, Hassan1; Denstedt, John D.1; Nott, Linda1; de la Rosette, Jean21Division of Urology, Department of Surgery, The University of Western Ontario, London, ON,Canada; 2Department of Urology, AMC University Hospital, Amsterdam, Netherlands
0940-1010 Break in Exhibit Hall / Pause dans le hall d’exposition
Room – Salle: Van Horne BC and/et Foyer
1000-1100 CUASF Scientific Council / Conseil scientifique de la FBAUC
Room – Salle: Empress
SUNDAY / DIMANCHE JUNE 24 JUIN
CUA 2012 BANFF 75
76 CUA 2012 BANFF
1010-1100 EF1Educational Forum 1 / Forum éducatif 1
Room – Salle: Van Horne A
Complications of Stone ManagementComplications de la prise en charge des calculs rénaux
Objectives / Objectifs
1 To review the complications and management of operative surgical proceduresfor kidney stones including extracorporeal shockwave lithotripsy, ureteroscopyand percutaneous nephrolithotomy
2 To review complications of residual stone fragments and their natural history
3 To review complications of medical management of kidney stone diseaseincluding medication interactions and side effects
1 Examiner les complications et la gestion des interventions chirurgicales visantl’extraction des calculs rénaux, dont la lithotripsie extracorporelle par ondes dechoc, l’urétéroscopie et la néphrolithotomie percutanée
2 Examiner les complications liées aux fragments résiduels de calculs et leurévolution naturelle
3 Examiner les complications de la prise en charge par médicaments des calculsrénaux, y compris les interactions médicamenteuses et les effets secondaires
1015-1115 Continuing Professional Development MeetingRéunion du comité de développement professionnel continu (CDP)
Room – Salle: Strathcona
Moderator/Modérateur:Ben Chew, Vancouver, BC
Faculty/Faculté: Trevor Schuler, Edmonton, ABJohn Dushinski, Calgary, AB
SUNDAY / DIMANCHE JUNE 24 JUIN
1100-1130 SOA2State-of-the-Art Lecture 2 (CAUS Lecture) / Conférence d'honneur 2 (Conférence de la CAUS)
Room – Salle: Van Horne A
Uretheral Reconstruction: What Does the Evidence Support?Reconstruction urétrale : Vers quoi pointent les données?
Objectives / Objectifs1 The attendees will after this lecture have an understanding of the current
terminology and anatomy of the urethra, as they relate to Urethralreconstruction
2 The attendees will after this lecture have an understanding of the thinkingmechanisms related to selection of urethral management or curative techniques
3 The attendees will after this lecture have been exposed to select techniques ofurethral reconstruction as they relate to the general urologists practice
4 The attendees will have been apprised concerning the methodology of analysisregarding the literature supported recommendations presented
1 Après cette présentation, les participants auront une bonne compréhension del’anatomie de l’urètre et de la terminologie connexe, en particulier en lien avecla reconstruction urétrale
2 Après cette présentation, les participants auront une bonne compréhension desmécanismes de réflexion en lien avec la sélection des techniques de prise encharge ou de traitement des troubles urétraux
3 Après cette présentation, les participants auront pris connaissance detechniques particulières de reconstruction urétrale pouvant être utilisées dansla pratique générale de l’urologie
4 Les participants auront été informés au sujet de la méthodologie analytiqueutilisée avec les recommandations appuyées par la documentation
1100-1200 CUA Astellas Grant Program Scientific CouncilConseil Scientifique de l’AUC - Programme de bourse Astellas
Room – Salle: Empress
1130-1230 Opening Brunch in the Exhibit HallBrunch de bienvenue dans le hall d'exposition
Room – Salle: Van Horne BC and/et Foyer
Introduction: Keith Rourke, Edmonton, AB
Speaker/Conférencier: GeraldJordan, Norfolk, VA
SUNDAY / DIMANCHE JUNE 24 JUIN
CUA 2012 BANFF 77
78 CUA 2012 BANFF
1230-1320 EF2Educational Forum 2 / Forum éducatif 2
Room – Salle: Van Horne A
Current Management of Genitourinary TraumaPrise en charge actuelle des traumatismes de l’appareil génito-urinaire
Objectives / Objectifs1 Outline the acute management options for a posterior urethral disruption
2 Gain an appreciation for the treatment of pelvic fracture urethral distractiondefects (PFUDD)
3 Discuss the diagnosis and treatment of common genital injuries
1 Faire ressortir les options de prise en charge aiguë d’une rupture de l’urètrepostérieur
2 Comprendre le traitement des lésions urétrales après fracture pelvienne
3 Discuter du diagnostic et du traitement des lésions génitales courantes
1300-1500 CUASF Administrative Council / Comité administratif de la FBAUC
Room – Salle: Empress
1320-1330 AUA Presidential Address / Allocution du Président de l'AUA
Room – Salle: Van Horne AIntroduction: Michael Chetner, Calgary, ABSpeaker/Conférencier: Dr. Pramod Sogani, New York, NY
1330-1730 Pediatric Urologists of Canada (PUC) Meeting / Réunion de la PUC
Room – Salle: Ivor Petrak
1330-1430 POD-02Podium Session 2: Oncology Séance Podium 2: Oncologie
Room – Salle: Van Horne A
Moderator/Modérateur:Keith Rourke, Edmonton, AB
Faculty/Faculté:Ron Kodama, Toronto, ONGerald Jordan, Virgina, VAKeith Rourke, Edmonton, AB
Moderators/Modérateurs:John Izawa, London, ONYves Fradet, Quebec, QC
SUNDAY / DIMANCHE JUNE 24 JUIN
1330-1340 POD-02.01 MDV3100, an Androgen Receptor Signaling Inhibitor (ARSI), ImprovesOverall Survival in Prostate Cancer Patients Post-docetaxel: Results from the Phase 3 Affirm Study
Saad, Fred1; Scher, Howard2; Fizazi, Karim3; Mulders, Peter4; Taplin, Mary Ellen5; Sternberg,Cora6; Miller, Kurt7; de Wit, Ron8; Hirmand, Mohammad9; Selby, Bryan9; De Bono, Johann101Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada; 2Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 3University of ParisSud, Villejuif, France; 4Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands;5Dana-Farber Cancer Institute, Boston, MA, United States; 6San Camillo-Forlanini Hospital,Rome, Italy; 7Charité Universitätsmedizin, Berlin, Germany; 8Erasmus University MedicalCenter, Rotterdam, Netherlands; 9Medivation Inc., San Francisco, CA, United States; 10The Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom
1340-1350 POD-02.02 Neoadjuvant Gemcitabine/Cisplatin Chemotherapy for Muscle InvasiveUrothelial Carcinoma of the Bladder: a Single Institution Experience
El-Gehani, Faraj1; Venner, Peter2; Ghosh, Sunita2; North, Scott21Department of Medical Oncology, Edmonton, AB, Canada; 2Cross Cancer Institute, Edmonton, AB, Canada
1350-1400 POD-02.03 Regional Differences in Practice Patterns and Outcomes after Radical Cystectomy
Bachir, Bassel G.1; Yafi, Faysal A.1; Aprikian, Armen1; Chin, Joseph L.2; Izawa, Jonathan2;Fradet, Yves3; Lacombe, Louis3; Drachenberg, Darrel4; Estey, Eric5; Farey, Adrian5; Rendon,Ricardo6; Bell, David6; Lattouf, Jean-Baptiste7; Cagiannos, Ilias8; Kassouf, Wassim1
1McGill University Health Center, Montreal, QC, Canada; 2University of Western Ontario,London, ON, Canada; 3Laval University, Quebec, QC, Canada; 4University of Manitoba,Winnipeg, MB, Canada; 5University of Alberta, Edmonton, AB, Canada; 6Dalhousie University,Halifax, NS, Canada; 7University of Montreal, Montreal, QC, Canada; 8University of Ottawa,Ottawa, ON, Canada
1400-1410 POD-02.04 The Association between Statin Medication Use and Progression after Surgery for Localized Renal Cell Carcinoma
Hamilton, Robert; Morilla, Daniel; Cabrera, Fernando; Bernstein, Melanie; Reuter, Victor; Russo, PaulMemorial Sloan-Kettering Cancer Center, New York, NY, United States
SUNDAY / DIMANCHE JUNE 24 JUIN
CUA 2012 BANFF 79
80 CUA 2012 BANFF
1410-1420 POD-02.05 Does Surgeon and Hospital Volume Impact Outcomes of Surgery for Renal Cell Carcinoma with Inferior Vena Caval Involvement? Results of a Canadian Population-based Study
Toren, Paul1; Abouassaly, Robert2; Yap, Stanley1; Timilshina, Narhari1; Kulkarni, Girish1; Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2Case Western University, Cleveland, OH, United States
1420-1430 POD-02.06 The Association between Renal Tumor Scoring System and Partial Nephrectomy Complications
Darren Desantis, Darren1; Lavallée, Luke T.1; Breau, Rodney H.1; Kamal, Fadi1; Watterson, James1; Blew, Brian1; Mallick, Ranjeeta2; Fergusson, Dean2; Morash, Chris1; Cagiannos, Ilias11University of Ottawa / The Ottawa Hospital, Ottawa, ON, Canada; 2The Ottawa HospitalResearch Institute, Ottawa, ON, Canada
1430-1500 Break in Exhibit Hall and Laparascopic Skills CompetitionPause dans le hall d'exposition et concours d’adresse en laparoscopie
Room – Salle: Van Horne BC and/et Foyer
1500-1530 SOA3State-of-the-Art Lecture 3 / Conférence d'honneur 3
Room – Salle: Van Horne A
Testis CancerCancer du testicule
Objectives / Objectifs1 Discuss controversies in the management of low stage testis cancer
2 Discuss different approaches to the post chemotherapy mass in high stagetestis cancer
3 Identify long term side effects of testis cancer chemotherapy
1 Discuter des controverses entourant la prise en charge du cancer du testiculeaux premiers stades
Introduction:Niels Jacobsen, Edmonton, AB
Speaker/Conférencier:Richard Foster, Indianapolis, IN
SUNDAY / DIMANCHE JUNE 24 JUIN
2 Discuter différentes approches thérapeutiques en cas de massepostchimiothérapie dans les cancers du testicule aux stades avancés
3 Identifier les effets secondaires à long terme de la chimiothérapie utiliséecontre le cancer du testicule
1530-1620 EF3Educational Forum 3 / Forum éducatif 3
Room – Salle: Van Horne A
High Risk Superficial Bladder CancerCancer vésical superficiel à risque élevé
Objectives / Objectifs1 Define high risk non-muscle invasive urothelial carcinoma of the bladder
(high risk NMIBC) and describe its natural history
2 Describe intravesical options for management of high risk NMIBC
3 Describe salvage options for high risk NMIBC
1 Définir le carcinome urothélial de la vessie à risque élevé sans envahissementmusculaire et décrire son évolution naturelle
2 Décrire les options thérapeutiques intravésicales dans ce type de carcinome
3 Décrire les options de sauvetage possibles avec ce type de carcinome
Moderator/Modérateur: Bobby Shayegan, Hamilton, ON
Faculty/Facultés:Wassim Kassouf, Montreal, QCJonathan Izawa, London, ONBobby Shayegan, Hamilton, ON
SUNDAY / DIMANCHE JUNE 24 JUIN
CUA 2012 BANFF 81
82 CUA 2012 BANFF
1620-1650 SOA4State-of-the-Art Lecture 4 / Conférence d'honneur 4
Room – Salle: Van Horne A
Quality Assurance in Bladder CancerAssurance de la qualité dans le cancer de la vessie
Objectives / Objectifs1 Understand the morbidity of cystectomy
2 Understand strategies for minimizing morbidity related to cystectomy
3 Understand the alternatives to cystectomy
1 Comprendre la morbidité associée à la cystectomie
2 Comprendre les stratégies permettant de réduire au minimum la morbidité liéeà la cystectomie
3 Comprendre les options de rechange à la cystectomie
1900-2230 CUA Fun Night / Grande soirée de l'AUCThe Fairmont Banff Springs Hotel
Rooms – Salles: Riverview Lounge, Alberta & New Brunswick
Introduction:Eric Hyndman, Calgary, AB
Speaker/Conférencier:Mark Schoenberg, Baltimore, MD
SUNDAY / DIMANCHE JUNE 24 JUIN
0700-0900 CUA Annual General Meeting / Assemblée générale annuelle de l’AUC
Rooms – Salles: Baron Shaughnessy/Beatty
0900-1130 Canadian Male Sexual Health Council (CMSHC)Conseil Canadian sur la santé sexuelle de l’homme (CMSHC)
Room – Salle: Strathcona
0910-0920 CP1Clinical Pearls That Could Change Your PracticeDes perles cliniques qui pourraient changer votre pratique
Room – Salle: Van Horne ASpeaker/Conférencier:Niels Jacobsen, Edmonton, AB
0920-0950 SOA5State-of-the-Art Lecture 5 / Conférence d’honneur 5
Room – Salle: Van Horne A
Men’s Health-Diet and Supplementation from A to Z: What Works and What is Worthless?Santé des hommes – Alimentation et suppléments de A à Z : Ce qui fonctionne et ce qui ne vaut pas le coup
Objectives / Objectifs1 To discuss rules and regulations regarding diet and supplements for men’s health
2 To discuss clinical studies hat support recommending specific dietary changesand supplements to your patients
3 To discuss clinical studies that do NOT support recommending some specificdietary changes and supplements to your patients
1 Discuter des règles concernant l’alimentation et les suppléments dans la santédes hommes
2 Discuter des études cliniques appuyant la recommandation de modificationsparticulières à l’alimentation et l’emploi de suppléments précis pour vos patients
3 Discuter des études cliniques qui n’appuient PAS la recommandation demodifications particulières à l’alimentation et l’emploi de suppléments précispour vos patients
Introduction:Martin Duffy, Calgary, AB
Speaker/Conférencier: Mark Moyad,Ann Arbour, MI
MONDAY / LUNDI JUNE 25 JUIN
CUA 2012 BANFF 83
84 CUA 2012 BANFF
0950-1020 Break in Exhibit Hall / Pause dans le hall d’exposition
Room – Salle: Van Horne BC and/et Foyer
1020-1120 POD-03Podium Session 3: General TopicsSéance Podium 3: Sujets générales
Room – Salle: Van Horne AModerators/Modérateurs:Andrew McNeilly, Vancouver, BC Hiep Ngyen, Boston, MA
1020-1030 POD-03.01 Laparoscopic Ureteric Clipping: a Simple Alternative in the Treatmentof Ectopic Ureters Associated with a Non-functioning Upper Moiety
Romao, Rodrigo L.P.; Figueroa, Victor H.; Pippi Salle, Joao L.; Koyle, Martin; Bagli, Darius; Lorenzo, Armando J.The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
1030-1040 POD-03.02The Association between Continence, Shunt, and Quality of Life in Spina Bifida
Olesen, Jamie; Kiddoo, Darcie; Metcalfe, PeterUniversity of Alberta, Edmonton, AB, Canada
1040-1050 POD-03.03Does Antibiotic Prophylaxis Prevent Urinary Tract Infections in Infantswith Antenatally Detected Hydronephrosis? A Systematic Review andMeta-analysis
Braga, Luis1; Lorenzo, Armando2; Pemberton, Julia1; DeMaria, Jorge1; Kim, Soojin1; Milijovic, Hana11McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada
1050-1100 POD-03.04 Role of a Novel Internet Mediated Feedback Instrument in a New Ageof Simulation Training: a Randomized Control Study
Weber, Bryce1; Bagli, Darius2; Carnahan, Heather3; Gualdron, David Rojas4; Cheung, Jeffrey4;Dubrowski, Adam3
1Alberta Children’s Hospital, Calgary, AB, Canada; 2Hospital for Sick Children, Toronto, ON,Canada; 3Wilson Centre, Toronto, ON, Canada; 4Sick Kids Learning Institute, Toronto, ON,Canada
MONDAY / LUNDI JUNE 25 JUIN
1100-1110 POD-03.05 Solitary Solid Renal Mass: Can We Predict Malignancy?
Philippe Violette1, Samuel Abourbih1, Konrad M. Szymanski1, Simon Tanguay1, ArmenAprikian1, Keith Matthews1, Fadi Brimo2, and Wassim Kassouf11Division of Urology, McGill University Health Centre, Montreal, QC, Canada; 2Division ofPathology, McGill University Health Centre, Montreal, QC, Canada
1110-1120 POD-03.06 A Prospective Randomized Trial of Povidone-iodine ProphylacticCleansing of the Rectum prior to Transrectal Ultrasound-guidedProstate Biopsy
Abughosh, Zeid1; Margolick, Joseph1; Goldenberg, Larry1; Afshar, Kourosh1; Taylor, Stephen1;Gleave, Martin1; Bowie, William2; Roscoe, Diane1; Machan, Lindsay1; Black, Peter11Vancouver Prostate Centre, Vancouver, BC, Canada; 2University of British Columbia,Vancouver, BC, Canada
1120-1150 SOA6State-of-the-Art Lecture 6 / Conférence d’honneur 6
Room – Salle: Van Horne A
BPH & ED / HBP et DE
Objectives / Objectifs1 Know the relationships between ED and LUTS
2 Know how treatment of LUTS may impact sexual function
3 Know the impact of ED meds on LUTS
4 Understand the metabolic risks on the development of LUTS/BPH
5 Gain an awareness of how to prevent the development of LUTS through lifestylemanagement
1 Connaître le lien entre la DE et les TUBA
2 Savoir comment le traitement des TUBA peut influer sur la fonction sexuelle
3 Connaître l’effet des médicaments contre la DE sur les TUBA
4 Comprendre les risques métaboliques sur l’apparition de TUBA ou d’une HBP
5 Découvrir comment prévenir l’apparition de TUBA par les modifications au stylede vie
Introduction:Jay Lee, Calgary, AB
Speaker/Conférencier: Kevin McVary, Chicago, IL
MONDAY / LUNDI JUNE 25 JUIN
CUA 2012 BANFF 85
86 CUA 2012 BANFF
1150-1300 Lunch in Exhibit Hall / Déjeuner dans le hall d’exposition
Room – Salle: Van Horne BC and/et Foyer
1200-1300 SIU Canadian Section / Section Canadienne de la SIU
Room – Salle: Beatty
1300-1350 EF4Educational Forum 4 / Forum éducatif 4
Room – Salle: Van Horne A
Medial vs Early Surgical Intervention for Benign Prostatic Hyperplasia: Treatment Decisions are Driven by Risks, Benefits and CostsIntervention médicamenteuse ou chirurgicale précoce dans l’hyperplasie bénigne de la prostate : Les décisions quant au traitement sont fondées sur les risques, les avantages et les coûts
Objectives / Objectifs1 To understand how potential risks (side effects/complications) of medical
and surgical intervention for benign prostatic enlargement drives patientdecision-making
2 To learn that long term financial implications of medical and surgicalmanagement for benign prostatic enlargement does not play a role in currentdecision-making
3 To determine whether a new strategy of therapeutic decision-making for benignprostatic hyperplasia should be the future
1 Comprendre comment les risques potentiels (effets secondaires/complications)des interventions médicamenteuses et chirurgicales utilisées pour traiterl’hyperplasie bénigne de la prostate (HBP) influent sur le processus décisionneldes patients
2 Voir que les répercussions financières à long terme de la prise en chargemédicamenteuse et chirurgicale de l’HBP ne jouent aucun rôle dans le processusdécisionnel actuel
3 Déterminer si une nouvelle stratégie décisionnelle quant au traitement de l’HBP est requise pour l’avenir
Moderator/Modérateur:Ryan Paterson, Vancouver, BC
Faculty/Facultés: Curtis Nickel, Kingston, ON(Pro-medical Therapy / Pour le traitement médicamenteux)
Paul Whelan, Hamilton, ON(Pro-surgical Therapy / Pour le traitement chirurgical)
MONDAY / LUNDI JUNE 25 JUIN
1350-1420 CUASF Lecture / Allocution de la FBAUC
Room – Salle: Van Horne A
Male Infertility: The Canary in the Coal MineMale Infertility Is a Marker for Men’s Health: Past, Present and FutureInfertilité masculine : le canari dans la mine de charbonL’infertilité comme marqueur de la santé chez les hommes : passé, présent et futur
Objectives / Objectifs1 To understand what medical issues are associated with male infertility
(Metabolomic syndrome etc.)
2 To understand the future health problems for men with infertility (higher risk ofcancer etc.)
3 To understand which tests are needed to identify men with these other healthproblems
1 Comprendre les enjeux médicaux associés à l’infertilité masculine (syndromemétabolique, etc.)
2 Comprendre les problèmes de santé futurs des hommes infertiles (risque accrude cancer, etc.)
3 Comprendre quels examens sont requis pour cerner les hommes présentant cesautres problèmes de santé
1420-1450 SOA7State-of-the-Art Lecture 7 / Conférence d’honneur 7
Room – Salle: Van Horne A
The Use of Synthetic Mesh in Vaginal Surgery: Past, Present and FutureUtilisation de filet synthétique en chirurgie vaginale: passé, présent et avenir
Introduction:Ethan Grober, Toronto, ON
Speaker/Conférencier:Keith Jarvi, Toronto, ON
Introduction:Kevin Carlson, Calgary, AB
Speaker/Conférencier:Victor Nitti, New York, NY
MONDAY / LUNDI JUNE 25 JUIN
CUA 2012 BANFF 87
88 CUA 2012 BANFF
Objectives / Objectifs1 To understand the development of mesh for vaginal prolapse and incontinence
surgery
2 To know the common complications of vaginal mesh and why they happen
3 To understand the current state of governmental and society positions on the useof transvaginal mesh and how this may affect practice
1 Comprendre l’utilisation de filet en chirurgie pour le prolapsus vaginal etl’incontinence.
2 Connaître les complications courantes de l’utilisation de filet vaginal et lesraisons de ces complications
3 Comprendre les positions actuelles au niveau du gouvernement et de la sociétéconcernant l’utilisation du filet transvaginal et son impact sur la pratique
1450-1520 Break in Exhibit Hall / Pause dans le hall d’exposition
Room – Salle: Van Horne BC and/et Foyer
1520-1610 EF5Educational Forum 5 / Forum éducatif 5
Room – Salle: Van Horne A
Office Evaluation and Management of LUTs: Focus on OABÉvaluation et prise en charge des TUBA en cabinet : Point de mire sur la vessie hyperactive
Objectives / Objectifs1 Develop a strategy for the evaluation and management of a patient
with OAB failing an initial trial of anticholinergic therapy
2 Formulate a rational and effective plan for the evaluation and treatment of men with OAB symptoms
3 Formulate a rational and effective plan for the evaluation and treatment of elderly patients with OAB symptoms
1 Élaborer une stratégie pour l’évaluation et la prise en charge de cas de vessiehyperactive après échec d’un traitement initial par anticholinergique
2 Formuler un plan rationnel efficace pour l’évaluation et le traitement des hommes affichant des symptômes de vessie hyperactive
3 Formuler un plan rationnel efficace pour l’évaluation et le traitement despersonnes âgées affichant des symptômes de vessie hyperactive
Moderator/Modérateur:Kevin Carlson, Calgary, AB
Faculty/Faculté:Greg G. Bailly, Halifax, NSVictor Nitti, New York, NYKevin Carlson, Calgary, AB
MONDAY / LUNDI JUNE 25 JUIN
1600-1730 Bladder Cancer Canada Medical Advisory Board and Medical Research Board MeetingCancer de la vessie Canada et Réunion du Conseil de recherchemédicale
Room – Salle: Frontenac
1600-1800 Urology Nurses of Canada / Infirmières en urologie Canada
Room – Salle: Baron Shaughnessy
1610 - 1640 SOA8State-of-the-Art Lecture 8 / Conférence d’honneur 8
Room – Salle: Van Horne A
The Genetic of Vesicoureteral Reflux: Not as Straightforward as We ThinkLa génétique du reflux vésico-urétéral : pas aussi simple qu’on le croit
Objectives / Objectifs1 To understand the genetic basis for vesicoureteral reflux
2 To understand the principles of SNPs genome wide analysis
3 To correlate clinical findings of VUR with its genetic basis
1 Comprendre le fondement génétique du reflux vésico-urétéral
2 Comprendre les principes de l’analyse des SNP à l’échelle génomique
3 Établir des corrélations entre les résultats cliniques liés au reflux vésico-urétéral et le fondement génétique
1645-1745 POD-04Podium Session 4: Lower Urinary TractSéance Podium 4: Troubles du bas appareil urinaire
Room / Salles: Van Horne AModerators/Modérateurs:Sender Herschorn, Toronto, ONCurtis Nickel, Kingston, ON
Introduction:Dawn McLellan, Halifax, NS
Speaker/Conférencier:Hiep Nguyen, Boston, MA
MONDAY / LUNDI JUNE 25 JUIN
CUA 2012 BANFF 89
90 CUA 2012 BANFF
1645-1655 POD-04.01 Mirabegron Improves Patient-reported Outcomes in Patients withOveractive Bladder Syndrome: Results from a North-American Study
Nitti, Victor1; Herschorn, Sender2; Auerbach, Stephen3; Martin, Nancy4; Blauwet, Mary Beth41NYU School of Medicine, New York, NY, United States; 2University of Toronto, Toronto, ON,Canada; 3Hoag Memorial Presbyterian Hospital, Newport Beach, CA, United States; 4Astellas,Deerfield, IL, United States
1655-1705 POD-04.02 Greenlight HPS-120W vs XPS-180W Laser Vaporization of the Prostate for Benign Prostatic Hyperplasia: a ProspectiveComparative Outcomes Analysis
Zorn, Kevin; Liberman, Dan; Hueber, Pierre-Alain; Ben-Zvi, Tal; Péloquin, FrançoisUniversity of Montreal Hospital Center (CHUM), Montreal, QC, Canada
1705-1715 POD-04.03Changes in Erectile Function after Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia
Abdulla, Alym; Zareba, Piotr; Bowen, Jim; Hopkins, Rob; Tarride, Jean-Eric; Whelan, PaulMcMaster University, Hamilton, ON, Canada
1715-1725 POD-04.04 A Prospective Analysis of Consultation for Difficult Urinary Catheter Insertion at Tertiary Care Centers in Northern Alberta
Rourke, Keith; Van Zyl, Stephan; Bacsu, Chasta-DawneUniversity of Alberta, Edmonton, AB, Canada
1725-1735 POD-04.05 A Novel Urethral Catheter Design for Safer Placement and Outcomes
Garcia, Maurice1; Wu, Alex1; Bullock, Thomas1; Aaronson, David21University of California San Francisco, San Francisco, CA, United States; 2The KaiserPermanente Medical Group, Oakland, CA, United States
1735-1745 POD-04.06 Urethroplasty for Pelvic Fracture Urethral Distraction Defects (PFUDD):Factors Influencing Surgical Outcome and Erectile Dysfunction
Kinnaird, Adam; Zorn, Jeff; Rourke, KeithUniversity of Alberta, Edmonton, AB, Canada
MONDAY / LUNDI JUNE 25 JUIN
1700-1800 International Volunteer Urology - CancircBénévoles en urologie internationale - Cancirc
Room – Salle: Beatty
1900-2300 President’s Reception and Banquet (Cocktails at 18:30) Réception et banquet présidentiel de l’AUC (Réception à 18h30)
Room – Salle: Alberta & New Brunswick
MONDAY / LUNDI JUNE 25 JUIN
CUA 2012 BANFF 91
CUA 2012 BANFF 93
0630-0800 Council of Canadian University Urology Chairs (CCUUC) / CCUUC
Room – Salle: Palliser
0700-0710 CP2Clinical Pearls That Could Change Your PracticeDes perles cliniques qui pourrait changer votre pratique
Room – Salles: Van Horne ASpeaker/Conférencier:Anil Kapoor, Hamilton, ON
0710-0800 EF6Educational Forum 6 / Forum éducatif 6
Room – Salle: Van Horne A
Managing the Negative Prostate BiopsyPrise en charge de la biopsie prostatique negative
Objectives / Objectifs1 To review the management options for a patient with negative prostate biopsy
2 To appreciate the use of MRI in prostate biopsy decision-making
3 To review the evidence for and against the use of 5-ARI in this setting.
4 To determine the selection criteria for repeating a prostate biopsy
5 To better understand the interpretation of PIN and ASAP in prostate biopsy reports
1 Examiner les options de prise en charge dans le cas d’un patient ayant desrésultats négatifs lors d’une biopsie prostatique
2 Comprendre l’usage de l’IRM dans le processus décisionnel en lien avec unebiopsie prostatique
3 Examiner les données pour et contre l’usage des I5AR dans ce contexte
4 Établir les critères de sélection pour la répétition d’une biopsie prostatique
5 Mieux comprendre l’interprétation de la néoplasie intraépithéliale prostatique(PIN) et de la petite prolifération acineuse atypique (ASAP) dans les rapports debiopsie prostatique
Moderator/Modérateur:Armen Aprikian, Montreal, QC
Faculty/Faculté:Neil Fleshner, Toronto, ONRobert Siemens, Kingston, ON,Bryan Donnelly, Calgary, AB
TUESDAY / MARDI JUNE 26 JUIN
94 CUA 2012 BANFF
0800-0900 POD-05Podium Session 5: Prostate CancerSéance Podium 5: Cancer de la prostate
Room – Salle: Van Horne AModerators/Modérateurs:Eric Estey, Edmonton, ABArmen Aprikian, Montreal, QC
0800-0810 POD-05.01 Effect of Denosumab on Prolonging Bone-metastasis Free Survival in Men with Non-metastatic Castrate-resistant Prostate CancerPresenting with Aggressive Prostate-specific Antigen Kinetics
Saad, Fred1; Oudard, Stephane2; Smith, Matthew3; Shore, Neal4; Miller, Kurt5; Tombal,Bertrand6; Sieber, Paul7; Fizazi, Karim8; Van Veldhuizen, Peter9; Damiao, Ronald10; Marx,Gavin11; Morote, Juan12; Feng, Amy13; Dansey, Roger13; Goessl, Carsten131Hôpital Notre-Dame du CHUM, Montréal, QC, Canada; 2Georges Pompidou Hospital, Paris,France; 3Massachusettes General Hospital Cancer Center, Boston, MA, United States;4Carolina Urological Research Center, Myrtle Beach, SC, United States; 5Charité Berlin, Berlin,Germany; 6Université Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles,Belgium; 7Urological Associates of Lancaster, Lancaster, PA, United States; 8Institut GustaveRoussy, University of Paris Sud, Paris, France; 9Kansas City VA Medical Center, Kansas City,MO, United States; 10Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil; 11SydneyHaematology and Oncology Clinic, Wahroonga NSW, Australia; 12Hospital Vall d’Hebron,Barcelona, Spain; 13Amgen Inc, Thousand Oaks, CA, United States
0810-0820 POD-05.02Need for Intervention and Survival in a Cohort of Patients on ActiveSurveillance (AS) for Low-risk Prostate Cancer
Preston, Mark1; Paly, Jonathan1; Carrasquillo, Robert2; Coen, John1; Zietman, Anthony1; Smith,Matthew R.1; Wu, Chin-Lee1; McDougal, W. Scott1; Feldman, Adam S.11Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School,Boston, MA, United States
0820-0830 POD-05.03 A Population-based Analysis of Pathological Outcomes FollowingRadical Prostatectomy in Academic vs. Non-academic Institutions
Nayak, Jasmir; Mau, Elke; Drachenberg, Darrel; Suderman, Derek; Guilbert, Kimi; Mak,Giselle; Lambert, Pascal; Quon, HarveyUniversity of Manitoba, Winnipeg, MB, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 95
0830-0840 POD-05.04 Between-surgeon Variation in Outcomes of Radical Prostatectomy forClinically Localized Prostate Cancer: Analysis of 1014 ConsecutiveMen Treated at the University of Alberta
Fairey, Adrian1; Jacobsen, Niels2; Yasui, Yataku2; Liu, Qi2; Voaklander, Don2; Estey, Eric21University of Southern California, Los Angeles, CA, United States; 2University of Alberta,Edmonton, AB, Canada
0840-0850 POD-05.05 Population-based Study of Long-term Rates of Surgery for UrinaryIncontinence following Radical Prostatectomy for Prostate Cancer
Nam, Robert; Herschorn, Sender; Loblaw, Andrew; Liu, Ying; Klotz, Laurence; Carr, Lesley;Kodama, Ronald; Saskin, Refik; Law, CalvinSunnybrook Health Sciences Centre, Toronto, ON, Canada
0850-0900 POD-05.06 A Randomized Trial Comparing External Beam Radiation andCryotherapy in Localized Prostate Cancer: 10 Year Follow-up
Donnelly, Bryan1; Saliken, John2; Brasher, Penny2; Lau, Harold2; Trpkov, Kiril3; Robinson, John31Prostate Cancer Centre Calgary, Calgary, AB, Canada; 2Tom Baker, Calgary, AB, Canada;3Calgary Lab Services, Calgary, AB, Canada
0800-1000 CUAJ Editorial Board MeetingComité de rédaction du Journal de l’AUC
Room – Salle: Angus
0900-0950 EF7Educational Forum 7 / Forum éducatif 7
Room – Salle: Van Horne A
Controversies in Castrate-resistant Metastatic Prostate CancerControverses entourant le cancer métastatique de la prostate résistant à la castration
Objectives / Objectifs1 Review the new developments and recent clinical trial results of novel agents in
patients with castrate resistant prostate cancer (CRPC)
Moderator/Modérateur:Alan So, Vancouver, BC
Faculty/Faculté:Neil Fleshner, Toronto, ON
TUESDAY / MARDI JUNE 26 JUIN
96 CUA 2012 BANFF
2 Define the role of the Urologist as well as multi-disciplinary approach to the management of CRPC
3 Assess state-of-the-art management of CRCP, both in terms of guidelines as well as novel agents that will be available in the near future
1 Examiner les récents développements et résultats d’essais cliniques portant surles nouveaux agents chez les patients atteints d’un cancer de la prostaterésistant à la castration (CPRC)
2 Établir le rôle de l’urologue et d’une approche multidisciplinaire dans la prise encharge du CPRC
3 Évaluer la prise en charge de pointe du CPRC, tant sur le plan des lignesdirectrices que des nouveaux agents qui seront lancés sur le marché dans un avenir rapproché
0950-1010 Break / Pause
Room – Salle: Foyer
1010-1040 SOA9State-of-the-Art Lecture 9 / Conférence d’honneur 9
Room – Salle: Van Horne A
Robotics and Innovation / Robotique et innovation
Objectives / Objectifs1 Understand the new technologies such as robotics, surgical rehearsal and other
innovations which are improving the practice of surgery and how to implementthem into daily practice
2 Discover how the new technologies in the laboratory, such as nanotechnologyand tissue engineering, will require a fundamental change in the practice of surgery
3 Be aware of the moral and ethical implications of advanced medical technologiesand their impact on individuals, behavior, society and human kind
1 Comprendre les nouvelles technologies comme la robotique, les systèmes de répétition des interventions chirurgicales et autres innovations améliorant lapratique chirurgicale et comment les mettre en œuvre dans la pratiquequotidienne
2 Découvrir comment les nouvelles technologies utilisées en laboratoire, comme lananotechnologie et l’ingénierie tissulaire, exigeront un changement fondamentaldans la pratique de la chirurgie
3 Réfléchir aux répercussions morales et éthiques des technologies médicalesavancées et leur impact sur les particuliers, les comportements, la société et
Introduction:Trevor Schuler, Edmonton, AB
Speaker/Conférencier:Richard Satava, Seattle, WA
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 97
l’humanité
1040-1125 Urological Jeopardy / Jeu “Les grosses têtes” de l’urologie
Room – Salle: Van Horne A
1125-1240 EF8Educational Forum 8 and LUNCH / Forum éducatif 8 et DÉJEUNER
Room – Salle: Van Horne A
Exploring New Options in the Treatment of ED/BPH?: Uts and Testosterone Replacement TherapyExplorer des nouvelles options dans le traitement de l’ED, de l’HBP et des TUBA et le traitement de remplacement de la testostérone
Objectives / Objectifs1 To critically evaluate evolving data on hypogonadal men and androgen
replacement therapy
1 To assess the existing scientific support for use of PDE5i’s in BPH/LUTS
3 To understand the role of PDE5’s in the use of LUTS and ED in the comorbidpatient
1 Évaluer, avec un sens critique, les données en évolution sur les hommes atteintsd’hypogonadisme et le traitement de remplacement androgénique
2 Évaluer les données scientifiques existantes appuyant le recours aux inhibiteursde la PDE5 dans le traitement de l’HBP ou des TUBA
3 Comprendre le rôle des inhibiteurs de la PDE5 dans le traitement des TUBA et dela DE chez le patient atteint de comorbidités
1240-1440 MP-01Moderated Poster Session 1: Prostate CancerSéance de posters modérés 1: Cancer de la prostate
Room – Salle: Baron ShaughnessyModerators/Modérateurs: Bryan Donnelly, Calgary, AB
Moderator/Modérateur:Gerald Brock, London, ON
Faculty/Faculté:François Bénard, Montréal, QC,Curtis Nickel, Kingston, ON, Gerald Brock, London, ON
TUESDAY / MARDI JUNE 26 JUIN
98 CUA 2012 BANFF
MP-01.01The Impact of a Sensitivity Adapted Antimicrobial ProphylacticStrategy on Prostate Biopsy Sepsis
Rowe, Neal; Breau, Rodney H.; Cagiannos, Ilias; Zvonar, Rosemary; Fergusson, Dean;Lavallee, Luke T.; Mallick, Ranjeeta; Morash, Christopher G.University of Ottawa, Ottawa, ON, Canada
MP-01.02 Serum Adipokine Levels Improve Prostate Cancer PredictionCompared to Clinical Data Only
Margel, David1; Trottier, Greg1; Yap, Stanley1; Connor, Mike2; Elharram, Malik1; Bhindi, Bimal1;Kulkarni, Girish1; Finelli, Antonio1; Zlotta, Alexandre1; Fleshner, Neil11Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2University of York, Toronto, ON, Canada
MP-01.03 PCA3 Test as an Adjunct in Diagnosis of Prostate Cancer
Yutkin, Vladimir1; Al-Zahrani, Ali1; Williams, Andrew1; Hidas, Guy2; Martinez, Carlos1; Izawa,Jonathan1; Pode, Dov2; Chin, Joseph11University of Western Ontario, Uro-Oncology Fellowship Program, London, ON, Canada;2Hadassah and Hebrew University Medical Center, Jerusalem, Israel
MP-01.04 Percentage of Gleason 4 on Repeat Biopsy: How Much Matters?
Punnen, Sanoj; Glass, Allison; Cowan, Janet; Carroll, PeterUniversity of California, San Francisco, CA, United States
MP-01.05 Diagnostic Accuracy of Seminal Vesicle Biopsy in Evaluating SeminalVesicle Invasion: Comparison with MRI
Suntharasivam, Thiru; Hameed, Ammar; Doble, AndrewUrology Department, Addenbrookes University Hospital, Cambridge, United Kingdom
MP-01.06 Ultra-extended Prostate Biopsy Improves Detection of PathologicProgression in Patients on Active Surveillance for Prostate Cancer
Wong, Lih-Ming1; Trottier, Greg1; Fleshner, Neil1; Lawrentchuk, Nathan1; Kulkarni, Girish1;Zlotta, Alexander2; Trachtenberg, John1; Toi, Ants3; Timilshina, Narhari4; Finelli, Antonio11Department of Urology, Princess Margaret Hospital, Toronto, ON, Canada; 2Department ofUrology, Mount Sinai Hospital, Toronto, ON, Canada; 3Department of Radiology, PrincessMargaret Hospital, Toronto, ON, Canada; 4Division of General Internal Medicine & ClinicalEpidemiology, University Health Network, Toronto, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 99
MP-01.07Is There a Role for Routine Anterior Zone Sampling during TransrectalUltrasound Guided Saturation Prostate Biopsy
Cole, Eric1; Shayegan, Bobby1; Matsumoto, Edward1; Greenspan, Michael1; Daya, Dean2;Patlas, Michael3; Pinthus, Jehonathan11McMaster Institute of Urology, Hamilton, ON, Canada; 2McMaster Department of Pathology,Hamilton, ON, Canada; 3McMaster University Department of Radiology, Hamilton, ON, Canada
MP-01.08 International Multi-centre Study Examining Selection Criteria forActive Surveillance in Men Undergoing Radical Prostatectomy
Wong, Lih-Ming1; Neal, David2; Johnston, Richard2; Shah, Nimesh2; Warren, Anne2; Hovens, Chris3; Goldenberg, Larry4; Gleave, Martin4; Costello, Anthony3; Corcoran, Niall31Princess Margaret Hospital, Toronto, ON, Canada; 2Addenbrookes Hospital, Cambridge,United Kingdom; 3The Australian Prostate Cancer Centre at Epworth and Departments ofUrology and Surgery, Royal Melbourne Hospital, Melbourne, Australia; 4The VancouverProstate Centre, Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada
MP-01.09Gleason Upgrading and Increased Cancer Volume on Repeat ProstateBiopsy in Patients on Active Surveillance (AS)
Preston, Mark A.1; Carrasquillo, Robert2; Paly, Jonathan J.1; Coen, John J.1; Zietman, AnthonyI.1; Smith, Matthew R.1; Wu, Chin-Lee1; McDougal, W. Scott1; Feldman, Adam S.11Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School,Boston, MA, United States
MP-01.10Multi-institutional Validation of the CAPRA-S Score to PredictOutcomes after Radical Prostatectomy
Punnen, Sanoj1; Freedland, Stephen2; Presti, Joseph3; Aronson, William4; Terris, Martha5;Kane, Christopher6; Amling, Christopher7; Carroll, Peter1; Cooperberg, Matthew1
1University of California, San Francisco, CA, United States; 2Duke University, Durham, NC,United States; 3Stanford University, Palo Alto, CA, United States; 4University of California, LosAngeles, CA, United States; 5Medical School of Georgia, Augusta, GA, United States;6University of California, San Diego, CA, United States; 7Oregon Health Sciences University,Portland, OR, United States
MP-01.11 High Intensity Focused Ultrasound for Localized Prostate Cancer:Impact of Nadir PSA on Cancer Control
Shayegan, Bobby1; Dason, Shawn1; Pinthus, Jehonathan1; Farrokhyar, Forough2; Orovan,William1
1Division of Urology, McMaster University, Hamilton, ON, Canada; 2Department of Surgery,McMaster University, Hamilton, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
100 CUA 2012 BANFF
MP-01.12Radical Prostatectomy in Patients with High Risk Prostate Cancer:Predicting Oncological Outcomes in a Single Series
Autran Gomez, Ana Maria; Chin, Joseph; Izawa, JonathanLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada
MP-01.13Prospective, Randomized Use of the VLOC Vesicourethral Anastamosisduring Robot-assisted Radical Prostatectomy: Long-term Follow-up
Zorn, Kevin1; Trinh, Quoc-Dien2; Liberman, Dan2; Elhakim, Assaad21University of Montréal (CHUM), Montréal, QC, Canada; 2University of Montreal Hospital Center(CHUM), Montreal, QC, Canada
MP-01.14Comparison of Open and Robotic-assisted Prostatectomy: The University of British Columbia Experience
Gagnon, Louis-Olivier; Lynch, Kenny; Hurtado, Antonio; Goldenberg, Larry; Gleave, MartinDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
MP-01.15 How Does Robot-assisted Laparoscopic Radical ProstatectomyCompare to Open Surgery in Men with High Risk Prostate Cancer?
Punnen, Sanoj; Cowan, Janet; Carroll, PeterUniversity of California, San Francisco, CA, United States
MP-01.16 Positive Surgical Margins at Radical Prostatectomy: Population-based Averages within PSA and Gleason Strata
Izard, Jason1; Salazar, Marco2; Chatterjee, Suman3; Lin, Daniel1; Wright, Jonathan11Department of Urology, University of Washington, Seattle, WA, United States; 2SoundUrological Associates, Edmonds, WA, United States; 3William Osler Health Centre, Brampton,ON, Canada
MP-01.17 Prostate Cancer Less than Two Cells from the Surgical MarginPredicts Biochemical Recurrence
Izard, Jason1; True, Lawrence2; May, Philip1; Ellis, William1; Lange, Paul1; Lin, Daniel1; Wright, Jonathan11Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Pathology, University of Washington, Seattle, WA, United States
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 101
MP-01.18 Striated Muscle in Radical Prostatectomy Specimens: Is It Predictive of Post-prostatectomy Urinary Incontinence?
Skeldon, Sean; Gani, Johan; Evans, Andrew; Van der Kwast, Theo; Radomski, SidneyUniversity of Toronto, Toronto, ON, Canada
MP-01.19Radiotherapy after Radical Prostatectomy: TreatmentRecommendations Differ between Urologists and RadiationOncologists
Lavallée, Luke T.1; Fergusson, Dean2; Grenon, Renee3; Morgan, Scott4; Momoli, Franco2;Morash, Christopher1; Cagiannos, Ilias1; Breau, Rodney H.11Division of Urology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; 2OttawaHospital Research Institute, University of Ottawa, Ottawa, ON, Canada; 3Children’s Hospital ofEastern Ontario, Ottawa, ON, Canada; 4Division of Radiation Oncology, The Ottawa Hospital,University of Ottawa, Ottawa, ON, Canada
MP-01.20 Osteoporosis Management Program Decreases the Incidence of HipFracture in Prostate Cancer Patients on Androgen Deprivation Therapy
Chien, Gary1; Zhumkhawala, Ali1; Gleason, Joseph1; Cheetham, Craig1; Niu, Fang1; Dell,Richard2; Jacobsen, Steven31Kaiser Permanente, Los Angeles, CA, United States; 2Kaiser Permanente, Downey, CA, UnitedStates; 3Kaiser Permanente, Pasadena, CA, United States
MP-01.21Testosterone Suppression: Impact of Testosterone Level on DiseaseProgression in Advanced Prostate Cancer
Dason, Shawn; Tong, Justin; Allard, Christopher; Shayegan, BobbyDivision of Urology, McMaster University, Hamilton, ON, Canada
MP-01.22Inadequate Testosterone Suppression in Prostate Cancer PatientsFailing on GnRH Agonists: Preliminary Data from the Delay Study
Casey, Richard1; Morales, Alvaro2; Siemens, Robert31The Male Health Centre, Oakville, ON, Canada; 2Queen’s University, Kingston, ON, Canada;3Queen’s University, Oakville, ON, Canada Richard Casey1 and Alvaro Morales2
TUESDAY / MARDI JUNE 26 JUIN
102 CUA 2012 BANFF
1240-1440 MP-02Moderated Poster Session 2: Endourology/StonesSéance de posters modérés 2: Endo-urologie/Lithiases
Room – Salle: BeattyModerators/Modérateurs:Ryan Paterson, Vancouver, BC Darren Beiko, Kingston, ON
MP-02.01 Holmium Laser Enucleation of the Prostate for Glands Larger than 200 Grams
Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States
MP-02.02 Impact of 5-alpha Reductase Inhibitors on Enucleation andMorcellation Efficiency during Holmium Laser Enucleation of the Prostate
Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States
MP-02.03 Early Outcomes of Office-based Laser Vaporization of the Prostatewith the High Power Diode Laser
Davis, Jeffrey; Patel, Roshan; Culkin, Daniel; Sindhwani, PuneetUniversity of Oklahoma, Health Sciences Center, Oklahoma City, OK, United States
MP-02.04 Novel Ultra-low Dose Non-contrast CT (NCCT) for Urolithiasis:Prospective Comparison of Diagnostic Accuracy with ConcurrentStandard Dose Imaging
Sivalingam, Sri; Pickhardt, Perry; Ruma, Julie; Nakada, Stephen Y.University of Wisconsin, WI, United States
MP-02.05 Does a Routine Baseline Plain Radiograph Influence the Need forSubsequent Imaging Studies in Patients with Ureteral Calculi?
Foell, Kirsten1; Ordon, Michael2; Ghiculete, Daniela2; Honey, R. John D’A.2; Pace, Kenneth T.21St. Michael’s Hospital, Toronto, ON, Canada; 2St. Michael’s Hospital, University of Toronto,Toronto, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 103
MP-02.06 Urolithiasis Prevention Beginning in the Emergency Room: Support forEarly Intervention During the Acute Event
Sivalingam, Sri; Penniston, Kris; Nakada, Stephen Y.University of Wisconsin, Madison, WI, United States
MP-02.07 Characterization of Patients with Heterozygous Cystinuria
Elkoushy, Mohamed; Andonian, Sero
MP-02.08 Office-based Ureteral Stent Placement Is Feasible and Effective forAcute, Obstructing Ureteral Calculi
Sivalingam, Sri; Tamm-Daniels, Inge; Nakada, Stephen Y.University of Wisconsin, Madison WI, United States
MP-02.09 Variations among Urology Trainees in Their Use of Fluoroscopy duringUreteroscopy
Elkoushy, Mohamed; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada
MP-02.10 Prediction of Calcium Oxalate Monohydrate Stone Composition duringUreteroscopy
Hamidizadeh, Reza; Teichman, Joel M. H.Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada
MP-02.11 Backstop Eliminates Retropulsion and Withstands Ho:YAG Energy
Melnyk, Megan1; Sea, Jason1; Teichman, Joel1; Qiu, Jinze3; Wang, Bingqing3; Milner, Thomas2;Chew, Ben1; Robinson, Michael11University of British Columbia, Vancouver, BC, Canada; 2University of Texas, Austin, TX, UnitedStates
MP-02.12 The Safety of Percutaneous Nephrolithotomy (PNL) in an ElderPopulation: Outcomes and Complications of Septuagenarians,Octogenarians and Nonagenarians
De, Shubha1; Thalivasan, Simone2; Pareek, Gyan2; Haleblian, George21Dalhousie University, Department of Urology, Halifax, NS, Canada; 2Brown University,Department of Urology, Providence, RI, United States
TUESDAY / MARDI JUNE 26 JUIN
104 CUA 2012 BANFF
MP-02.13 Withdrawn
MP-02.14 Retrograde Access for Percutaneous Nephrolithotomy: Is This The Way to Go?
Sivalingam, Sri1; Al-Essawi, Turki2; Hosking, Denis21University of Wisconsin, Madison, WI, United States; 2University of Manitoba, Winnipeg, MB,Canada
MP-02.15 Without Stone Culture Infectious Kidney Organisms Are Misidentifiedin almost 1/4 of Patients Undergoing Percutaneous Nephrolithotomy
Bhojani, Naeem1; Williams, James C.2; Mandeville, Jessica A.1; Lingeman, James E.11Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States; 2IndianaSchool of Medicine, Department of Anatomy, Indianapolis, IN, United States
MP-02.16 Interim Analysis of a Multi-centre Randomized Controlled TrialComparing Three Different Modalities of Newer Lithotrites forIntracorporeal Lithotripsy
Arsovska, Olga1; Miller, Nicole2; Krambeck, Amy3; Humphreys, Mitchell3, Matlaga, Brian4;Nakada, Stephen5; Nadler, Robert6; Lingeman, James7; Razvi, Hassan8; Paterson, Ryan1;Chew, Ben11University of British Columbia, Vancouver, BC, Canada; 2Vanderbilt University Medical Center,Nashville, TN, United States; 3Mayo Clinic College of Medicine, Phoenix, AZ, United States;4Johns Hopkins -Baltimore, MD, United States; 5University of Wisconsin, Madison, WI, UnitedStates; 6Northwestern University, Chicago, IL, United States; 7Methodist Urology, Indianapolis,IN, United States; 8University of Western Ontario, London, ON, Canada
MP-02.17 Combined Percutaneous Nephrolithotomy/Parathyroidectomy underOne Anesthetic in Patients with Primary Hyperparathyroidism andStones
Bhojani, Naeem1; Mandeville, Jessica A.1; Graffis, Richard2; Lingeman, James E.21Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States; 2Indiana School of Medicine, Department of General Surgery, Indianapolis, IN, United States
MP-02.18 Shock Wave Lithotripsy Referral Patterns Changes Over a Decade at aSingle Centre
Elkoushy, Mohamed; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 105
MP-02.20 How Accurate Are Urologists at Estimating Lesion SizeEndoscopically?
Massaro, Peter1; Abdolell, Mohamed2; Norman, Richard11Department of Urology, Dalhousie University, Halifax, NS, Canada; 2Department of DiagnosticRadiology, Dalhousie University, Halifax, NS, Canada
1240-1440 MP-03Moderated Poster Session 3: RenalSéance de posters modérés 3: Rénal
Room – Salle: Van Horne BModerators/Modérateurs:Anil Kapoor, Hamilton, ONJun Kawakami, Calgary, AB
MP-03.01Does the Method of Bladder Cuff Excision Affect Disease Recurrenceafter Nephrouretectomy for Upper Tract Urothelial Carcinoma? A Single-centre Comparison of Three Bladder Cuff Excision Methods
Allard, Christopher; Alamri, Abdulaziz; Matsumoto, Edward; Dason, Shawn; Kapoor, AnilMcMaster Institute of Urology, Hamilton, ON, Canada
MP-03.02Regional Differences in Practice Patterns and Associated Outcomesfor Upper Tract Urothelial Carcinoma in Canada: Outcomes from the Canadian Upper Tract Collaboration
Wassim, Kassouf1; Rendon, Ricardo2; Bell, David2; Izawa, Jonathan3; Chin, Joseph3; Kapoor,Anil4; Matsumoto, Edward4; Lattouf, Jean-Baptiste5; Saad, Fred5; Lacombe, Louis6; Fradet,Yves6; Fairey, Adrian7; Jacobson, Niels7; Drachenberg, Darryl8; Cagiannos, Ilias9; So, Alan10;Black, Peter10; Metcalfe, Michael101McGill University, Montréal, QC, Canada; 2Dalhousie University, Halifax, NS, Canada;3University of Western Ontario, London, ON, Canada; 4McMaster University, Hamilton, ON,Canada; 5University of Montreal, Montreal, QC, Canada; 6Laval University, Quebec, QC,Canada; 7University of Alberta, Edmonton, AB, Canada; 8University of Manitoba, Winnipeg, MB, Canada; 9University of Ottawa, Ottawa, ON, Canada; 10University of British Columbia,Vancouver, BC, Canada
TUESDAY / MARDI JUNE 26 JUIN
106 CUA 2012 BANFF
MP-03.03Impact of Body Mass Index (BMI) on Outcomes of Patients with Upper and Lower Urinary Tract Cancers Treated by Radical Surgery:Results from a Canadian Multicenter Collaboration
Bachir, Bassel G.1; Aprikian, Armen G.1; Izawa, Jonathan I.2; Chin, Joseph L.2; Fradet, Yves3;Fairey, Adrien4; Estey, Eric4; Jacobsen, Niels4; Rendon, Ricardo5; Cagiannos, Ilias6; Lacombe,Louis3; Tanguay, Simon1; Lattouf, Jean-Baptiste7; Kapoor, Anil8; Matsumoto, Edward8; Saad,Fred7; Bell, David5; Black, Peter C.9; So, Alan I.9; Drachenberg, Darrel10; Kassouf, Wassim1
1McGill University Health Center, Montreal, QC, Canada; 2University of Western Ontario,London, ON, Canada; 3Laval University, Quebec, QC, Canada; 4University of Alberta, Edmonton,AB, Canada; 5Dalhousie University, Halifax, NS, Canada; 6University of Ottawa, Ottawa, ON,Canada; 7University of Montreal, Montreal, QC, Canada; 8McMaster University, Hamilton, ON,Canada; 9University of British Columbia, Vancouver, BC, Canada; 10University of Manitoba,Winnipeg, MB, Canada
MP-03.04A Population-based Study of Surgeon Characteristics Associated withthe Uptake of Contemporary Techniques in Renal Surgery
Yap, Stanley1; Alibhai, Shabbir1; Margel, David1; Abouassaly, Robert2; Timilshina, Narhari1;Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2University Hospitals Case Medical Center,Cleveland, OH, United States
MP-03.05Association between Comorbidity and Survival after RadicalNephroureterectomy: Results from the Canadian Upper TractCollaboration
Fairey, Adrian1; Jacobsen, Niels2; Tanguay, Simon3; Rendon, Ricardo4; Bell, David4; Izawa,Jonathan5; Chin, Joe5; Kapoor, Anil6; Matsumoto, Edward6; Black, Peter7; So, Alan7; Lattouf,Jean-Baptiste8; Saad, Fred8; Drachenberg, Darrell9; Cagiannos, Ilias10; Lacombe, Louis11;Fradet, Yves11; Kassouf, Wassim3
1University of Southern California, Pasadena, CA, United States; 2University of Alberta,Edmonton, AB, Canada; 3McGill University, Montréal, QC, Canada; 4Dalhousie University,Halifax, NS, Canada; 5University of Western Ontario, London, ON, Canada; 6McMasterUniversity, Hamilton, ON, Canada; 7University of British Columbia, Vancouver, BC, Canada;8University of Montreal, Montreal, QC, Canada; 9University of Winnipeg, Winnipeg, MB,Canada; 10University of Ottawa, Ottawa, ON, Canada; 11Laval University, Quebec City, QC,Canada
MP-03.06Ipsilateral Adrenalectomy at the Time of Radical Nephrectomy - Does It Impact Overall Survival?
Yap, Stanley1; Alibhai, Shabbir1; Abouassaly, Robert2; Timilshina, Narhari1; Margel, David1;Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2University Hospitals Case Medical Center,Cleveland, OH, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 107
MP-03.07Oncolytic Virotherapy Combined with Targeted Therapy for theTreatment of Renal Cell Carcinoma
Lawson, Keith1; Shi, Zhong Qiao1; Spurrell, Jason1; Kawakami, Jun2; Morris, Don11Department of Oncology, University of Calgary, Calgary, AB, Canada; 2Division of Urology,Department of Surgery, University of Calgary, Calgary, AB, Canada
MP-03.08Clinical Role of the SWI/SNF Complex Gene PBRM1 in Clear Cell RenalCell Carcinoma
Morales, Carlos; Kurban, Ghada; Matevski, Donco; Massey, Christine; Evans, Andrew; Gallie,Brenda L.; Jewett, Michael A.S.University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
MP-03.09Canadian Kidney Cancer Information System (CKCis): a ProspectivePlatform to Better Understand Outcomes of Patients with KidneyCancer
Tanguay, Simon1; Kapoor, Anil2; Wood, Lori3; Heng, Daniel4; Zhihui, Liu5; Hanley, James5; Lane, Kelly6; Chow, Raymond6; Hamilton, Wendella1; Jewett, Michael71McGill University Health Center, Montreal, QC, Canada; 2McMaster University, Hamilton, ON,Canada; 3Capital District Health Authority, Halifax, NS, Canada; 4Alberta Health Services,Calgary, AB, Canada; 5McGill University, Montréal, QC, Canada; 6University Health Network,Toronto, ON, Canada; 7University Health Center, Toronto, ON, Canada
MP-03.10Validation of a Partial Nephrectomy Bench Model Developed via aNovel Material Engineering Process
Alamri, Abdulaziz; Abdulla, Alym; Madjeruh, John; Matsumoto, EdwardMcMaster University, Hamilton, ON, Canada
MP-03.11Laparoscopic Partial Nephrectomy for ≥ 4 cm Renal Masses Alyami, FahadDalhousie University, Halifax, NS, Canada
MP-03.12Defining Small Renal Masses “trifecta” after Laparoscopic PartialNephrectomies
Blouin, Annie-Claude1; Dujardin, Thierry2; Audet, Jean-François2; Caumartin, Yves2; Lacombe,Louis2; Imbeault, Annie2; Fradet, Vincent2; Fradet, Yves2; Pouliot, Frédéric21Université Laval, Quebec, QC, Canada; 2Centre hospitalier universitaire de Québec, Quebec,QC, Canada
TUESDAY / MARDI JUNE 26 JUIN
108 CUA 2012 BANFF
MP-03.13Fuhrman Grade Does Not Improve the Discriminant Ability in Patientswith Papillary Renal Cell Carcinoma
Ismail, Salima; Sun, Maxine; Abdo, Al’a; Djahangirian, Orchid; Hanna, Nawar; Karakiewicz, PierreCancer Prognostics and Health Outcome Unit, University of Montreal Health Center, Montreal, QC, Canada
MP-03.14Comparative Study for Carbonic Anhydrase-ix, Vascular EndothelialGrowth Factor and Platelet Derived Growth Factor Receptor-alphaImmunohitochemical Expression in Renal Cell Carcinoma
Bishr, Mohamed1; Le Page, Cecile1; Gannon, Philippe O.1; Barres, Véronique1; Albadine, Roula2;Saad, Fred2; Lattouf, Jean-Baptiste21Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institutdu cancer de Montréal, Montréal, QC, Canada; 2Centre hospitalier de l’Université de Montréal(CHUM), Montréal, QC, Canada
MP-03.15Percutaneous Renal Cryoablation: Results from a Prospective Study
Metcalfe, Charles1; Welsh, Mike2; Donnelly, Bryan31University of British Columbia, Vancouver, BC, Canada; 2University of Calgary, Department ofRadiology, Calgary, AB, Canada; 3University of Calgary, Division of Urology, Calgary, AB,Canada
MP-03.16Contrast-enhanced Ultrasound for Follow-up after RadiofrequencyAblation of Small Renal Masses
Kapoor, Anil1; Allard, Christopher1; Matsumoto, Edward1; Coret, Andu21McMaster University, Institute of Urology, Hamilton, ON, Canada; 2McMaster University,Department of Radiology, Hamilton, ON, Canada
MP-03.17Prophylactic vs. Selective Ureteral Stenting in Preventing UretericComplications Post Renal Transplant: a Retrospective Review
Ordon, Michael; Ghiculete, Daniela; Stewart, Robert; Pace, Kenneth; Honey, R. John D’A.St. Michael’s Hospital, Toronto, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 109
MP-03.18Supplemental Hydrogen Sulphide Reduces Graft Inflammation and Modulates Inflammatory and Anti-apoptotic Gene Expression in Renal Grafts Transplanted Following Prolonged Cold Storage
Lobb, Ian1; Liu, Weihua2; Garcia, Bertha2; Lan, Zhu3; Sener, Alp41Microbiology and Immunology, University of Western Ontario, Matthew Mailing Centre,London, ON, Canada; 2Pathology, University of Western Ontario, London, ON, Canada;3Surgery, University of Western Ontario, Matthew Mailing Centre, London, ON, Canada;4Surgery and Microbiology and Immunology, University of Western Ontario, Matthew MailingCentre, London, ON, Canada
MP-03.19Does Donor Side Affect Outcomes? A Comparison of Right versus LeftAllografts in Deceased Donor Renal Transplantation
Ordon, Michael; Ghiculete, Daniela; Stewart, Robert; Pace, Kenneth; Honey, R. John D’A.St. Michael’s Hospital, Toronto, ON, Canada
MP-03.20 Detrimental Effects of Prolonged Warm Renal Ischemia ReperfusionInjury Are Abrogated by Supplemental Hydrogen Sulphide: an AnalysisUsing Real-time Intravital Microscopy
Zhu, Justin1; Kalbfleisch, Melanie1; Bihari, Relka1; Lobb, Ian1; Davison, Michael1; Mok, Amy1;Lawendy, Abdel1; Sener, Alp21University of Western Ontario, London, ON, Canada; 2Matthew Mailing Center forTranslational Transplant Studies, London, ON, Canada
MP-03.21En Bloc Adult Organ Transplantation
Tran, Kim-Chi1; Taqi, Ali1; Warren, Jeff2; Caumartin, Yves3; Nguan, Christopher4; McAlister,Vivian1; Luke, Patrick11University of Western Ontario, London, ON, Canada; 2University of Ottawa, Ottawa, ON,Canada; 3University of Laval, QC, Canada; 4University of British Columbia, Vancouver, BC,Canada
MP-03.22Maximal Kidney Length Predicts Need for Native Nephrectomy in Patients with Autosomal Dominant Polycystic Kidney DiseaseUndergoing Renal Transplantation
Cristea, Octav1; Yanko, Daniel2; Langford, Sarah2; House, Andrew2; Stitt, Larry1; Sener, Alp2; Luke, Patrick21Schulich School of Medicine & Dentistry, London, ON, Canada; 2London Health SciencesCentre, London, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
110 CUA 2012 BANFF
MP-03.23Risk Stratification and Management Strategy for UndetectedThrombophilia in Pediatric Renal Transplant Recipients
Davis, Jeffrey; Sindhwani, Puneet; Turman, MartinUniversity of Oklahoma, Health Sciences Center, Oklahoma City, OK, United States
1240-1440 MP-04Moderated Poster Session 4: Voiding DysfunctionSéance de posters modérés 4: Troubles mictionnels
Room – Salle: Van Horne CModerators/Modérateurs:Ron Gerridzen, Ottawa, ONRichard Baverstock, Calgary, AB
MP-04.01The Role of Dutasteride in Preventing BPH Clinical Progression inAsymptomatic Men with an Enlarged Prostate
Toren, Paul; Margel, David; Kulkarni, Girish; Finelli, Antonio; Zlotta, Alexandre; Fleshner, NeilUniversity of Toronto, Toronto, ON, Canada
MP-04.02Comparison of Ultrasound and Fluoroscopic Imaging for UrodynamicAssessment of Non-neurogenic Voiding Dysfunction in Males
Bacsu, Chasta-Dawne1; Tse, Vincent2; Chan, Lewis21Concord Repatriation General Hospital, Saskatoon, SK, Canada; 2Concord RepatriationGeneral Hospital, Sydney, Australia
MP-04.03Does Independently-interpreted Retrograde Urethrography AccuratelyDiagnose and Stage Anterior Urethral Stricture Disease?
Bach, Phil; Rourke, KeithUniversity of Alberta, Edmonton, AB, Canada
MP-04.04Do Cuff Size/Reservoir Size Impact Erosion, Revision, Infection andOutcome Rates in Patients Who Underwent AUS Placement for StressUrinary Incontinence after Primary Treatment for Prostate Cancer
Popovic, Mihailo; Lucas, Steven; Haddad, Joseph; Singla, AjayWayne State University, School of Medicine, Urology, Detroit, MI, United States
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 111
MP-04.05The Sphincter Sum: a Practical and Effective Tool for EvaluatingPatients with Post-prostatectomy Incontinence
Gustafson, PaulUniversity of British Colombia Urology, Vancouver, BC, Canada
MP-04.06Revision Urethroplasty for Recurrent Urethral Stricture: a ComparativeAnalysis of Efficacy and Outcomes
Levine, Max A.; Kinnaird, Adam S.; Rourke, Keith F.Division of Urology, University of Alberta, Edmonton, AB, Canada
MP-04.07Primary Realignment versus Suprapubic Cystostomy for theManagement of Posterior Urethral Distraction Defects: a SystematicReview and Meta-analysis
Barrett, Keith; Braga, Luis H.; Davies, Timothy O.McMaster University, Division of Urology, Hamilton, ON, Canada
MP-04.08The Mesh Wallstent (UroLume) in the Treatment of Detrusor ExternalSphincter Dyssynergia in Men with Spinal Cord Injury
Binsaleh, Saleh1; Laplante, Michael21King Saud University, Faculty of Medicine, Riyadh, Saudi Arabia; 2McGill University, Montréal,QC, Canada
MP-04.09Surgical Treatment of Male Incontinence Using the Argus Male Sling:Our First 5-Case Experience
Baverstock, Richard1; Carlson, Kevin1; Amaral, Nicole1; Herschorn, Sender21vesia [Alberta Bladder Centre], Division of Urology, University of Calgary, Calgary, AB,Canada; 2Division of Urology, University of Toronto, Toronto, ON, Canada
MP-04.10A Potential Gold Standard for Reconstruction of Long Segment BulbarUrethral Strictures - Intermediate Outcomes of the Dorsal OnlayAugmented Anastomosis with Buccal Mucosa Graft
Hoy, Nathan; Kinnaird, Adam; Rourke, KeithUniversity of Alberta, Division of Urology, Edmonton, AB, Canada
TUESDAY / MARDI JUNE 26 JUIN
112 CUA 2012 BANFF
MP-04.11Effect of Baseline Characteristics of Subjects with Overactive Bladderon Changes in Daytime and Nighttime Urgency Urinary IncontinenceEpisodes Following Antimuscarinic Treatment
Herschorn, Sender1; Wang, Joseph2; Ntanios, Fady21University of Toronto, Toronto, ON, Canada; 2Pfizer Inc., New York, NY, United States
MP-04.12The Selective B3-Adrenoreceptor Agonist Mirabegron Is Effective and Well Tolerated in Patients with Overactive Bladder Syndrome
Herschorn, Sender1; Nitti, Victor2; Auerbach, Stephen3; Lee, Misun4; Martin, Nancy41University of Toronto, Toronto, ON, Canada; 2New York University School of Medicine, NewYork, NY, United States; 3Hoag Memorial Presbyterian Hospital, Newport Beach, CA, UnitedStates; 4Astellas, Deerfield, IL, United States
MP-04.13Open-label, Ascending Dose Cohort Study of LiRIS (lidocaine-releasingintravesical system) in Women with Moderate to Severe InterstitialCystitis
Steele, Stephen S.1; Nickel, J. Curtis1; Steinhoff, Gary2; Egerdie, Blair3; Gajewski, Jerzy4; Bailly, Greg4; Himes, Julie51Queen’s University, Kingston, ON, Canada; 2University of British Columbia, Victoria, BC,Canada; 3The University of Western Ontario, Kitchener, ON, Canada; 4Dalhousie University,Halifax, NS, Canada; 5Taris Biomedical, Lexington, MA, United States
MP-04.14Noninvasive Diagnosis of Painful Bladder Syndrome / InterstitialCystitis Using Near Infrared Spectroscopy
Shadgan, Babak; Stothers, Lynn; Macnab, AndrewUniversity of British Columbia, Vancouver, BC, Canada
MP-04.15Monitoring of Lower Urinary Tract Function in Patients with SpinalCord Injury Using Near Infrared Spectroscopy
Shadgan, Babak; Stothers, Lynn; Macnab, Andrew; Nigro, MarkUniversity of British Columbia, Vancouver, BC, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 113
MP-04.16The Signal Transduction of Skin Electrode Can Launch on the Bladderof Diabetic Rabbits and Ameliorate Its Hypomotility
Wang, Xinmin1; Zhang, Qingmei1; Xu, Ping1; Cao, Lin1; Xue, Meng1; Wang, Wei21Department of Endocrinology, The Second Clinical Medical College of Jinan University(Shenzhen Peoples Hospital), Shenzhen, China;2H. Medical and Health Physics, McMaster University, Hamilton, ON, Canada
MP-04.17Cost-effectiveness of Sacral Neuromodulation in RefractoryOveractive Bladder: a Canadian Perspective
Gajewski, Jerzy1; Corcos, Jacques2; Dwyer, Neil T3; Gray, Gary4; Hassouna, Magdy5; Magali,Robert6; Tu, Le-Mai7; Sadri, Hamid81Dalhousie University, Halifax, NS, Canada; 2Jewish General Hospital, Montreal, QC, Canada;3Moncton Hospital, Moncton, NB, Canada; 4Royal Alexandra Hospital, Edmonton, AB, Canada;5Toronto Western Hospital, Toronto, ON, Canada; 6Foothills Hospital, Calgary, AB, Canada;7Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada; 8Medtronic ofCanada, Brampton, ON, Canada
MP-04.18Sacral Neuromodulation Failures
Chang, Michelle; Gajewski, JerzyDepartment of Urology, Dalhousie University, Halifax, NS, Canada
MP-04.19A Cost-effectiveness Analysis of Tension-free Vaginal Tape vs. Burch Colposuspension for Female Stress Incontinence
Elterman, Dean; Chughtai, Bilal; Laudano, Melissa; Li, Philip; Tyagi, Renuka; Kavaler,Elizabeth; Te, Alexis; Kaplan, Steven; Lee, RichardWeill Medical College of Cornell University, New York, NY, United States
MP-04.20Urinary Tract Mesh Erosion Following Female Pelvic Surgery
Cox, Ashley; Herschorn, Sender; Carr, LesleySunnybrook Health Science Centre, Toronto, ON, Canada
MP-04.21Long-term Outcomes of Pessary Use in Women with Pelvic Organ Prolapse
Ramsay, Sophie; Bouchard, Frederick; Tu, Le MaiUniversité de Sherbrooke, Sherbrooke, QC, Canada
TUESDAY / MARDI JUNE 26 JUIN
114 CUA 2012 BANFF
MP-04.22Management and Outcomes of Complex versus Simple Female Urethral Diverticula
Carlson, KevinUniversity of Calgary/vesia [Alberta Bladder Centre], Calgary, AB, Canada
MP-04.23Developing a Multi-disciplinary Lower Urinary Tract Centre: the vesia [Alberta Bladder Centre] Experience
Baverstock, Richard1; Carlson, Kevin21vesia [Alberta Bladder Centre], Calgary, AB, Canada; 2vesia [Alberta Bladder Centre] Divisionof Urology, University of Calgary, Calgary, AB, Canada
1440-1450 Break / Pause
Room – Salle: Foyer
1450-1600 MP-05Moderated Poster Session 5: Pediatric UrologySéance de posters modérés 5: Urologie pédiatrique
Room – Salle:Van Horne CModerators/Modérateurs:Peter Metcalfe, Edmonton, AB Peter Anderson, Halifax, NS
MP-05.01Impact of Side of Allograft Placement and Location of ArterialAnastomosis on Delayed Renal Function after Pediatric RenalTransplantation
Figueroa, Victor H.; Lorenzo, Armando J.; Kim, Wooheon T.; Romao, Rodrigo L.P.; Pippi Salle,Joao L.; Koyle, Martin A.; Taylor, KatherineThe Hospital for Sick Children, Toronto, ON, Canada
MP-05.02Minimally Invasive Open Technique for Management of Upper PoleEctopic Ureter in Children with Duplicated Systems
Sheikh, Adeel1; Zaidi, Adil2; DeMaria, Jorge1; Luis, Braga11McMaster Institute of Urology, Hamilton, ON, Canada; 2St. George’s University, Great River,NY, United States
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 115
MP-05.03 Observation versus Immediate Intervention in Ureteropelvic Junction Obstruction: Does It Matter?
Stearns, Gillian1; Reeder, Jay1; Barrieras, Diego2; Houle, Anne-Marie2; Franc-Guimond, Julie2;Riddell, Jonathan11SUNY Upstate, Syracuse, NY, United States; 2CHU Sainte-Justine, Montréal, QC, Canada
MP-05.04A Prospective Study Using a New Bulking Agent for the Treatment of Pediatric Vesicoureteral Reflux: Bulkamid®
Cloutier, Jonathan1; Blais, Anne-Sophie2; Moore, Katherine2; Bolduc, Stéphane21Division of Urology CHUL, CHUQ, Quebec, QC, Canada; 2Division of Urology, CHUL-CHUQ,Université Laval, Quebec, QC, Canada
MP-05.05Does Routine Ultrasounds Change Management in the Follow-up of Patients with Vesicoureteral Reflux?
Wildgoose, Petra1; Weber, Bryce2; Lorenzo, Armando3; Bagli, Darius3; Farhat, Walid3; Harvey, Elizabeth3; Pippi Salle, Joao Luiz31McMaster Medical School, Calgary, AB, Canada; 2Alberta Children’s Hospital, Calgary, AB,Canada; 3Hospital for Sick Children, Toronto, ON, Canada
MP-05.06Methodological Quality Assessment of Randomized Controlled Trials inHypospadias Literature
Braga, Luis1; Lorenzo, Armando2; Vizcarra, Rachel1; Pemberton, Julia1; DeMaria, Jorge1;Byrne, Roisin31McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada;3University of Calgary, Calgary, AB, Canada
MP-05.07Is There a Role for Prophylactic Antibiotics after Stented HypospadiasRepair?
Kanaroglou, Niki; Alotay, Abdulhakim; Romao, Rodrigo; Koyle, Martin; Lorenzo, Armando;Bagli, Darius; Farhat, WalidSick Kids, Toronto, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
116 CUA 2012 BANFF
MP-05.08The Effect of Androgen Stimulation on Post-operative ComplicationRates after Penoscrotal Hypospadias Repair: a Systematic Review and Meta-analysis
Cole, Eric1; Wright, Ian1; Lorenzo, Armando2; Pemberton, Julia1; Vizcarra, Rachel1; Farrokhyar, Forough1; Braga, Luis11McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada
MP-05.09Clitoroplasty and Vaginoplasty in Adolescents and Adults with Disorders of Sex Development (DSD): Lessons Learned
Pippi Salle, Joao L.1; Romao, Rodrigo L.P.1; Allen, Lisa1; DeMaria, Jorge2; Braga, Luis H.P.2; Jednak, Roman3; Dave, Sumit4; Lorenzo, Armando J.1; Farhat, Walid1; Koyle, Martin1; Bagli, Darius11The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 2McMaster University, Hamilton, ON, Canada; 3McGill University, Montréal, QC, Canada;4University of Western Ontario, London, ON, Canada
MP-05.10Correlation of Ultrasound (US) with Laparoscopy (LAP) in KuwaitiPatients (pts) with Unilateral Non-palpable Testicles (NPT): Impact of Weight (WT) and Contralateral Testicular Size
Elsawy, Mohamed1; El-Hout, Yaser2; Gupta, Vipul1; Farhat, Walid2; Alsaid, Abdulnasser11Ibn Sina Hospital, Sulaibikhat, Kuwait; 2Sick Kids Hospital, Toronto, ON, Canada
MP-05.11Attempt at Fertility Preservation in Two Children with ParatesticularRhadomyosarcoma
Spelliscy, Courtney; Kiddoo, DarcieUniversity of Alberta, Edmonton, AB, Canada
MP-05.12 Urodynamic Improvements after Medical Treatment of Partial BladderOutlet Obstruction in an Animal Model
Maciejewski, Conrad1; Tredget, Edward2; Metcalfe, Peter11University of Alberta, Division of Urology, Edmonton, AB, Canada; 2University of Alberta,Division of Plastic Surgery, Edmonton, AB, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 117
MP-05.13Outcomes Following Fecal Continence Procedures in Patients with Neurogenic Bowel Dysfunction
Kiddoo, Darcie; Metcalfe, Peter; Hoy, NathanUniversity of Alberta, Edmonton, AB, Canada
MP-05.14Onabotulinumtoxin A Endoscopic Detrusor Injection for the Treatmentof Neurogenic Bladder in Children: Effect of Dose Adjustment, MultipleInjections and Avoidance of Reconstructive Procedures
Figueroa, Victor H.; Romao, Rodrigo L.P.; Pippi-Salle, Joao L.; Kanaroglou, Niki; Koyle, MartinA.; Bagli, Darius J.; Lorenzo, Armando J.The Hospital for Sick Children, Toronto, ON, Canada
1450-1600 MP-06Moderated Poster Session 6: ED, Peyronie’s Disease, InfertilitySéance de posters modérés 6: ED, maladie de La Peyronie etinfertilité
Room – Salle: BeattyModerators/Modérateurs: Serge Carrier, Montreal, QCPeter Pommerville, Victoria, BC
MP-06.01Antinuclear Antibody Titres Are Not Significantly Altered in Peyronie’sDisease
Shamloul, Rany1; Bella, Anthony J.1; Zappagigna, Christopher21University of Ottawa, Civic Hospital, Ottawa, ON, Canada; 2University of Ottawa, Ottawa, ON,Canada
MP-06.02A Novel Rat Model for Peyronie’s Disease That DemonstratesDurability and Functional Detriments
Garcia, Francisco1; De Young, Ling2; Chung, Eric3; Brock, Michael2; Brock, Gerald41Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON,Canada; 2Lawson Health Research Institute, London, ON, Canada; 3Department of Urology,Princess Alexandria Hospital, Brisbane, Australia; 4St. Joseph’s Health Care, Division ofUrology, London, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
118 CUA 2012 BANFF
MP-06.03Efficacy and Histologic Changes of Repeated Saline or IntralesionalVerapamil Injections and Traction Therapy in an Animal Model ofPeyronie’s Disease
Garcia, Francisco1; Chung, Eric2; De Young, Ling3; Wang, Peter1; Brock, Michael3; Brock,Gerald41Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON,Canada; 2Department of Urology, Princess Alexandria Hospital, Brisbane, Australia; 3LawsonHealth Research Institute, London, ON, Canada; 4St. Joseph’s Health Care, Division of Urology,London, ON, Canada
MP-06.04Do Patients Know Their Nerve-sparing Status Following RadicalProstatectomy?
Skeldon, Sean; Gani, Johan; Radomski, SidneyUniversity of Toronto, Toronto, ON, Canada
MP-06.05 Erectile Function Recovery Following Nerve Sural Grafting in OpenRadical Prostatectomy
Autran Gomez, Ana Maria; Izawa, Jonathan; Chin, JosephLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada
MP-06.06Resident Training Laboratory, Held in Conjunction with Conference,Meaningfully Impacts Resident Technical Skills and Perceptions forPenile Implant Surgery
Zappavigna, Christopher1; Christine, Brian2; Bella, Anthony J.11University of Ottawa, Division of Urology, Ottawa, ON, Canada; 2Urology Centers of Alabama, Birmingham, AL, United States
MP-06.07Robotic Assisted versus Pure Microsurgical Vasectomy Reversal:Prospective Control Trial
Gudeloglu, Ahmet1; Brahmbahtt, Jamin2; Priola, Karen1; Parekattil, Sijo11University of Florida and Winter Haven Hospital, Winter Haven, FL, United States; 2University of Tennessee, Memphis, TN, United States
MP-06.08 Cost-effectiveness of Varicocelectomy and Percutaneous Embolizationin the Management of Varicocele-associated Infertility
Klinghoffer, Zachary; Kovac, Jason; Fischer, Marc AnthonyMcMaster University, Hamilton, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 119
MP-06.09Use of Clomiphene Citrate for Male Idiopathic Infertility: InterimAnalysis of a Prospective Study Langille, Gavin1; Spencer, Leia2; Jarvi, Keith2; Grober, Ethan2; Lo, Kirk C.21Dalhousie University, Halifax, NS, Canada; 2University of Toronto, Toronto, ON, Canada
1450-1600 MP-07Moderated Poster Session 7: BladderSéance de posters modérés 7: Vessie
Room – Salle: ColemanModerators/Modérateurs:Fred Saad, Montreal, QCJoseph Chin, London, ON
MP-07.01Safety of Intravesical Mycobacterial Cell Wall-DNA Complex GivenImmediately Postsurgery in Patients with Non-muscle-invasiveBladder Cancer
Morales, Alvaro1; Jablonski, David2; Lihou, Christine3; Lang, Zig3; Champagne, Monique4;Cohen, Zvi41Queen’s University, Kingston, ON, Canada; 2Winter Park Urology Associates, Orlando, FL,United States; 3Endo Pharmaceuticals Inc, Chadds Ford, PA, United States; 4Bioniche LifeSciences Inc, Pointe-Claire, QC, Canada
MP-07.02 The Impact of Concomitant Carcinoma in Situ on Upstaging FollowingRadical Cystectomy for Bladder Cancer
Yafi, Faysal1; Aprikian, Armen1; Chin, Joseph2; Fradet, Yves3; Izawa, Jonathan2; Estey, Eric4;Fairey, Adrian4; Rendon, Ricardo5; Cagiannos, Ilias6; Lacombe, Louis3; Lattouf, Jean-Baptiste7;Bell, David5; Drachenberg, Darrel8; Kassouf, Wassim1
1McGill University, Montréal, QC, Canada; 2University of Western Ontario, London, ON, Canada;3Laval University, Quebec, QC, Canada; 4University of Alberta, Edmonton, AB, Canada;5Dalhousie University, Halifax, NS, Canada; 6University of Ottawa, Ottawa, ON, Canada;7University of Montreal, Montreal, QC, Canada; 8University of Manitoba, Winnipeg, MB, Canada
MP-07.03Young Age Predicts Favorable Disease Characteristics and Outcomesamong Patients with Urothelial Carcinoma of the Bladder
Izard, Jason1; Wright, Jonathan1; Black, Peter2; Porter, Michael11Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Urologic Sciences, University of British Colombia, Vancouver, BC, Canada
TUESDAY / MARDI JUNE 26 JUIN
120 CUA 2012 BANFF
MP-07.04Evaluation of the Survival Benefit of Multidisciplinary Care in HighRisk Bladder Cancer
Sandhu, Gurdarshan1; Nepple, Kenneth1; Schoenberg, Mark2; Strope, Seth11Washington University School of Medicine, St. Louis, MO, United States; 2The JamesBuchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD,United States
MP-07.05Increased Expenditures on Follow-up Care after Definitive Surgery for Bladder Cancer
Sandhu, Gurdarshan; Nepple, Kenneth; Grubb 3rd Robert; Yang, Liu; Strope, SethWashington University School of Medicine, St. Louis, MO, United States
MP-07.06Utilization of Peri-operative Chemotherapy for Bladder Cancer: a Population-based Study
Siemens, D. Robert1; Rhee, Jonathan1; Tannock, Ian2; Peng, Yingwei1; Li, Gavin1; Mackillop,William1; Booth, Chris11Queen’s University, Kingston, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Canada
MP-07.07Utilization and Predictors of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Veteran’s HealthAdministration
Sandhu, Gurdarshan1; Luo, Suhong2; Zeringue, Angelique2; Carson, Kenneth2; Nepple, Kenneth1; Strope, Seth1; Hudson, M’Liss2; Grubb 3rd, Robert21Washington University School of Medicine, St. Louis, MO, United States; 2VA St. LouisHealthcare System, Department of Veterans Affairs, St. Louis, MO, United States
MP-07.08 Laparoscopic Radical Cystectomy - Is There Evidence of LearningCurve? Experience of 60 Consecutive Cases Performed in a HighVolume Tertiary Cancer Centre
Khan, Faisal1; Abroaf, Ahmed2; Jackson, M1; Durkan, G C1; Heer, R1; Soomro, NA1; Johnson, MI11NHS, Newcastle, United Kingdom; 2NHS Freeman Hospital, Newcastle, United Kingdom
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 121
MP-07.09Hypoxia Is Independently Associated with Poor Outcome in UrothelialBladder Cancer Patients Treated with Radical Cystectomy
Bostrom, Peter J1; Thoms, John1; van Rhijn, Bas WG1; Ahmed, Omer1; Evans, Andrew1; Mirtti, Tuomas2; Sykes, Jenna1; Milosevic, Michael1; Zlotta, Alexandre R3; Bristow, Robert G1
1University Health Network, Toronto, ON, Canada; 2Helsinki University Hospital, Helsinki,Finland; 3Mount Sinai Hospital, University Health Network, Toronto, ON, Canada
MP-07.10Heat Shock Protein 70 (HSP70) as a Recurrence Marker for PT1Bladder Cancer
Stakhovskyi, Oleksandr1; Margel, David1; van der Kwast, Theodorus H.1; van Rhijn, Bas W.G.1;Bostrom, Peter J.1; Bristow, Robert G.1; Fleshner, Neil E.1; Jewett, Michael A.S.1; Bapat, Bharati2; Zlotta, Alexandre R.31University Health Network, Toronto, ON, Canada; 2Mount Sinai Hospital, Samuel LunenfeldResearch Institute, Toronto, ON, Canada; 3Mount Sinai Hospital, University Health Network,Toronto, ON, Canada
MP-07.11 How Should Locoregionally Recurrent or Advanced PrimaryMalignancies of the Bladder or Ureter Be Managed? Potential Role of Multimodality Therapy Incorporating Surgery and IntraoperativeRadiotherapy
Choo, Richard; Hallemeier, Christopher; Haddock, MichaelMayo Clinic, Rochester, MN, United States
MP-07.12 Tumor Stage on Re-staging Transurethral Resection PredictsRecurrence and Progression Free Survival of High Risk SuperficialBladder Cancer
Bishr, Mohamed1; Lattouf, Jean-Baptiste2; Latour, Mathiew2; Saad, Fred21Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM) and Institutdu cancer de Montréal, Montréal, QC, Canada; 2Centre hospitalier de l’université de Montréal(CHUM), Montréal, QC, Canada
1450-1600 MP-08Moderated Poster Session 8: MiscellaneousSéance de posters modérés 8: Sujets divers
Room – Salle: Van Horne BModerators/Modérateurs:Trevor Schuler, Edmonton, ABRobert Siemens, Kingston, ON
TUESDAY / MARDI JUNE 26 JUIN
122 CUA 2012 BANFF
MP-08.01Preliminary Results of the Resident Manpower Survey by the CUASocioeconomic Committee: Are We Training too Many Urologists?
Drachenberg, Darrel; Kaler, KamaljotUniversity of Manitoba, Winnipeg, MB, Canada
MP-08.02Incorporating Patient Simulation into In-training Exams to AssessCanMEDS Competencies in Urology Residents
Nguyen, Laura; Roberts, Matthew; Watterson, JamesUniversity of Ottawa/The Ottawa Hospital, Ottawa, ON, Canada
MP-08.03The Newly Graduated Canadian Urologist: Underemployed and Overtrained?
Welk, Blayne1; Kodama, Ron2; MacNeily, Andrew3
1University of Western Ontario, London, ON, Canada; 2University of Toronto, Toronto, ON,Canada; 3University of British Columbia, Vancouver, BC, Canada
MP-08.04 Trends in Matching to Urology Residency in Canada: Are We Becoming Non-competitive?
Melnyk, Megan; Mickelson, Jennifer J; MacNeily, Andrew EDepartment of Urological Sciences, University of British Columbia, Vancouver, BC, Canada
MP-08.05Video Laparoscopic Trainers vs. Less Expensive Simple LaparoscopicTrainers
Nguyen, Tim1; Braga, Luis2; Matsumoto, Edward21Queen’s University, Kingston, ON, Canada; 2McMaster University, Hamilton, ON, Canada
MP-08.06Do Hunner’s Ulcers Represent Bladder Ischemia?
Melnyk, Megan; Teichman, JoelUniversity of British Columbia, Department of Urological Sciences, Vancouver, BC, Canada
MP-08.07Trials and Tribulations of a Canadian Interstitial Cystitis ResearchClinic
Nickel, J Curtis; Irvine-Bird, Karen; Robb, SylviaQueen’s University, Kingston, ON, Canada
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 123
MP-08.08Cannabis (Marijuana) Use in Men with Chronic Prostatitis / ChronicPelvic Pain Syndrome
Nickel, J Curtis1; Tripp, Dean1; Katz, Laura1; Ginting, Jessica1; Ware, Mark2; Santor, Darcy31Queen’s University, Kingston, ON, Canada; 2Montreal General Hospital, Montreal, QC, Canada;3University of Ottawa, Ottawa, ON, Canada
MP-08.09The Clinical Spectrum of Anterior Urethral Stricture: Detailed Analysisof a Large Single Institution Cohort
Rourke, Keith; Hickle, JonathanUniversity of Alberta, Edmonton, AB, Canada
MP-08.10Impact of Radiotherapy on Surgical Repair and Outcomes in Patientswith Rectourethral Fistula
Elliott, Daniel; Poskus, Tomas; Umbreit, Eric; Larson, David; Beddy, David; Dozois, EricMayo Clinic, Rochester, MN, United States
MP-08.11Comprehension and Preferences for Graphical Representations of Quality of Life after Prostate Cancer Treatment
Izard, Jason1; Hartzler, Andrea2; Gore, John21Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Medical Education, University of Washington, Seattle, WA, United States
MP-08.12Population-based Assessment of Enterocystoplasty Complicationsamong Adult Patients
Welk, Blayne1; Herschorn, Sender2; Law, Calvin2; Nam, Robert21University of Western Ontario, London, ON, Canada; 2University of Toronto, Toronto, ON,Canada
1450-1600 MP-09Moderated Poster Session 9: Basic ScienceSéance de posters modérés 9: Science fondamentale
Room – Salle: Baron ShaughnessyModerators/Modérateurs:Alan So, Vancouver, BCPeter Black, Vancouver, BC
TUESDAY / MARDI JUNE 26 JUIN
124 CUA 2012 BANFF
MP-09.01Knockdown of Integrin-linked Kinase Reduces Invasive and Metastatic Potential of Renal Cell Carcinoma by Impeding Epithelial to Mesenchymal Transition
Han, Kyungseok; Raven, Peter; Awrey, Shannon; Li, Estelle; Ladan, Fazli; Gleave, Martin; So, AlanVancouver Prostate Centre, Vancouver, BC, Canada
MP-09.02Enhanced Tumor Oxygenation Following Short-term Sunitinib Therapyin a Renal Cell Carcinoma Model: an Unexpected Finding
Chapman, David; Wuest, Melinda; Mercer, John; Wiebe, Leonard; Moore, RonaldUniversity of Alberta, Edmonton, AB, Canada
MP-09.03Evasive Resistance to VEGF-targeted Anti-angiogenic Therapy Is Acquired by Activation Angiogenesis Pathways Independent of VEGF in Renal Cell Carcinoma
Han, Kyungseok; Raven, Peter; Gust, Kilian; Awrey, Shannon; Li, Estelle; Ladan, Fazli; Gleave, Martin; So, AlanVancouver Prostate Centre, Vancouver, BC, Canada
MP-09.04Quantitative Proteomic Analysis of Exosome-enriched ExtracellularMicrovesicles Obtained Following an in vitro Model of Urinary TractObstruction
Orton, Dennis1; Doucette, Alan1; Maksym, Geoffrey1; MacLellan, Dawn21Dalhousie University, Halifax, NS, Canada; 2Dalhousie University, IWK Health Centre, Halifax,NS, Canada
MP-09.05Rat Bone Marrow Derived Mesenchymal Stem Cell Therapy in a Parkinsonian Animal Model of Detrusor Overactivity
Campeau, Lysanne1; Soler, Roberto2; Pareta, Rajesh1; Sivanandane, Sittadjody1; Opara,Emmanuel1; Andersson, Karl Erik11Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, UnitedStates; 2Division of Urology, Federal University of Sao Paulo, Sao Paulo, Brazil
TUESDAY / MARDI JUNE 26 JUIN
CUA 2012 BANFF 125
MP-09.06Intrathecal Cannabinoid Agonist Effects in Cystometric Evaluation of Normal Rats
Campeau, Lysanne1; Füllhase, Claudius2; Russo, Andrea3; Hedlund, Petter3; Andersson, Karl Erik11Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, UnitedStates; 2Department of Urology, University Hospital Großhadern, LMU, Munich, Germany;3Urological Research Institute, San Raffaele University, Milan, Italy
MP-09.07Rational Targeting of Fibroblast Growth Factor Receptor (FGFR)-3 in Bladder Cancer
Gust, Kilian1; McConkey, David2; Hegarty, Paul2; Awery, Shannon1; Bondaruk, Jolanta1;Czerniak, Bogdan2; Dinney, Colin2; Black, Peter11Vancouver Prostate Centre, Vancouver, BC, Canada; 2MD Anderson Cancer Center, Houston, TX, United States
MP-09.08Circulating Interlukin-6 and Nerve Growth Factor Are Associated withPeriprostatic Fat Length and Cancer Detection among Non-obese MenPresenting for Prostate Biopsies
Margel, David1; Trottier, Greg1; Yap, Stanley1; Connor, Mike2; Elharram, Malik1; Bhindi, Bimal1;Fleshner, Neil11Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2University of York, Toronto, ON, Canada
MP-09.09Heat Shock Protein 70 (HSP70) and FGFR3 in Non-muscle-invasiveBladder Cancer Treated with BCG: Gene and Protein ExpressionAnalysis in Two Validation Cohorts
van Rhijn, Bas W.G.1; Stakhovskyi, Oleksandr1; Margel, David1; van der Kwast, Theodorus H.1;Bostrom, Peter J.1; Bristow, Robert G.1; Milosevic, Michael1; Bapat, Bharati2; Kim, Wun-Jae3;Zlotta, Alexandre R.41University Health Network, Toronto, ON, Canada; 2Mount Sinai Hospital, Samuel LunenfeldResearch Institute, Toronto, ON, Canada; 3Chungbuk National University College of Medicine,Chungbuk, Republic of Korea; 4Mount Sinai Hospital, University Health Network, Toronto, ON,Canada
TUESDAY / MARDI JUNE 26 JUIN
126 CUA 2012 BANFF
MP-09.10NF-κappa B p65 as Prognostic Tool in Prostate Cancer: an Immunohistochemical Study from Biopsy Samples
Labouba, Ingrid1; Gannon, Philippe O.1; Forest, Valérie1; Le Page, Cécile1; Storoz, Cristina1;Benaissa, Mustapha1; Pierrard, Aurore1; Lessard, Laurent1; Mes-Masson, Anne-Marie2; Saad, Fred31Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM), Montréal,QC, Canada; 2CRCHUM / Institut du cancer de Montréal, Department of Medicine, Universitéde Montréal, Montréal, QC, Canada; 3Division of Urology, CHUM, Université de Montréal,CRCHUM, Montréal, QC, Canada
MP-09.11A New Molecular Imaging System Based on Both Transcriptional andGenomic Amplification to Detect Prostate Cancer Cells in vivo
Pouliot, Frederic1; Sato, Makoto2; Huyn, Steve2; Karanikolas, Breanne2; Wu, Lily21Department of Surgery, Urology Division, Laval University, Quebec, QC, Canada; 2IMED andUCLA, Los Angeles, CA, United States
1600-1615 Closing Ceremonies, Awards, CUASF Astellas WinnersCérémonies de clôture, prix, gagnants Astellas FBAUC
Room – salle: Van Horne A
TUESDAY / MARDI JUNE 26 JUIN
UP-001 Orthotopic Continent Urinary Diversion vs. Ileal Conduit: Comparisonof Intraoperative and In-hospital Complications, Blood Transfusion,Length of Stay, and In-hospital Mortality
Djahangirian, Orchidee; Schmitges, Jan; Tian, Zhe; Karakiewicz, Pierre; Ismail, SalimaCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
UP-002 Techniques and Agents Used to Conserve Blood During RadicalCystectomy: a Survey of the Society of Urologic Oncology
Punjani, Nahid1; Lavallée, Luke T.2; Momoli, Franco3; Cagiannos, Ilias2; Morash, Chris2; Fergusson, Dean3; Breau, Rodney H.21University of Ottawa, Ottawa, ON, Canada; 2University of Ottawa, Division of Urology, Ottawa,ON, Canada; 3Ottawa Hospital Research Institute, Ottawa, ON, Canada
UP-003 Should CT Urogram Be the First Radiological Investigation to EvaluateVisible Haematuria?
Akhter, Waseem; Sheikh, Mazher; Kilburn, Karen; Peedikayil, Abraham; Palit, VictorUniversity Hospital of North Tees and Hartlepool NHS Trust, Hartlepool, United Kingdom
UP-004 Laparoscopic Robot-assisted Radical Cysto-prostatectomy
Bladou, FranckMcGill University, Jewish General Hospital, Montreal, QC, Canada
UP-005 Survival Impact of Postoperative Expenditures by High VolumeSurgeons Following Definitive Surgery for Bladder Cancer
Sandhu, Gurdarshan; Nepple, Kenneth; Yang, Liu; Grubb 3rd, Robert; Strope, SethWashington University School of Medicine, St. Louis, MO, United States
UP-006 Is There a Role for the mTOR Pathway in Non-muscle Invasive Bladder Cancer?
Blais, Jean-Philippe; Hovington, Hélène; Brisson, Hervé; Lacombe, Louis; Caumartin, YvesCentre Hospitalier Universitaire de Québec, Quebec, QC, Canada
UP-007 Meta-analysis of the Efficacy and Safety of Darifenacin and OtherAnticholinergics for Managing Overactive Bladder
Elhilali, Mostafa1; Piwko, Charles2; Vincente, Colin2; Sabapathy, Suthacar2; Tu, Le Mai3;Valiquette, Luc4; Finarson, Thomas R.5; Ahmad, Asma61Mcgill University, Royal Victoria Hospital, Montreal, QC, Canada; 2Pivina Consulting, Montreal,QC, Canada; 3FRCSC University of Sherbrooke, QC, Canada; 4FRCSC Université de Montréal,Montreal, QC, Canada; 5University of Toronto, Toronto, ON, Canada; 6Pivina Consulting,Mississauga, ON, Canada
CUA 2012 BANFF 127
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
128 CUA 2012 BANFF
UP-008 Pre-operative Sarcopenia Associated with Renal Function Outcomesin Patients Treated for Renal Masses by Extirpative Surgery
Hennessey, Katherine K.; Michael, Amanda; Elias, Rami; Kapoor, Anil; Shayegan, Bobby;Matsumoto, Edward D.; Mourtzakis, Marina; Di Sebastiano, Katie; Duivenvoorden, Helga;Pinthus, Jehonathan H.McMaster University, Hamilton, ON, Canada
UP-009 Renal Tumor Ablation for pT1 Lesions: Patterns of Recurrence andFollow-up Recommendations
Rutkowski, John; Muruve, NicCleveland Clinic Florida, Weston, FL, United States
UP-010 Cystatin C for Early Detection of Acute Kidney Injury afterLaparoscopic Partial Nephrectomy
Al Esawi, Anwar; Nadeau, Geneviève; Caumartin, Yves; Bergeron, Alain; Guimezap, Jackson;Fradet, Vincent; Caron, André; Dujardin, Thierry; Fradet, Yves; Lacombe, LouisCHUQ-Laval University, Quebec, QC, Canada
UP-011 Ex-vivo Partial Nephrectomy with Autotransplant to Treat ComplexRenal Tumors: Case Report and Review of the Literature
Nayak, Jasmir; Archambault, Jason; Koulack, Joshua; McGregor, ThomasUniversity of Manitoba, Winnipeg, MB, Canada
UP-012 LKB1 Drives Adiponectin Receptor 1 Expression in Clear Cell RenalCell Carcinoma: from Tumor Development to Disease Characteristics
Zareba, Piotr; Duivenvoorden, Wilhelmina; Beatty, Laura; Lhotak, Sarka; Lu, Jian-Ping; Austin, Richard; Daya, Dean; Pinthus, JehonathanMcMaster University, Hamilton, ON, Canada
UP-013 Kidney Cancer Survivorship Survey: Gap Between Urologist andSurvivor Perceptions
Basiuk, Joan1; Jewett, Michael2; Maskens, Deborah3; Canil, Christina41Kidney Cancer Canada, Toronto, ON, Canada; 2Princess Margaret Hospital / University ofToronto, Toronto, ON, Canada; 3Kidney Cancer Canada, Guelph, ON, Canada; 4The OttawaHospital Cancer Centre / University of Ottawa, Ottawa, ON, Canada
UP-014 Comparison of Renal Function Outcomes Between LaparoscopicPartial Nephrectomy with Early Unclamping versus LaparoscopicPartial Nephrectomy with Zero Ischemia
Tse, Richard1; Karreman, Erwin2; Maslany, Jogan1; Knaus, Russel1; Tse, Edward11University of Saskatchewan, Regina, SK, Canada2University of Saskatchewan, Regina Qu’Appelle Health Region, Regina, Saskatchewan
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-015 Reduction of Renal Parenchymal Volume and Renal Function inPatients after Partial Nephrectomy for Renal Cell Carcinoma (RCC)
Ajzenberg, Henry1; Legere, Laura1; Satkunasivam, Raj2; Finelli, Antonio1; Kachura, John3;O’Malley, Martin3; Tuchscherer, Paul4; Quinn, Paul4; Choi, Jung4; Jewett, Michael11Princess Margaret Hospital, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada;3Toronto General Hospital, Toronto, ON, Canada; 4Toronto Western Hospital, Toronto, ON,Canada
UP-016 Results of a Survey on the Management of Upper Tract Urothelial Cancer
Zappavigna, Christopher; Rowe, Neal; Morash, Christopher G.; Breau, Rodney; Cagiannos, IliasUniversity of Ottawa, Division of Urology, Ottawa, ON, Canada
UP-017 Management of Collecting Duct Carcinoma: a Systematic Review,Management Approach, and Case Series
Dason, Shawn1; Sheridan-Jonah, Anna1; Allard, Christopher1; Kajal, Babita2; Aziz, Tariq2; Gill,Jaskirat3; Jamshaid, Hira3; Kapoor, Anil11Division of Urology, McMaster University, Hamilton, ON, Canada, 3Department of Pathologyand Molecular Medicine, McMaster University, Hamilton, ON, Canada; 4McMaster University,Hamilton, ON, Canada
UP-018 Withdrawn
UP-019 Improving Outcomes Through the Development of Quality Indicators(QI) in Renal Cell Cancer (RCC)
Finelli, Anthony1; Bjarnason, Georg2; Black, Peter3; Cagiannos, Ilias4; Heng, Daniel5; Kapoor,Anil6; Kollmannsberger, Christian7; Mohammadzadeh, Forough8; Moore, Ronald9; Soulieres,Denis10; Tanguay, Simon11; Venner, Peter12; Jewett, Michael1; Rendon, Ricardo13; Wood, Lori131Princess Margaret Hospital (UHN), Toronto, ON, Canada; 2Sunnybrook Odette Cancer Center,Toronto, ON, Canada; 3Department of Urological Sciences, UBC, Vancouver, BC, Canada;4University of Ottawa, Ottawa, ON, Canada; 5Tom Baker Cancer Center, University of Calgary,Calgary, AB, Canada; 6Juravinski Cancer Center, Hamilton, ON, Canada; 7BCCA VancouverCancer Center, University of British Colombia, Vancouver, BC, Canada; 8UHN, Toronto, ON,Canada; 9Department of Urology, University of Alberta, Edmonton, AB, Canada; 10Departmentof Medicine, Université de Montréal, Montreal, QC, Canada; 11McGill University Health Center,McGill University, Montreal, QC, Canada; 12Cross Cancer Institute, University of Alberta,Edmonton, AB, Canada; 13QEII HSC, Dalhousie University, Halifax, NS, Canada
UP-020 Rising Incidence of Upper Tract TCC (UTTCC) in Kettering, UnitedKingdom
Khan, Faisal1; Payne, David2; Al-Sudani, Mohammed2; Khan, Zeb2; England, Roland21Freeman Hospital, Newcastle, United Kingdom; 2NHS, Kettering, United Kingdom
CUA 2012 BANFF 129
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
130 CUA 2012 BANFF
UP-021 The Fer Kinase, a Nuclear Effector of Growth-promoting FactorsFavoring Castration-resistant Prostate Cancer
Rocha, Joice1; Zouanat, Fatima1; Benidir, Tarik1; Zoubeidi, Amina2; Hamel, Lucie1; Scarlata, Eleonora1; Aprikian, Armen1; Chevalier, Simone11Urologic Oncology Research Group, McGill University, Montreal, QC, Canada; 2The VancouverProstate Cancer, University of British Columbia, Vancouver, BC, Canada
UP-022 Single Photon Emission Computed Tomography/CT Imaging ofMetastases Using Prostate Specific Membrane Antigen Antibody
Chevalier, Simone1; Derbekyan, Vilma1; Scarlata, Eleonora1; Moffett, Serge2; Hamel, Lucie1;Zouanat, Fatima1; Aprikian, Armen1; Anidjar, Maurice11McGill University Health Centre Research Institute, Montreal, QC, Canada; 2ProScan,Montreal, QC, Canada
UP-023 PSA Bounce Following Prostate Brachytherapy for Clinically LocalizedProstate Adenocarcinoma: a Single Institution Study with Minimum 3Years Follow-up
Nayak, Jasmir; Ong, Aldrich; Bews, Jeff; Chowdhury, Amit; Drachenberg, DarrelUniversity of Manitoba, Winnipeg, MB, Canada
UP-024 Is Perineural Invasion in Prostate Biopsies Associated with AdversePathological Outcomes? Old Paradigm Revisited
Margel, David1; Elharram, Malik1; Finelli, Antonio1; Zlotta, Alexandre1; Trachtenberg, John1;Evans, Andrew2
1Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2Department of Pathology, University Health Network,University of Toronto, Toronto, ON, Canada
UP-025 The Association between Male Pattern Baldness and Second to ForthFinger Ratio with Prostate Cancer: a Prospective Cohort Study
Margel, David; Venkateswaran, Seetha; Darwish, Abbas; Chadwick, Karen; Fleshner, NeilDivision of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, ON, Canada
UP-026 Coexisting Prostate Cancer Found at the Time of Holmium LaserEnucleation of the Prostate for Benign Prostatic Hyperplasia:Predicting Its Presence and Grade in Analyzed Tissue
Bhojani, Naeem; Boris, Ronald S.; Mandeville, Jessica A.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-027 Prostate Cancer Screening: Attitudes and Practices of FamilyPhysicians in Ontario
Allard, Christopher1; Lusis, Janis2; Dason, Shawn1; Kapoor, Anil11McMaster Institute of Urology, Hamilton, ON, Canada; 2Brampton Hospital, Brampton, ON,Canada
UP-028 Transrectal Ultrasound with Vibroelastography for the Detection ofProstate Cancer
Gagnon, Louis-Olivier1; Mahdavi, Sara2; Moradi, Mehdi2; Baghani, Ali2; Jones, Edward3;Salcudean, Septimiu2; Goldenberg, Larry11Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada;2Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada;3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,BC, Canada
UP-029 Human Prostate Cancer Magnetic Resonance Elastography andCorrelation with Histology
Gagnon, Louis-Olivier1; Sahebjavaher, Ramin2; Garteiser, Philippe3; Sinkus, Ralph3; Baghani,Ali2; Moradi, Mehdi2; Jones, Edward4; Nguan, Chris1; Goldenberg, Larry1; Salcudean, Septimiu21Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada;2Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada;3Hôpital Beaujon, Centre de Recherche Biomédicale Bichat Beaujon (CRB3), Paris, France;4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,BC, Canada
UP-030 Changes in Positive Surgical Margins over Time Reflect a RiskMigration in Patients Undergoing Radical Prostatecomy at a TertiaryCare Center
Longpre, Michelle; Gleave, Martin; Harriman, David; Hurtado-Coll, AntonioUniversity of British Columbia, Vancouver, BC, Canada
UP-031 Holmium Laser Ablation of the Prostate Gland (HoLAP) Followed byBrachytherapy (BT) for Treatment of Patients with Clinically LocalizedProstate Carcinoma (PC) and Obstructive Urinary Symptoms (LUTS)
Kumar, SurendraOakwood Annapolis Hospital, Wayne, MI, United States
UP-032 Identification of Thrombotic Risk for Men with Advanced ProstateCancer: a Pilot Study Evaluating Hemostatic Status UsingThromboelastography
Siemens, D. Robert; Toukh, Mazen; Othman, Maha; Black, Angela; Graham, CharlesQueen’s University, Kingston, ON, Canada
CUA 2012 BANFF 131
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
132 CUA 2012 BANFF
UP-033 Predictors of Failing Active Surveillance on the 2nd Prostatic Biopsy
Wong, Lih-Ming1; Trottier, Greg1; Fleshner, Neil1; Lawrentchuk, Nathan1; Kulkarni, Girish1;Zlotta, Alexandre2; Trachtenberg, John1; Toi, Ants3; Finelli, Antonio11Division of Uro-oncology, Princess Margaret Hospital, Toronto, ON, Canada; 2Division ofUrology, Mount Sinai Hospital, Toronto, ON, Canada; 3Department of Radiology, PrincessMargaret Hospital, Toronto, ON, Canada
UP-034 Prostate Cancer Detection after Multiple Negative Biopsies
Metcalfe, Charles; Metcalfe, Michael; Goldenberg, Larry; Gleave, Martin; Black, Peter; So, AlanUniversity of British Columbia, Vancouver, BC, Canada
UP-035 Intermediate Clinical Outcomes of Robot-assisted LaparoscopicProstatectomy (RALP)
Wong, Carson1; Gu, Xiao2; Spaliviero, Massimiliano21SouthWest Urology, Inc., Middleburg Heights, OH, United States; 2University of OklahomaHealth Sciences Center, Oklahoma, OK, United States
UP-036 Factors Influencing Choice of Robotic-assisted vs. Open RadicalProstatectomy for Prostate Cancer Treatment
Chien, Gary; Chang, Allen; Thomas, Anil; Derboghossians, Armen; Slezak, JeffreyKaiser Permanente, Los Angeles, CA, United States
UP-037 What Is the Prevalence and Impact of Depression, Anxiety, andDistress in Patients with Newly Diagnosed Localized Prostate Cancer?
Punnen, Sanoj; Cowan, Janet; Whitson, Jared; Carroll, Peter; Cooperberg, MatthewUniversity of California, San Francisco, CA, United States
UP-038 Autologous Retropubic Urethral Sling: a Novel, Quick, IntraoperativeTechnique for Improving Continence after Robot-assistedLaparoscopic Prostatectomy
Punnen, Sanoj; Cowan, Janet; Whitson, Jared; Carroll, PeterUniversity of California, San Francisco, CA, United States
UP-039 Predictors of Gleason 8 Cancer among Men with Gleason 7 and 8Cancer on Prostate Biopsy Cores
Heimrath, Olivier P.; Belanger, Eric C.; Kos, Zuzana; Cagiannos, Ilias; Morash, Christopher G.; Lavallée, Luke T.; Preston, Mark; Breau, Rodney H.University of Ottawa, Ottawa, ON, Canada
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-040 Comparison of Serum Testosterone Levels in Prostate Cancer PatientsReceiving LHRH Agonist Therapy with or without the Removal of theProstate
Venkateswaran, Seetha1; Margel, David1; Yap, Stanley1; Hersey, Karen1; Locke, Jennifer1; Yip, Paul2; Fleshner, Neil11Princess Margaret Hospital, Toronto, ON, Canada; 2Toronto General Hospital, Toronto, ON,Canada
UP-041 A Prospective Phase II Trial of Stereotaxic Hypofractionated Cyberknife(CK) Treatment for Locally Recurrent Prostate AdenocarcinomaFollowing External Beam Radiotherapy (EBRT)
Fortin, Israel; Bahary, Jean-Paul; Saad, Fred; Péloquin, Laurence; Lambert, Carole; Barkati, Maroie; Nguyen, Thu Van; Waters, AlexandraCHUM, Montreal, QC, Canada
UP-042 Involvement of TBK1 in Prostate Cancer Progression through IKKεCellular Localization Control
Huon, Yannick1; Péant, Benjamin1; Mes-Masson, Anne-Marie1; Saad, Fred21CRCHUM, ICM and Faculty of Medicine, Université de Montréal, Montreal, QC, Canada;2CRCHUM, ICM, Faculty of Medicine and Division of Urology, CHUM, Université de Montréal,Montreal, QC, Canada
UP-043 The Association between Aspirin and Non-steroidal Anti-inflammatoryDrug Use and the Risk of Prostate Cancer Detection upon Biopsy
Bhindi, Bimal; Margel, David; Fernandes, Kimberly; Trottier, Greg; Hersey, Karen; Finelli,Antonio; Trachtenberg, John; Toi, Ants; Evans, Andrew; van der Kwast, Theodorus; Fleshner,NeilUniversity Health Network, Toronto, ON, Canada
UP-044 Withdrawn
UP-045 Withdrawn
UP-046 Active Surveillance for Prostate Cancer in Patients with a PSA >10
Toren, Paul; Timilshina, Narhari; Kulkarni, Girish; Fleshner, Neil; Finelli, AntonioUniversity of Toronto, Toronto, ON, Canada
CUA 2012 BANFF 133
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
134 CUA 2012 BANFF
UP-047 Targeting the Proprotein Convertases in Prostate Cancer
Day, Robert1; D’Anjou, François1; Couture, Frédéric1; Levesque, Christine1; Kwaitkowska,Anna1; Routhier, Sophie1; Desjardins, Roxane1; Guérin, Brigitte2; Doueik, Alexandre3; Carmel,Michel3; Sabbagh, Robert31Institut de pharmacologie de Sherbrooke et Université de Sherbrooke, Sherbrooke, QC,Canada; 2Centre d’imagerie moléculaire de Sherbrooke et Université de Sherbrooke,Sherbrooke, QC, Canada; 3Centre hospitalier universitaire de Sherbrooke et Université deSherbrooke, Sherbrooke, QC, Canada
UP-048 Histopathological Features Following Prostate High Intensity FocusUltrasound Salvage Therapy for Radiation-failure
Autran Gomez, Ana Maria; Chang, Susanne; Gomez-Lemus, Jose; Lee, Linda; Izawa,Jonathan; Chin, JosephLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada
UP-049 Insight into Dietary Prevention of Prostate Cancer: Effects of Fish Oiland Krill Oil on Inflammation
Moreel, Xavier; Dong, Ruijing; Julien, Pierre; Fradet, VincentLaval University, Quebec, QC, Canada
UP-050 Inconsistent Testosterone Monitoring and Antiandrogen Use inProstate Cancer Patients Receiving Androgen Deprivation Therapy
Dalla Nora, Sergio1; Shayegan, Bobby21Ferring Inc., North York, ON, Canada; 2Juravinski Cancer Centre, McMaster University,Hamilton, ON, Canada
UP-051 Single Nucleotide Polymorphisms (SNPs) Associated with LateRadiation Toxicity after Prostate Brachytherapy
Leong, Nelson1; Parliament, Matthew1; Martell, Kevin2; Ghosh, Sunita2; Pervez, Nadeem1;Pedersen, John1; Yee, Don1; Murtha, Albert1; Amanie, John1; Usmani, Nawaid11Cross Cancer Institute, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada
UP-052 Prostate Cancer Antigen 3 Density Shows Similar Predictive Value of Positive Prostate Biopsy as Prostate Cancer Antigen 3 Alone
Dovirak, Ostap1; Goode, Roland2; Marshall, Susan2; Consiglio, Joseph2; Duff, Michael2; Chevli,Kent21State University of New York at Buffalo, Department of Urology, Buffalo, NY, United States;2State University of New York at Buffalo, Buffalo, NY, United States
UP-053 Use of Patient Educational Technologies (PET) by Patients Diagnosedwith Prostate Cancer
Carlson, Kevin1; Crump, R. Trafford2; Baverstock, Richard11University of Calgary, Calgary, AB, Canada; 2University of British Columbia/Centre for HealthServices and Policy Research, Vancouver, BC, Canada
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-054 Comparison of Pathological Outcomes of Radical Prostatectomy inAfrican Americans and Caucasians Who Are Potential Candidates forActive Surveillance
Popovic, Mihailo; Lucas, StevenWayne State University, School of Medicine, Urology, Detroit, MI, United States
UP-055 Ontario’s First 18th Choline Prostate PET Images: Histology and Multi-parametric MRI Correlation
Gibson, Eli1; Rachinsky, Irina2; Gaed, Mena3; Romagnoli, Cesare2; Lee, Ting-Yim1; Gómez, José A.4; Moussa, Madeleine4; Crukley, Cathie3; Chin, Joseph L.5; Bauman, Glenn S.6; Ward, Aaron D.71Robarts Research Institute, The University of Western Ontario, London, ON, Canada;2Department of Medical Imaging, The University of Western Ontario, London, ON, Canada;3Lawson Health Research Institute, London, ON, Canada; 4Department of Pathology, TheUniversity of Western Ontario, London, ON, Canada; 5Department of Urology, The University ofWestern Ontario, London, ON, Canada; 6Department of Oncology, The University of WesternOntario, London, ON, Canada; 7Department of Medical Biophysics, The University of WesternOntario, London, ON, Canada
UP-056 Laparoscopic Robot-assisted Extended Pelvic Lymph Node Dissectionfor High Risk Prostate Cancer
Bladou, Franck1; Luz, Murillo2; Anidjar, Maurice21McGill University, Jewish General Hospital, Montreal, QC, Canada; 2McGill University,Montreal, QC, Canada
UP-057 Comparative Morbidity between Salvage High Intensity FocusedUltrasound and Cryotherapy for Radiorecurrent Prostate Cancer
Al-Zahrani, Ali; Yutkin, Vladimir; Autran Gomez, Ana Maria; Chin, JosephDivision of Urology, Department of Surgery, London Health Sciences Centre, University ofWestern Ontario, London, ON, Canada
UP-058 A Nomogram Containing the NF-kappa B p65 Biomarker PredictsBiochemical Recurrence of Prostate Cancer Patients Following Radical Prostatectomy
Gannon, Philippe O.1; Lessard, Laurent1; Stevens, Louis-Mathieu2; Labouba, Ingrid1; Forest,Valérie1; Bégin, Louis R.3; Minner, Sarah4; Tennstedt, Pierre5; Schlomm, Thorsten5; Mes-Masson, Anne-Marie6; Saad, Fred71Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM), Montreal,QC, Canada; 2Division of Cardiac Surgery, CHUM, CRCHUM, Montreal, QC, Canada; 3Division ofAnatomic Pathology, Hopital Sacré-Coeur de Montréal, Montreal, QC, Canada; 4Institute ofPathology, University Medical Center Hamburg-Eppendorff, Hamburg, Germany; 5Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorff, Hamburg,Germany; 6CRCHUM / Institut du cancer de Montréal, Department of Medicine, Université deMontréal, Montreal, QC, Canada; 7Division of Urology, CHUM, Université de Montréal,CRCHUM, Montreal, QC, Canada
CUA 2012 BANFF 135
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
136 CUA 2012 BANFF
UP-059 Management of Post Radiation Therapy Complications amongProstate Cancer Patients: a Single Surgeon Experience
Flannigan, Ryan1; Baverstock, Richard21University of British Columbia, Vancouver, BC, Canada; 2vesia [Alberta Bladder Centre],Division of Urology, University of Calgary, Calgary, AB, Canada
UP-060 Salvage High Intensity Focused Ultrasound for Local Prostate CancerRecurrence after Brachytherapy
Alzahrani, Ali1; Yutkin, Vladimir2; Autran Gomez, Ana Maria2; Chin, Joseph21London Health Sciences Centre, London, ON, Canada; 2Division of Urology, Department ofSurgery, London Health Sciences Centre, University of Western Ontario, London, ON, Canada
UP-061 Holmium Laser Transurethral Incision of the Prostate (Hol-TUIP):Predictors of Long Term Outcome
Elshal, Ahmed; Elmansy, Hazem; Elhilali, MostafaMcGill University, Urology Department, Montreal, QC, Canada
UP-062 Evaluation of Autonomic Nervous System Activity by 24 Hour HolterMonitorization in Men with Benign Prostate Hyperplasia
Zorba, Orhan Ünal; Uzun, Hakki; Cicek, Yuksel; Kirbas, Serkan; Erdogan, Turan; Yazar, SelimRize University, Rize Medical Faculty, Rize, Turkey
UP-063 Randomized Double-blind Placebo Controlled Trial of IntradetrusorInjections of Botulinum Toxin for the Treatment of RefractoryOveractive Bladder Secondary to Benign Prostatic Hyperplasia
Elterman, Dean; Lee, Daniel; Sheth, Seema; Chughtai, Bilal; Lee, Richard; Kaplan, Steven; Te, AlexisWeill Medical College of Cornell University, New York, NY, United States
UP-064 Evaluation of Prostate Cancer Cells Responsiveness to an EGFRTargeting Combi-molecule
Poisson, Alexis; Delvoye, Nathalie; Le Page, Cecile; Peant, Benjamin; Mes-Masson, Anne-Marie; Saad, FredICM/CHUM, Montreal, QC, Canada
UP-065 Dynamic MRI Urethrography: Fluid Turbulence in a Urethral StrictureModel
Moles, Jonathan; Thornhill, Rebecca; Shabana, Wael; Saltel, EricThe Ottawa Hospital, Ottawa, ON, Canada
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-066 Spicing up Radiation Treatment for Prostate Cancer
Venier, Natalie1; Colquhoun, Alexandra1; Loblaw, Andrew D.1; Fleshner, Neil2; Klotz, Laurence1;Venkateswaran, Vasundara11Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2Princess Margaret Hospital,University Health Network, Toronto, ON, Canada
UP-067 Canadian Urology Resident Scholarly Performance
Andrews, J. Matthew; Norman, Richard W.Department of Urology, Dalhousie University, Halifax, NS, Canada
UP-068 Virtual Problem-based Learning (PBL): a Needs AssessmentExamining Traditional versus Virtual Problem-based Learning
Mickelson, Jennie1; Lim, Rachel2; Amandeep, Ghuman2; Gourlay, William2; Masterson, John2;MacNeily, Andrew2
1University of British Columbia , Department of Urologic Sciences, Vancouver, BC, Canada;2University of British Columbia, Vancouver, BC, Canada
UP-069 A National Survey of Chief Residents on the Communicator Role inUrology Residency: Are We Communicating the Message?
Roberts, Gregory; Fuoco, Michael; Beiko, Darren; Touma, Naji; Siemens, RobertQueen’s University, Urology, Kingston, ON, Canada
UP-070 Is Online Script Concordance Test a Good CPD Tool to InduceReflection on Controversial Issues in the Management of ProstateCancer?
Bénard, François1; St-Germain, France2; Lamoureux, Cristine1; Saad, Fred3; Charlin, Bernard11University of Montreal, Montreal, QC, Canada; 2Sanofi-Aventis Canada, Laval, QC, Canada;3Centre hospitalier universitaire de l’Université de Montréal (CHUM), Montreal, QC, Canada
UP-071 A Systematic Review on the Effect of Lysine Analogs on Blood Lossand Transfusion Requirements during Pelvic Surgery
Punjani, Nahid1; Kokolo, Madzouka B.2; Fergusson, Dean A.2; Cagiannos, Ilias3; Knoll, Gregory4; Momoli, Franco2; Morash, Chris3; Lavallée, Luke T.3; Tinmouth, Alan5; Breau, Rodney H.31University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Ottawa, ON,Canada; 3University of Ottawa - Division of Urology, Ottawa, ON, Canada; 4University ofOttawa - Division of Nephrology, Ottawa, ON, Canada; 5University of Ottawa - Division ofClinical Hematology, Ottawa, ON, Canada
UP-072 Antibiotic Prophylaxis Prescribing Patterns for Trans-urethralResection of Prostate: a Need for Canadian Guidelines?
Lawson, Keith1; Vicas, Ingrid2; Hofmeister, Marianna2; Lockyer, Jocelyn2; Carlson, Kevin11Division of Urology, University of Calgary, Calgary, AB, Canada; 2Physician Learning Program,University of Calgary, Calgary, AB, Canada
CUA 2012 BANFF 137
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
138 CUA 2012 BANFF
UP-073 En Bloc Vascular Stapling of Renal Hilum during LaparoscopicNephrectomy
McKay, Jeffrey1; Goodman, Saul2; Neville, Christopher3; Cripps, Stephanie4; Perks, Alexandra41University of British Columbia, Chilliwack, BC, Canada; 2Fraser Health Authority, Chilliwack,BC, Canada; 3Fraser Health Authority, Abbotsford, BC, Canada; 4Fraser Health Authority,Langley, BC, Canada
UP-074 Evaluation of Autonomic Nervous System Activity by 24 Hour HolterMonitorization in Women with Idiopathic Overactive Bladder
Zorba, Orhan Ünal; Uzun, Hakki; Cicek, Yuksel; Kirbas, Serkan; Bostan, MehmetRize University, Rize Medical Faculty, Rize, Turkey
UP-075 Seasonal Variation in Urological Pelvic Pain Syndromes: Seven Yearsof Google™ Search Trends
Roberts, Gregory1; Williamson, Tyler2; Teichman, Joel3; Nickel, Curtis11Queen’s University Urology, Kingston, ON, Canada; 2Centre for Studies in Primary Care,Kingston, ON, Canada; 3Department of Urological Sciences, University of British Colombia,Vancouver, BC, Canada
UP-076 Sub-inhibitory Antibiotic Concentrations Negatively Affects Both theUropathogen Staphylococcus Saprophyticus and Host Imm uneResponses
Fahmy, Nader; Fuller, Andrew; Goneau, Lee; MacDonald, Kyle; Erdeljan, Petar; Bathini,Varunkumar; Razvi, Hassan; Cadieux, PeterThe University of Western Ontario, London, ON, Canada
UP-077 First Inflatable Penile Prosthesis Infections and a Proposed Survey forPost-implant Monitoring
Narayanan, Ramkishen; Aliotta, Jessica; Leung, Tony; Duff, Michael; Barlog, Kevin; Chevli, K. KentUniversity at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, United States
UP-078 How Many Semen Samples Are Required to Make the Diagnosis ofAzoospermia?
Khambati, Aziz1; Jarvi, Keith2; Lo, Kirk21University of Toronto Urology, Toronto, ON, Canada; 2Mount Sinai Hospital, Toronto, ON,Canada
UP-079 Fertility of Patients with a History of Bilateral Cryptorchidism Treated:a Comparative Study about 120 Patients
Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziDepartment of Urology, Sahloul, Sousse, Tunisia
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-080 Spectrum of Ureteropelvic Junction Obstruction (UPJO) MorphologicalCharacteristics from Infancy to Adulthood and Implications in SurgicalManagement
Romao, Rodrigo L.P.1; Foell, Kirsten2; Figueroa, Victor1; Lorenzo, Armando J.1; Farhat, Walid1;Pace, Kenneth T.2; Bagli, Darius1; Koyle, Martin1; Honey, R. John D’A.2; Pippi Salle, Joao L.11The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 2St. Michael’sHospital, University of Toronto, Toronto, ON, Canada
UP-081 The Challenge and Morbidity of Intermittent Ureteropelvic JunctionObstruction (IUPJO) in Children
Romao, Rodrigo L.P.; Figueroa, Victor H.; Pippi Salle, Joao L.; El-Naeema, Aziza; Lorenzo,Armando J.; Bagli, Darius; Farhat, Walid; Koyle, MartinThe Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
UP-082 Role of Magnetic Resonance Urography in Girls with UrinaryIncontinence: a Single Centre Experience
Figueroa, Victor H.; Chavhan, Govind; Romao, Rodrigo L.P.; Lee, Justin K.; Pippi Salle, Joao L.;Bagli, Darius J.; Koyle, Martin A.; Lorenzo, Armando J.; Farhat, Walid The Hospital for Sick Children, Toronto, ON, Canada
UP-083 Peristeen Anal Irrigation as a Substitute of Mace Procedure in ChildrenWho Are in Need of Reconstructive Bladder Surgery
Alhazmi, Hamdan; Alenezi, Husain; Salem, Mahmoud; Fouda Neel, KhalidKing Saud University, Riyadh, Saudi Arabia
UP-084 Hemorrhagic Cystitis Secondary to BK Virus: a Case Report ofManagement with Intravesical Cidofovir in the Pediatric Patient andReview of Literature
Bidnur, Samir; Wu, Christopher; Rassekh, Rod; Mickelson, Jennifer; MacNeily, AndrewUniversity of British Columbia, Vancouver, BC, Canada
UP-085 The Use of EMLA Cream During Circumcision: a Prospective Studyabout Sixty Children
Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouzDepartment of Urology, Sahloul, Sousse, Tunisia
UP-086 Glandular Amputation during Circumcision: a Review of 12 CasesResults of a New Technique for Glans Self-transplantation
Mallat, Faouzi; Hmida, Wissem; Hhidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Mosbah, Ali FaouziUrology, Sahloul, Sousse, Tunisia
CUA 2012 BANFF 139
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
140 CUA 2012 BANFF
UP-087 Cystic Intratesticular Lesions in Pediatric Patients: a RetrospectiveCase Series
Hoag, Nathan; Afshar, Kourosh; Youssef, David; Masterson, John; Murphy, James; MacNeily,AndrewUniversity of British Columbia, Vancouver, BC, Canada
UP-088 Retrospective Review of Diagnosis of Testicular Torsion in BoysPresenting to Pediatric Emergency Department with Acute ScrotalPain
Liang, Teresa1; Metcalfe, Peter2; Sevcik, William2; Noga, Michelle21University of British Columbia, Burnaby, BC, Canada; 2University of Alberta, Edmonton, AB, Canada
UP-089 Penoscrotal Lymphedema: Sexuality, Fertility, Functional and AestheticOutcome of the Surgical Treatment - Our Experience about 14 Cases
Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slam, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziDepartment of Urology, Sahloul, Sousse, Tunisia
UP-090 Comparison of Apoptotic Gene Expression Profiles between Peyronie’sDisease Plaque and Control Tunica Albuginea
Zorba, Orhan Ünal1; Ozgon, Gulay2; Sirma, Sema2; Ozbek, Ugur2; Kadıoglu, Ates21Rize University, Rize Medical Faculty, Rize, Turkey; 2Istanbul University, Istanbul MedicalFaculty, Istanbul, Turkey
UP-091 Climacturia Post-prostatectomy Remains a Largely Unknown ClinicalEntity in Contemporary Urologic Training Based on Results Obtained at a Resident Training Laboratory
Zappavigna, Christopher1; Christine, Brian2; Bella, Anthony J.1University of Ottawa, Division of Urology, Ottawa, ON, Canada; 2Urology Centers of Alabama,Birmingham, AL, United States
UP-092 Post-prostatectomy Penile Rehabilitation and Erectile DysfunctionTreatment: Senior Resident Perceptions and Institutional PracticesBased on Results Obtained at a Resident Training Laboratory
Zappavigna, Christopher; Bella, Anthony J.University of Ottawa, Division of Urology, Ottawa, ON, Canada
UP-093 Leadership in Canadian Urology: What Is the Right Stuff?
Robinson, Michael; MacNeily, Andrew; McInnes, Colin; Lennox, Peter; Carr, Nicholas; Skarlicki,Daniel; Masterson, John; Arneja, JugpalUniversity of British Columbia, Vancouver, BC, Canada
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-094 What Is the Best Local Anesthesia during Extracorporeal ShockwaveLithotripsy? Prospective Randomized Clinical Study Comparing EMLAand Lidocaine
Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziUrology, Sahloul, Sousse, Tunisia
UP-095 Trans-splenic Percutaneous Nephrolithotomy with SecondaryProcedure via the Same Tract
Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States
UP-096 Uric Acid Stone Prevalence Doubles in the Severely and MorbidlyObese (BMI>35) Compared to the Overweight (BMI 25-30)
Sivalingam, Sri; Penniston, Kris; Nakada, Stephen Y.University of Wisconsin, Madison, WI, United States
UP-097 Targeted Intervention versus Conservative Intervention for thePrevention of Kidney Stone Recurrence
Arsovska, Olga; Wu, Christopher; Sutton, Roger A. L.; Paterson, Ryan F.; Chew, Ben H.University of British Columbia, Vancouver, BC, Canada
UP-098 Pulsed Fluoroscopy in Ureteroscopy and PercutaneousNephrolithotomy
Elkoushy, Mohamed; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada
UP-099 Laparoscopic Nephrectomy with Intact Specimen Extraction forMassive Polycystic Kidney Disease: Updated Technique and OutcomeAnalysis
Bansal, Rahul Kumar; Tu, Hin Yu Vincent; Kapoor, AnilMcMaster Institute of Urology, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
UP-100 Urologists in Cyberspace: Evaluating Quality of American Urologists’Websites on the Internet
Yan, Hanmu; Margel, David; Fleshner, Neil; Wong, Lih-MingDepartment of Urology, Princess Margaret Hospital, Toronto, ON, Canada
UP-101 Robotic-assisted Microsurgery: the Initial 603 Case Experience
Gudeloglu, Ahmet; Priola, Karen; Parekattil, SijoUniversity of Florida and Winter Haven Hospital, Winter Haven, FL, United States
CUA 2012 BANFF 141
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
142 CUA 2012 BANFF
UP-102 Assessment of the Understanding of Androgen Deprivation Therapy(ADT) Associated Side Effects in Primary Care Physicians
Soeyonggo, Tony1; Locke, Jennifer1; Del Giudice, Lisa2; Alibhai, Shabbir3; Fleshner, Neil4;Warde, Padraig51Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Family andCommunity Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3Departmentof Medicine, University Health Network, Toronto, ON, Canada; 4Department of Surgery(Urology), Princess Margaret Hospital, Toronto, ON, Canada; 5Department of RadiationOncology, Princess Margaret Hospital, Toronto, ON, Canada
UP-103 Senior Resident Perceptions of Industry Interaction with ProstheticUrologists Based on Results Obtained at a Resident TrainingLaboratory
Zappavigna, Christopher; Bella, Anthony J.University of Ottawa, Division of Urology, Ottawa, ON, Canada
UP-104 Factors Affecting Surgical Performance and Operating Room Safety in Urology: a Preliminary Evaluation
Lee, Jason Y.1; Gettman, Matthew2; Landman, Jaime3; McDougall, Elspeth M.3; Sundaram, Chandru P.4; Sweet, Robert5; Zorn, Kevin C.61St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 2Mayo Clinic, Rochester,MN, United States; 3University of California - Irvine, Orange, CA, United States; 4IndianaUniversity, Indianapolis, IN, United States; 5University of Minnesota, Minneapolis, MN, UnitedStates; 6University of Montreal (CHUM), Montreal, QC, Canada
UP-105 The Management of Post-transplant Lymphoceles: Changes in Practice at l’Hôtel-Dieu de Québec
Deschênes-Rompré, Marie-Pier; Diallo, Yoro; DeSerres, Sacha; Houde, Isabelle; Caumartin, YvesCentre hospitalier universitaire de Québec, Quebec, QC, Canada
UP-106 Factors Associated with an Increased Risk of Delayed Graft Functionin Donation after Cardiac Death Kidneys
Boyle, S.L.1; McGregor, Thomas B.2; Moser, Mike3; Sharpe, Mike3; Luke, Patrick31The University of Western Ontario, Department of Surgery, Division of Urology, London, ON,Canada; 2University of Manitoba, Department of Surgery, Division of Urology, Transplant andMIS, Winnipeg, MB, Canada; 3The University of Western Ontario, Department of Surgery,Division of Urology and Transplant, London, ON, Canada
UP-107 Debilitating Lower Urinary Tract Symptoms in the Post-renalTransplant Population Can Be Predicted Pre-transplantation
Dion, Marie; Cristea, Octav; Langford, Sarah; Luke, Patrick; Sener, AlpUniversity of Western Ontario, London, ON, Canada
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
UP-108 Thymoglobulin Differentially Increases CDR Naive T-cell ProliferationFollowing Renal Transplantation
Ullah, Shahnoor1; Telfer, Siobhan2; Mok, Amy3; Jevnikar, Anthony4; Luke, Patrick2; Sener, Alp51Schulich School of Medicine, The University of Western Ontario, London, ON, Canada;2Department of Surgery, The University of Western Ontario, London, ON, Canada; 3Departmentof Microbiology and Immunology, The University of Western Ontario, London, ON, Canada;4Department of Medicine, The University of Western Ontario, London, ON, Canada;5Department of Surgery, Department of Microbiology and Immunology, The University ofWestern Ontario, London, ON, Canada
UP-109 Retubularization of the Ileocystoplasty Pouch for Conversion into an Ileal Conduit Diversion
Massaro, Peter; Gajewski, Jerzy; Bailly, GregDepartment of Urology, Dalhousie University, Halifax, NS, Canada
UP-110 Conservative Management of High Post-void Residual Urine inAsymptomatic Men; Retrospective Analysis of Outcomes
Kalyanaraman, Balaji; Bracken, R. BruceUniversity of Cincinnati, Cincinnati, OH, United States
UP-111 No Show Rates for Follow-up after Visual Internal Urethrotomy: a Single Surgeon Experience
Patel, Premal1; Baverstock, Richard21University of Calgary, Calgary, AB, Canada; 2vesia [Alberta bladder centre], Calgary, AB,Canada
UP-112 Genitourinary Tuberculosis or Not Genitourinary Tuberculosis: Case Series and Critical Look at the Challenging Diagnosis ofGenitourinary Tuberculosis
Boyle, Shawna1; Amman, Justin2; Chin, Joseph3; Paulter, Stephen3; Denstedt, John3; Izawa,Jonathan3; Razvi, Hassan31University of Western Ontario, London, ON, Canada; 2Department of Medical Imaging, TheUniversity of Western Ontario, London, ON, Canada; 3Division of Urology, Department ofSurgery, The University of Western Ontario, London, ON, Canada
UP-113 Common Urological Presentations of the Penitentiary Populationin Kingston: a Chart Review
Lee, Taehyoung; Leveridge, Michael; Touma, NajiQueen’s University, Kingston, ON, Canada
CUA 2012 BANFF 143
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
144 CUA 2012 BANFF
UP-114 Targeted Robotic-assisted Microsurgical Denervation of the Spermatic Cord for Chronic Orchialgia
Gudeloglu, Ahmet; Wharton, Jessica; Priola, Karen; Parekattil, SijoUniversity of Florida and Winter Haven Hospital, Winter Haven, FL, United States
UP-115 Should Large Adrenal Myelolipomas (>6cm) Be Removed? Case Series and Review of Literature
Michael, Amanda; Elias, Rami; Kapoor, AnilMcMaster University, Hamilton, ON, Canada
UP-116 Withdrawn
UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS
CUA 2012 BANFF 145
Bailly, Greg G. EF5
Bénard, François EF8
Brock, Gerald EF8
Carlson, Kevin EF5
Chetner, Michael AUA, welcome
Donnelly, Bryan EF6
Dushinski, John EF1
Fleshner, Neil EF6, EF7
Foster, Richard SOA3
Izawa, Jonathan EF3
Jacobsen, Niels CP1
Jarvi, Keith CUASS
Jordan, Gerald EF2, SOA2
Kapoor, Anil CP2
Kassouf, Wassim EF3
Kodama, Ron EF2
McVary, Kevin SOA6
Monga, Manoj SOA1
Moyad, Mark SOA5
Nguyen, Hiep SOA8
Nickel, Curtis EF4, EF8
Nitti, Victor EF5, SOA7
Rourke, Keith EF2
Satava, Richard SOA9
Schuler, Trevor EF1
Shayegan, Bobby EF3
Schoenberg, Mark SOA4
Siemens, Robert EF6
So, Alan EF7
Sogani, Pramod C. AUA
Whelan, Paul EF4
INVITED SPEAKERS INDEX / INDEX DES CONFÉRENCIERS INVITÉS
146 CUA 2012 BANFF
AAbdulla, Alym POD-04.03
Ajzenberg, Henry UP-015
Akhter, Waseem UP-003
Al Esawi, Anwar UP-010
Alamri, Abdulaziz MP-03.10
Alhazmi, Hamdan UP-083
Allard, Christopher MP-03.01, MP-03.16, UP-027
Alyami, Fahad MP-03.11
Al-Zahrani, Ali UP-057, UP-060
Andrews, J. Matthew UP-067
Aprikian, Armen UP-022
Archambault, Jason POD-01.02
Arsovska, Olga MP-02.16, UP-097
Autran Gomez, Ana Maria MP-01.12, MP-06.05, UP-048
BBach, Phil MP-04.03
Bachir, Bassel G. POD-02.03, MP-03.03
Bacsu, Chasta-Dawne POD-04.04, MP-04.02
Barrett, Keith MP-04.07
Baverstock, Richard MP-04.09, MP-04.23
Bénard, François UP-070
Bhindi, Bimal UP-043
Bhojani, Naeem MP-02.01, MP-02.02, MP-02.15, MP-02.17, UP-026, UP-095
Bidnur, Samir UP-084
Binsaleh, Saleh MP-04.08
Bishr, Mohamed MP-03.14, MP-07.12
Black, Peter POD-03.06, MP-09.07
Bladou, Franck UP-004, UP-056
Blais, Jean-Philippe UP-006
Blouin, Annie-Claude MP-03.12
Bostrom, Peter J. MP-07.09
Boyle, Shawna UP-106, UP-112
Braga, Luis POD-03.03, MP-05.06
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
CUA 2012 BANFF 147
CCampeau, Lysanne MP-09.05, MP-09.06
Carlson, Kevin MP-04.22
Chang, Michelle MP-04.18
Chapman, David MP-09.02
Chien, Gary MP-01.20, UP-036
Chin, Joseph L. UP-055
Choo, Richard MP-07.11
Cloutier, Jonathan MP-05.04
Cole, Eric MP-01.07, MP-05.08
Cox, Ashley MP-04.20
Crump, R. Trafford UP-053
DDason, Shawn MP-01.11, MP-01.21
Davis, Jeffrey MP-02.03, MP-03.23
Day, Robert UP-047
De, Shubha MP-02.12
Desantis, Darren POD-02.06
Deschênes-Rompré, Marie-Pier UP-105
Dion, Marie UP-107
Djahangirian, Orchidée UP-001
Donnelly, Bryan POD-05.06
Dovirak, Ostap UP-052
EElharram, Malik UP-024
Elhilali, Mostafa UP-007
Elias, Rami MP-02.19
Elkoushy, Mohamed POD-01.04, MP-02.07, MP-02.09, MP-02.18, UP-098
Elliott, Daniel MP-08.10
Elsawy, Mohamed MP-05.10
Elshal, Ahmed UP-061
Elterman, Dean MP-04.19, UP-063
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
148 CUA 2012 BANFF
FFahmy, Nader UP-076
Fairey, Adrian POD-05.04, MP-03.05
Figueroa, Victor H. MP-05.01, MP-05.14, UP-082
Finelli, Antonio UP-019
Flannigan, Ryan UP-059
Fleshner, Neil UP-102
Foell, Kirsten MP-02.05
Fortin, Israel UP-041
Fuoco, Michael UP-069
GGagnon, Louis-Olivier MP-01.14, UP-028, UP-029
Gajewski, Jerzy MP-04.17
Garcia, Francisco MP-06.02, MP-06.03
Garcia, Maurice POD-04.05
Gudeloglu, Ahmet MP-06.07, UP-101, UP-114
Gustafson, Paul MP-04.05
H-IHamidizadeh, Reza MP-02.10
Hamilton, Robert POD-02.04
Han, Kyungseok MP-09.01, MP-09.03
Heimrath, Olivier P. UP-039
Herschorn, Sender MP-04.11, MP-04.12
Hoag, Nathan UP-087
Hoy, Nathan MP-04.10, MP-05.13
Huon, Yannick UP-042
Ismail, Salima MP-03.13
Izard, Jason MP-01.16, MP-01.17, MP-07.03, MP-08.11
J-KJewett, Michael A.S. UP-013
Kaler, Kamaljot MP-08.01
Kalyanaraman, Balaji UP-110
Kanaroglou, Niki MP-05.07
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
CUA 2012 BANFF 149
Kapoor, Anil MP-03.09
Khambati, Aziz UP-078
Khan, Faisal MP-07.08, UP-020
Kinnaird, Adam S. POD-04.06
Klinghoffer, Zachary POD-01.05, MP-06.08
Klotz, Laurence UP-066
Kumar, Surendra UP-031
LLabouba, Ingrid MP-09.10, UP-058
Langille, Gavin MP-06.09
Lavallée, Luke MP-01.19
Lawson, Keith MP-03.07, UP-072
Lee, Jason Y. UP-104
Lee, Taehyoung UP-113
Leong, Nelson UP-051
Levine, Max A. MP-04.06
Liang, Teresa UP-088
Lobb, Ian MP-03.18
Longpre, Michelle UP-030
MMaciejewski, Conrad MP-05.12
MacLellan, Dawn MP-09.04
Mallat, Faouzi UP-079, UP-085, UP-086, UP-089, UP-094
Margel, David MP-01.02, MP-09.08, UP-025, UP-040
Massaro, Peter MP-02.20, UP-109
McKay, Jeffrey UP-073
Melnyk, Megan MP-08.04, MP-08.06
Metcalfe, Charles MP-03.15, UP-034
Metcalfe, Michael MP-03.02
Michael, Amanda UP-008, UP-115
Mickelson, Jennifer J. UP-068
Moles, Jonathan UP-065
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
150 CUA 2012 BANFF
Morales, Alvaro MP-07.01
Morales, Carlos MP-03.08
Moreel, Xavier UP-049
NNam, Robert POD-05.05
Narayanan, Ramkishen UP-077
Nayak, Jasmir POD-05.03, UP-011, UP-023
Nguyen, Laura MP-08.02
Nguyen, Tim MP-08.05
Nickel, J. Curtis MP-08.07, MP-08.08, UP-075
Nitti, Victor POD-04.01
North, Scott POD-02.02
O-POlesen, Jamie POD-03.02
Ordon, Michael POD-01.01, MP-03.17, MP-03.19
Patel, Premal UP-111
Pippi Salle, Joao L. MP-05.09
Poisson, Alexis UP-064
Popovic, Mihailo MP-04.04, UP-054
Pouliot, Frédéric MP-09.11
Preston, Mark A. POD-05.02, MP-01.09
Punjani, Nahid UP-002, UP-071
Punnen, Sanoj MP-01.04, MP-01.10, MP-01.15, UP-037, UP-038
RRamsay, Sophie MP-04.21
Razvi, Hassan POD-01.06
Rhee, Jonathan MP-07.06
Robinson, Michael MP-02.11, UP-093
Rocha, Joice UP-021
Romao, Rodrigo L.P. POD-03.01, UP-080, UP-081
Rourke, Keith MP-08.09
Rowe, Neal MP-01.01
Rutkowski, John UP-009
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
CUA 2012 BANFF 151
SSaad, Fred POD-02.01, POD-05.01
Sandhu, Gurdarshan MP-07.04, MP-07.05, MP-07.07, UP-005
Shamloul, Rany MP-06.01
Shayegan, Bobby UP-050
Sheikh, Adeel MP-05.02
Sheridan-Jonah, Anna UP-017
Siemens, D. Robert MP-01.22, UP-032
Sivalingam, Sri MP-02.04, MP-02.06, MP-02.08, MP-02.14, UP-096
Skeldon, Sean MP-01.18, MP-06.04
Spelliscy, Courtney MP-05.11
Stakhovskyi, Oleksandr MP-07.10
Stearns, Gillian MP-05.03
Steele, Stephen S. MP-04.13
Stothers, Lynn MP-04.14, MP-04.15
Suntharasivam, Thiru MP-01.05
TToren, Paul POD-02.05, MP-04.01, UP-046
Tran, Kim-Chi MP-03.21
Tse, Richard UP-014
Tu, Hin Yu Vincent UP-099
U-V-WUllah, Shahnoor UP-108
van Rhijn, Bas W.G. MP-09.09
Violette, Philippe POD-03.05
Wang, Xinmin MP-04.16
Weber, Bryce POD-03.04
Welk, Blayne MP-08.03, MP-08.12
Wildgoose, Petra MP-05.05
Wong, Carson UP-035
Wong, Lih-Ming MP-01.06, MP-01.08, UP-033
PRESENTER INDEX / INDEX DES PRÉSENTATEURS
152 CUA 2012 BANFF
Y-ZYafi, Faysal A. MP-07.02
Yan, Hanmu UP-100
Yanko, Daniel MP-03.22
Yap, Stanley MP-03.04, MP-03.06
Yutkin, Vladimir MP-01.03
Zadra, Joseph POD-01.03
Zappavigna, Christopher MP-06.06, UP-016, UP-091, UP-092, UP-103
Zareba, Piotr UP-012
Zhu, Justin MP-03.20
Zorba, Orhan Ünal UP-062, UP-074, UP-090
Zorn, Kevin POD-04.02, MP-01.13
PRESENTER INDEX / INDEX DES PRÉSENTATEURS